Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies
By using AAV vector to deliver anti-FAM19A5 antibodies, the problem of insufficient pharmacokinetics and tissue accessibility of existing antibody therapies in the central nervous system is solved, and the efficient antagonism and therapeutic effect of FAM19A5 is improved.
Patent Information
- Application Number
- CN201980030335.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-05-08
- Filing Date
- 2019-05-08
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-05-08
AI Technical Summary
Existing antibody therapies for treating central nervous system diseases have insufficient pharmacokinetics and tissue accessibility, resulting in high cost and limited therapeutic effects, requiring a more effective and economical delivery method.
Adeno-associated virus (AAV) vectors are used to encode antagonists against the FAM19A5 protein, including anti-FAM19A5 antibodies, to deliver antibodies to target cells through the AAV vector, achieving efficient antagonism of FAM19A5.
It achieves efficient antagonism of FAM19A5, reduces treatment costs, improves treatment effects, and can target the central nervous system and improves the symptoms of central nervous system-related diseases.
Smart Images

Figure CN112074605B_ABST
Abstract
Description
[0001] Reference to a sequence listing submitted electronically
[0002] The contents of the Sequence Listing submitted electronically as an ASCII text file (name: 3763_010PC01_SeqListing_ST25.txt; size: 261,643 bytes; and creation date: May 8, 2019) with the application are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to recombinant adeno-associated virus (AAV) vectors and uses thereof. More specifically, the present disclosure relates to AAV vectors comprising nucleic acids encoding antagonists directed against family 19 member A5 (FAM19A5) proteins with sequence similarity. In some aspects, the FAM19A5 antagonists are single-chain variable fragments that target the FAM19A5 protein. Background Art
[0004] FAM19A5 is a member of the TAFA protein subfamily, which consists of five highly homologous small proteins. Tang TY et al., Genomics 83(4):727-34 (2004). These proteins contain conserved cysteine residues at fixed locations and are distantly related to macrophage inflammatory protein 1-α (MIP-1-α), a member of the CC-chemokine family. Like many other TAFA proteins, FAM19A5 is primarily expressed in specific areas of the brain and spinal cord. It is believed to play an important role not only in the development, differentiation, and formation of the intact central nervous system, but also in the pathogenesis of many diseases associated with the central nervous system. Therefore, in vivo administration of anti-FAM19A5 antibodies has been shown to improve symptoms associated with central nervous system damage or disease. U.S. Patent No. 9,579,398.
[0005] Therapeutic antibodies have been successfully used to treat a variety of diseases. Ecker DM et al., MAbs 7:9-14 (2015). However, despite the efficacy of therapeutic antibodies, there are known limitations to antibodies that limit their widespread therapeutic use. For example, many antibodies have been described as having insufficient pharmacokinetics and tissue accessibility and impaired interactions with the immune system. Chames P et al., Br J Pharmacol 157(2):220-223 (2009). In addition, antibodies often have to be administered in large quantities to achieve clinical efficacy, resulting in high manufacturing costs. Therefore, there is a need for alternative methods for delivering therapeutic antibodies, such as anti-FAM19A5 antibodies, to subjects for the treatment of disease that are both effective and economical. Summary of the Invention
[0006] The present disclosure provides an adeno-associated virus (AAV) vector comprising a nucleic acid encoding an antagonist to a family of sequence similarity 19, member A5 (FAM19A5) protein. In some embodiments, the AAV vector further comprises an intron, a signal peptide, and / or one or more adeno-associated virus inverted terminal repeats (ITRs).
[0007] In some embodiments, the FAM19A5 antagonist is an anti-FAM19A5 antibody. Thus, in some embodiments, the AAV vector comprises a nucleic acid encoding an anti-FAM19A5 antibody. In some embodiments, the anti-FAM19A5 antibody comprises a Fab, Fab', F(ab')2, Fv, or single-chain Fv (scFv). In certain embodiments, the anti-FAM19A5 antibody is a scFv.
[0008] In some embodiments, the AAV vector comprises a codon-optimized nucleic acid. In some embodiments, the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, or SEQ ID NO: 301. In some embodiments, the scFv comprises the amino acid sequence set forth in SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203, or SEQ ID NO: 256.
[0009] In some embodiments, the anti-FAM19A5 antibody exhibits a property selected from the group consisting of: (a) a K of 10 nM or less as measured by enzyme-linked immunosorbent assay (ELISA); D Binds to soluble human FAM19A5; (b) binds to soluble human FAM19A5 with a K of 10 nM or less as measured by ELISA D Binds to membrane-bound human FAM19A5; or (c) both (a) and (b).
[0010] In some embodiments, the anti-FAM19A5 antibody cross-competes for binding to a human FAM19A5 epitope with a reference antibody comprising a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31; or (ii) wherein the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, and the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: NO:26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO:27, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:28; (iii) wherein the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO:11, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO:12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO:23, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO:24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:25; or (iv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:212, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:213, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:222, and the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: The light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 224.
[0011] In some embodiments, the anti-FAM19A5 antibody binds to the same FAM19A5 epitope as a reference antibody comprising a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31; and (ii) wherein the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: NO:26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO:27, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:28; (iii) wherein the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO:11, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO:12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO:23, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO:24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:25; or (iv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:212, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:213, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:222, and the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: The light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 224.
[0012] In some embodiments, the anti-FAM19A5 antibody binds to at least one FAM19A5 epitope, which is SEQ ID NO: 6 or SEQ ID NO: 9. In other embodiments, the anti-FAM19A5 antibody binds to only one FAM19A5 epitope, which is SEQ ID NO: 6 or SEQ ID NO: 9. In certain embodiments, the anti-FAM19A5 antibody further binds to an additional FAM19A5 epitope. In some embodiments, the additional FAM19A5 epitope is selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and any combination thereof.
[0013] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, wherein the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 16, or SEQ ID NO: 13. In some embodiments, the heavy chain CDR1 of the anti-FAM19A5 antibody comprises the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 14, SEQ ID NO: 11, or SEQ ID NO: 212. In some embodiments, the heavy chain CDR2 of the anti-FAM19A5 antibody comprises the amino acid sequence set forth in SEQ ID NO: 18, SEQ ID NO: 15, SEQ ID NO: 12, or SEQ ID NO: 213. In some embodiments, the light chain CDR1 of the anti-FAM19A5 antibody comprises the amino acid sequence set forth in SEQ ID NO: 29, SEQ ID NO: 26, SEQ ID NO: 23, or SEQ ID NO: 222. In some embodiments, the light chain CDR2 of the anti-FAM19A5 antibody comprises the amino acid sequence set forth in SEQ ID NO: 30, SEQ ID NO: 27, SEQ ID NO: 24, or SEQ ID NO: 225. In certain embodiments, the light chain CDR3 of the anti-FAM19A5 antibody comprises the amino acid sequence set forth in SEQ ID NO: 31, SEQ ID NO: 28, SEQ ID NO: 25, or SEQ ID NO: 224.
[0014] In some embodiments, the anti-FAM19A5 antibody comprises heavy chain CDR1, CDR2 and CDR3 and light chain CDR1, CDR2 and CDR3, wherein (i) the heavy chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 17, 18 and 19, respectively, and the light chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 29, 30 and 31, respectively; (ii) the heavy chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 14, 15 and 16, respectively, and the light chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 26, 27 and 28, respectively; (iii) the heavy chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 11, 12 and 13, respectively, and the light chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: NOs: 23, 24 and 25; or (iv) the heavy chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 212, 213 and 16, respectively, and the light chain CDR1, CDR2 and CDR3 comprise SEQ ID NOs: 222, 225 and 224, respectively.
[0015] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable domain comprising SEQ ID NO: 37, SEQ ID NO: 36, SEQ ID NO: 35, or SEQ ID NO: 236 and / or a light chain variable domain comprising SEQ ID NO: 41, SEQ ID NO: 40, SEQ ID NO: 39, or SEQ ID NO: 245. In certain embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable domain comprising SEQ ID NO: 37 and a light chain variable domain comprising SEQ ID NO: 41. In other embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable domain comprising SEQ ID NO: 36 and a light chain variable domain comprising SEQ ID NO: 40. In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable domain comprising SEQ ID NO: 35 and a light chain variable domain comprising SEQ ID NO: 39. In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable domain comprising SEQ ID NO: 236 and a light chain variable domain comprising SEQ ID NO: 245.
[0016] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 37, 36, 35, or 236. In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 41, 40, 39, or 245. In certain embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence shown in SEQ ID NO: 37, 36, 35, or 236; and wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence shown in SEQ ID NO: 41, 40, 39, or 245.
[0017] In some embodiments, the anti-FAM19A5 antibody inhibits binding of a reference antibody to human FAM19A5 by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%, as measured by a binding inhibition assay. In certain embodiments, the anti-FAM19A5 antibody reduces the concentration of FAM19A5 protein in a culture medium comprising an astrocyte cell line (e.g., C8-D1A) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%, as measured by ELISA.
[0018] Also provided herein is a method for producing recombinant adeno-associated virus (AAV) particles, the method comprising (a) culturing host cells that have been transfected with the AAV vector disclosed herein to provide a cell culture and (b) recovering the recombinant AAV particles from the supernatant of the cell culture.
[0019] The present disclosure also provides a method for delivering an antagonist against FAM19A5 protein to a subject in need thereof, the method comprising administering the AAV vector described herein to the subject.
[0020] The present disclosure further provides a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject an AAV vector as disclosed herein.
[0021] Also disclosed herein is a method of treating neuropathic pain in a subject in need thereof, comprising administering to the subject an AAV vector of the present disclosure. In some embodiments, the neuropathic pain is peripheral neuropathic pain.
[0022] The present disclosure provides a method for increasing the threshold or latency of an external stimulus in a subject in need thereof, comprising administering to the subject an AAV vector disclosed herein. In some embodiments, the external stimulus is a mechanical stimulus. In other embodiments, the external stimulus is a thermal stimulus.
[0023] In some embodiments, the AAV vectors of the present disclosure are administered intravenously, orally, parenterally, intrathecally, intracerebroventricularly, intrapulmonary, intramuscularly, subcutaneously, intraperitoneally, intravitreally, epidurally, subretinally, or intraventricularly. In some embodiments, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Provided is a diagram of the pscAAV construct used to generate the anti-FAM19A5 scFvAAV construct described in the Examples. Figure 1 As shown, pscAAV constructs include the following key elements: (i) human β-globin under the CMV promoter; (ii) a transgene encoding 3-2, 1-65, or 2-13 scFv; and (iii) left and right inverted terminal repeats (ITRs).
[0025] Figure 2A 、 2B 2C show the expression level of anti-FAM19A5 scFv after transduction of HEK293 cells with one of the following AAV constructs: (i) scAAV8-CMV-3-2-ScFv; (ii) scAAV9-CMV-3-2-ScFv; (iii) scAAV9-CMV-1-65-ScFv; or (iv) scAAV9-2-13-ScFv. Figure 2A HEK293 cells were transduced with scAAV8-CMV-3-2-ScFv at two different MOIs: 5 × 10 4 (white bar) or 1×10 5(Black bars). Antibody levels were measured on days 1, 4, and 8 after transduction. Figure 2B HEK293 cells were treated with scAAV9-CMV-3-2-ScFv (white bar: MOI = 1 × 10 5 ; Black bar = 2 × 10 5 ) were transduced. Antibody levels were measured at a single time point, 8 days after transduction. Figure 2C HEK293 cells were treated with scAAV9-CMV-1-65-ScFv (white bar: MOI = 1 × 10 5 ; Black bar = 2 × 10 5 ) or scAAV9-2-13-ScFv (white bars with dots: MOI = 1 × 10 5 ; Black bar with dots = 2×10 5 ) for transfection.
[0026] Figure 3A 、 3B 3C show the mean fluorescence intensity (MFI) of human FAM19A5-Fc binding to U87MG cells in the presence or absence of supernatants from cells transduced with different anti-FAM19A5 AAV constructs. Figure 3A Data for scAAV9-CMV-1-65-ScFv are shown. Number "1" indicates control (GFP), and number "2" indicates 1-65 scFv. Figure 3B Data for scAAV9-2-13-ScFv are shown. Number "1" indicates control (GFP), and number "2" indicates 2-13 scFv. Figure 3C Data for scAAV9-CMV-3-2-ScFv are shown. Number "1" indicates control (PBS), and number "2" indicates 3-2 scFv.
[0027] Figure 4A and 4B Shown are the levels of human FAM19A5 protein in C8-D1A cell cultures after treatment with supernatants from cells transduced with different anti-FAM19A5 AAV constructs. Figure 4A Shown is a comparison of FAM19A5 protein levels when C8-D1A cells were cultured with supernatants from cells transduced with scAAV8-CMV-3-2-ScFv alone or PBS. Figure 4B Shown is a comparison of FAM19A5 levels when C8-D1A cells were cultured with scAAV9-2-13-ScFv, scAAV9-CMV-1-65-ScFv, or a control construct (scAAV9-CMV-GFP). Figure 4A and 4BIn the figure, "naive" indicates C8-D1A cells that are not activated and therefore produce minimal FAM19A5 protein into culture.
[0028] Figure 5 Shown is the expression of anti-FAM19A5 (3-2) scFv in the brain 1 week (top row) and 2 weeks (bottom row) after intrathecal administration of scAAV8-CMV-3-2-ScFv into C57BL / 6 mice. The left image is from a naive animal (no administration). The right image is from a mouse that received the AAV construct. The arrow in the upper right image indicates positive staining.
[0029] Figure 6A and 6B The results show that scAAV8-CMV-3-2-ScFv administration can induce mechanical allodynia after peripheral nerve injury ( Figure 6A ) and thermal hyperalgesia ( Figure 6B ) role. Figure 6A In the study, the effect on mechanical allodynia was shown as the frequency with which the animals responded to stimulation of von Frey filaments in pain. Figure 6B The effect on thermal hyperalgesia is shown as paw withdrawal latency (the time it takes the animal to withdraw from the heat source). "*" indicates statistical significance p < 0.05 compared to the control group.
[0030] Figure 7A and 7B The results show that scAAV9-CMV-3-2-ScFv administration can induce mechanical allodynia after peripheral nerve injury ( Figure 7A ) and thermal hyperalgesia ( Figure 7B ) role. Figure 7A In the study, the effect on mechanical allodynia was shown as the frequency with which the animals responded to stimulation of von Frey filaments in pain. Figure 7B The effect on thermal hyperalgesia is shown as paw withdrawal latency (the time it takes the animal to withdraw from the heat source). "*" indicates statistical significance p < 0.05 compared to the control group.
[0031] Figure 8A and 8B Shown are the effects of scAAV1-CMV-3-2-ScFv administration on mechanical allodynia and thermal hyperalgesia, respectively. Figure 8A In the , the effect on mechanical allodynia is shown as the frequency with which the animals responded to stimulation of von Frey filaments (out of 10 stimuli) in pain. Figure 8B The effect on thermal hyperalgesia is shown as paw withdrawal latency (the time it takes the animal to withdraw from the heat source). "*" indicates statistical significance p < 0.05 compared to the control group.
[0032] Figure 9A and 9B Shown are the effects of scAAV9-CMV-2-13-ScFv administration on mechanical allodynia and thermal hyperalgesia, respectively. Figure 9A In the , the effect on mechanical allodynia is shown as the frequency with which the animals responded to stimulation of von Frey filaments (out of 10 stimuli) in pain. Figure 9B The effect on thermal hyperalgesia is shown as paw withdrawal latency (the time it takes the animal to withdraw from the heat source). "*" indicates statistical significance p < 0.05 compared to the control group.
[0033] Figure 10A and 10B Shown are the effects of scAAV9-CMV-1-30-ScFv administration on mechanical allodynia and thermal hyperalgesia, respectively. Figure 10A In the , the effect on mechanical allodynia is shown as the frequency with which the animals responded to stimulation of von Frey filaments (out of 10 stimuli) in pain. Figure 10B The effect on thermal hyperalgesia is shown as paw withdrawal latency (the time it takes the animal to withdraw from the heat source). "*" indicates statistical significance p < 0.05 compared to the control group.
[0034] Figure 11A 、 11B Figures 11 and 11C provide a comparison of the effects of different anti-FAM19A5 scFvAAV constructs alone or in combination with another therapeutic agent. Figure 11A In the , animals received one of the following: (i) scAAV1-CMV-GFP (open circles); (ii) scAAV1-CMV-3-2-ScFv (closed circles); (iii) scAAV9-CMV-mIL-10 (open squares); (iv) scAAV1-CMV-3-2-ScFv + scAAV9-CMV-mIL-10 (closed squares). Figure 11B In the , animals received one of the following: (i) scAAV9-CMV-GFP (open circles); (ii) scAAV9-CMV-2-13-ScFv (closed circles); (iii) scAAV9-CMV-mIL-10 (open squares); (iv) scAAV9-CMV-2-13-ScFv + scAAV9-CMV-mIL-10 (closed squares). Figure 11CAnimals received one of the following: (i) scAAV9-CMV-GFP (open circles); (ii) scAAV9-CMV-1-30-ScFv (closed circles); (iii) scAAV9-CMV-mIL-10 (open squares); (iv) scAAV9-CMV-1-30-ScFv + scAAV9-CMV-mIL-10 (closed squares). "*" indicates statistical significance p < 0.05 compared to the control group. DETAILED DESCRIPTION
[0035] Disclosed herein are compositions, such as adeno-associated virus (AAV) vectors, comprising nucleic acids encoding antagonists to family 19, member A5 (FAM19A5) proteins with sequence similarity. Also provided herein are methods of using such compositions as gene therapy for treating diseases or conditions, such as neuropathic pain.
[0036] To facilitate understanding of the disclosure provided herein, various terms and phrases are defined. Additional definitions are set forth throughout the detailed description.
[0037] I. Definition
[0038] Throughout this disclosure, the term "a" or "an" entity refers to one or more of said entities; for example, "antibody" is understood to mean one or more antibodies. Thus, the terms "a" (or "a kind"), "one or more species," and "at least one" can be used interchangeably herein.
[0039] Furthermore, the use of "and / or" herein should be understood as explicitly disclosing each of the two specified features or components with or without the other. Thus, the term "and / or" as used herein in phrases such as "A and / or B" is intended to encompass "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0040] It should be understood that whenever an aspect is described herein with the language "comprising," other similar aspects described with respect to "consisting of" and / or "consisting essentially of" are also provided.
[0041] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure relates. For example, the following commonly used dictionaries for many of the terms used in this disclosure are provided to those of skill in the art: the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, revised edition, 2000, Oxford University Press.
[0042] Units, prefixes and symbols are expressed in their SI accepted form. Numerical ranges include the numbers defining the range. Unless otherwise indicated, amino acid sequences are written from left to right in an amino to carboxyl orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be obtained by reference to this specification as a whole. Therefore, the terms defined below are more fully defined by reference to this specification in its entirety.
[0043] As used herein, the term "about" means approximately, roughly, around, or in the region of. When the term "about" is used in conjunction with a numerical range, the term modifies the range by extending the boundaries above and below the stated numerical value. Generally, the term "about" can modify the numerical value above and below the stated value by a variation of, for example, 10%, either above or below the stated value.
[0044] As used herein, the term "adeno-associated virus" or "AAV" refers to all adeno-associated viruses used in gene therapy, including derivatives thereof, virus subtypes, and naturally occurring and recombinant forms. The various serotypes of AAV can be used as recombinant gene transfer viruses to transduce many different cell types. Non-limiting examples of AAV serotypes include AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), AAV type 9 (AAV-9), avian AAV, cattle AAV, dog AAV, horse AAV, primate AAV, non-primate AAV, and sheep AAV. In certain embodiments, AAV is AAV type 8 (AAV-8) or AAV type 9 (AAV-9).
[0045] The genomic organization of all known AAV serotypes is very similar. The genome of AAV is a linear single-stranded DNA molecule of less than about 5,000 nucleotides (nt) in length. The genome includes three genes, rep (replication), cap (capsid) and aap (assembly). By using three promoters, alternative translation start sites and differential splicing, these three genes produce at least nine gene products. The AAV vectors of the present disclosure may contain additional elements that act in cis or trans. In specific embodiments, the AAV vector comprising the vector genome also has one or more inverted terminal repeat (ITR) sequences flanking the 5′ or 3′ end of the donor sequence; expression control elements (e.g., promoters or enhancers) that drive transcription of the donor sequence, such as constitutive or regulatable control elements, tissue-specific expression control elements, intron sequences, fillers or filler polynucleotide sequences; and / or a polyadenine sequence positioned 3′ of the donor sequence.
[0046] AAV has unique characteristics that make it useful as a vector for delivering foreign DNA to cells. AAV infection of cells in culture is generally non-cytopathic, and natural infection in humans and other animals is silent and asymptomatic. In addition, AAV infects many different types of mammalian cells, making it possible to target many different tissues in vivo. AAV also has additional advantages that make it a particularly attractive viral system for gene delivery, including promoting a milder immune response than other forms of gene delivery and being continuously expressed as a non-integrating vector in both dividing and resting cells. Moreover, AAV withstands conditions for inactivating adenoviruses (56°C to 65°C for several hours), making cold storage of rAAV-based vaccines less important. In some embodiments, the AAV of the present disclosure includes one or more of these features.
[0047] As used herein, the term "AAV vector" refers to a component comprising or derived from an adeno-associated virus (AAV) and is suitable for infecting mammalian cells (including human cells) of any tissue type in a variety of tissue types (such as brain, heart, lung, skeletal muscle, liver, kidney, spleen or pancreas) in vivo or in vitro. The term "AAV vector" can be used to refer to an AAV type virus particle (or virus particle) comprising at least a nucleic acid molecule encoding a protein of interest. In certain embodiments, the AAV vector is a "recombinant AAV vector", which refers to an AAV vector comprising a polynucleotide sequence that is not an AAV source (i.e., a polynucleotide heterologous to AAV, for example, an anti-FAM19A5 antibody), which is typically a sequence of interest for gene conversion of a cell. Heterologous polynucleotides are typically flanked by at least one and typically by two AAV inverted terminal repeats (ITRs). The term AAV vector encompasses both AAV vector particles and AAV vector plasmids.
[0048] As used herein, the term "ITR" refers to inverted terminal repeats. ITRs are generally involved in parvovirus (e.g., AAV) DNA replication and rescue or excision from prokaryotic plasmids (Daya, S. et al., Clin Microbiol Rev 21(4): 583-593 (2008)). In addition, ITRs are generally considered to be the minimum sequences required for AAV proviral integration and packaging of AAV DNA into virions. Therefore, these elements are essential for the efficient propagation of parvovirus genomes.
[0049] As used herein, the term "serotype" refers to an AAV subphylum that is identifiable by serological or DNA sequencing methods and that can be distinguished by its antigenic characteristics. Additionally, the term "isolate," when used in reference to AAV, means a specific AAV serotype obtained from a specific source. Based on the context in which the terms are used, one skilled in the art will readily recognize the difference between "isolated AAV," which refers to the relative purity of an AAV sample, and "AAV isolate," which refers to a clonally derived preparation of a specific AAV serotype.
[0050] The term "capsid-free" or "capsid-free" (or variants thereof) vector or nucleic acid molecule refers to a vector construct that does not contain a capsid. In some embodiments, the capsid-free vector or nucleic acid molecule does not contain a sequence encoding, for example, an AAV Rep protein.
[0051] In some embodiments, the AAV disclosed herein uses a helper virus for replication. As used herein, the "helper virus" of AAV refers to a virus that allows AAV (e.g., wild-type AAV) to be replicated and packaged by mammalian cells. Various such helper viruses for AAV are known in the art and include adenoviruses, herpes viruses, and pox viruses such as cowpox. Adenoviruses encompass many different subgroups, but the most commonly used is adenovirus type 5 in subgroup C. Many adenoviruses of human, non-human mammalian, and avian origin are known and available from storage facilities such as ATCC. Viruses of the herpes virus family include, for example, herpes simplex virus (HSV) and Epstein-Barr virus (EBV) as well as cytomegalovirus (CMV) and pseudorabies virus (PRV); these can also be obtained from storage facilities such as ATCC.
[0052] In some embodiments, the AAVs of the present disclosure have unique tissue targeting capabilities (e.g., tissue tropism). In some embodiments, AAVs further exhibit increased transduction or tropism in one or more human stem cell types compared to the non-variant parent capsid polypeptide. In some embodiments, human stem cell types include but are not limited to embryonic stem cells, adult tissue stem cells (i.e., somatic stem cells), bone marrow, progenitor cells, induced pluripotent stem cells, and reprogrammed stem cells. In some embodiments, adult stem cells may include organoid stem cells (i.e., stem cells derived from any organ or organ system of interest in the body). In some embodiments, the target tissue of AAV is a gonad, diaphragm, heart, stomach, liver, spleen, pancreas, or kidney. In some embodiments, AAV targets organs of the body including, but not limited to, skin, hair, nails, sensory receptors, sweat glands, oil glands, bones, muscles, brain, spinal cord, nerves, pituitary gland, pineal gland, hypothalamus, thyroid gland, parathyroid gland, thymus gland, adrenal gland, pancreas (islet tissue), heart, blood vessels, lymph nodes, lymphatic vessels, thymus gland, spleen, tonsils, nose, pharynx, larynx, trachea, bronchi, lungs, mouth, pharynx, esophagus, stomach, small intestine, large intestine, rectum, anal canal, teeth, salivary glands, tongue, liver, gallbladder, pancreas, appendix, kidneys, ureters, bladder, urethra, testicles, vas deferens (blood vessels), urethra, prostate, penis, scrotum, ovaries, uterus, uterine (fallopian) tubes, vagina, vulva, and mammary gland (breast). Organ systems of the body include, but are not limited to, the integumentary system, skeletal system, muscular system, nervous system, endocrine system, cardiovascular system, lymphatic system, respiratory system, digestive system, urinary system, and reproductive system. In some embodiments, transduction and / or tropism is increased by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 100%. In some embodiments, transduction and / or tropism is increased by about 5% to about 80%, about 10% to about 70%, about 20% to about 60%, or about 30% to about 60%.
[0053] The phrases "tropism" and "transduction" are interrelated, but there are differences. As used herein, the term "tropism" refers to the ability of an AAV vector or virion to infect one or more specified cell types, but can also encompass how a vector is used to transduce cells in the one or more specified cell types; that is, tropism refers to the preferential entry of an AAV vector or virion into one or more cell or tissue types and / or preferential interaction with a cell surface that is conducive to entry into certain cell or tissue types, optionally and preferably subsequently expressing (e.g., transcribing and optionally translating) sequences carried by the AAV vector or virion in the cell, such as for recombinant viruses, expressing one or more heterologous nucleotide sequences. As used herein, the term "transduction" refers to the ability of an AAV vector or virion to infect one or more specific cell types; that is, transduction refers to the entry of an AAV vector or virion into a cell and the transfer of genetic material contained within the AAV vector or virion into the cell to obtain expression from the vector genome. In some cases, but not all cases, transduction and tropism can be interrelated.
[0054] As used herein, the term "multiplicity of infection" or "MOI" refers to the ratio of integrating vector to host cells used during transfection or transduction of a host cell. For example, if 1,000,000 vectors are used to transduce 100,000 host cells, the multiplicity of infection is 10. Use of this term is not limited to events involving transduction, but encompasses introduction of vectors into a host by methods such as lipofection, microinjection, calcium phosphate precipitation, and electroporation.
[0055] The term "neuropathic pain" refers to pain that results from injury, damage, and / or malfunction at any level affecting the central nervous system (CNS) and / or peripheral nervous system. The term "neuropathic pain" encompasses any and all types of neuropathic pain, regardless of the cause of the neuropathic pain and any and all symptoms.
[0056] Neuropathic pain includes central neuropathic pain and peripheral neuropathic pain. As used herein, the term "central neuropathic pain" refers to pain caused by illness, congenital defects or central nervous system (i.e., brain or spinal cord) damage. As used herein, the term "peripheral neuropathic pain" refers to pain caused by damage or infection of peripheral sensory nerves.
[0057] Symptoms of neuropathic pain can include persistent / chronic pain, spontaneous pain, as well as allodynia (e.g., a painful response to a stimulus that is not normally painful), hyperalgesia (e.g., an exaggerated response to a painful stimulus that normally causes only mild discomfort, such as a pinprick), hyperesthesia (e.g., an excessive physical sensitivity to a stimulus, especially of the skin), or hyperalgesia (e.g., a situation where a brief discomfort becomes prolonged, severe pain). In some embodiments, symptoms can be persistent and persist after resolution of the primary cause, if any. Merck Manual, Neuropathic Pain, available at merckmanuals.com / professional / neurologic-disorders / pain / neuropathic-pain; Campbell JN and Meyer RA, Neuron 52(1):77-92 (2006).
[0058] In some embodiments, the types of neuropathic pain may include: (1) neuropathic pain, (2) deafferentation pain syndrome, (3) complex regional pain syndrome (CRPS), and (4) neuropathy (central or peripheral).
[0059] In some embodiments, neuropathic pain is neuralgia, which refers to pain that radiates along the course of one or more specific nerves (e.g., cranial nerves), typically in the absence of any demonstrable pathological changes in the neural structures. Neuropathic pain includes, but is not limited to, trigeminal neuralgia (TN), atypical trigeminal neuralgia (ATN), occipital neuralgia, glossopharyngeal neuralgia, postherpetic neuralgia (caused by herpes zoster or shingles), peripheral nerve injury pain, sciatica, low back pain, and atypical facial pain. Chemical irritation, chronic kidney disease, diabetes, inflammation, trauma (including surgery), compression of nerves by nearby structures (e.g., tumors), certain medications (e.g., cisplatin, paclitaxel, or vincristine), porphyria (blood disorders), and infections (e.g., herpes zoster (shingles), HIV / AIDS, Lyme disease, or syphilis) may all cause neuralgia.
[0060] In some embodiments, the neuropathic pain is a deafferentation pain syndrome, which may be caused by a loss of sensory input from a part of the body (e.g., caused by interruption of peripheral sensory fibers or nerves of the central nervous system). Deafferentation pain syndromes include, but are not limited to, brain or spinal cord injury, post-stroke pain, phantom pain, paraplegia, brachial plexus avulsion, and lumbar radiculopathy.
[0061] In some embodiments, neuropathic pain is " Complex Regional Pain Syndrome " (CRPS), which is a chronic pain condition that most commonly affects the arms or legs. In some embodiments, CRPS occurs after injury, surgery, stroke, or heart attack. In certain embodiments, CRPS is CRPS type I (CRPS-I) (also referred to as reflex sympathetic dystrophy syndrome). Individuals without a confirmed nerve injury are typically classified as having CRPS-I. In other embodiments, CRPS is CRPS type II (CRPS-II) (also referred to as causalgia), which is associated with a confirmed nerve injury.
[0062] In certain embodiments, neuropathic pain is neuropathy, and neuropathy refers to the pain caused by the function or pathological change (for example, disease or damage) of nerve. Neuropathy can usually be characterized clinically by sensory or motor neuron abnormality. In certain embodiments, neuropathy is central neuropathy (for example, the function or pathological change of central nervous system). In other embodiments, neuropathy is peripheral neuropathy (for example, the function or pathological change of one or more peripheral nerves, comprising motor nerve, sensory nerve, autonomic nerve or its combination). In certain embodiments, peripheral neuropathy is related to the function or pathological change (that is, mononeuropathy) to a single nerve or nerve group. In certain embodiments, peripheral neuropathy is related to the function or pathological change (that is, polyneuropathy) affecting multiple nerves (local or systemic). In certain embodiments, peripheral neuropathy is roughly the same (that is, symmetrical polyneuropathy) on both sides of the body. In certain embodiments, peripheral neuropathy affects the different areas of health (for example, mononeuritis multiplex, multifocal mononeuropathy or multiple mononeuropathy).
[0063] As used herein, "mononeuropathy" refers to a peripheral neuropathy involving the loss of movement or sensation in a region caused by damage or destruction to a single peripheral nerve or nerve group. Mononeuropathy is most commonly caused by damage or trauma to a local area, which, for example, results in prolonged compression of a single nerve. However, certain systemic conditions (e.g., mononeuritis multiplex) may also cause mononeuropathy. In some embodiments, damage or trauma to a local area causes destruction of the myelin sheath (covering) of a portion (axon) of a nerve or nerve cell, which may slow down or prevent impulse conduction through the nerve. In some embodiments, mononeuropathy can affect any part of the body. Examples of mononeuropathy pain include, but are not limited to, sciatic nerve dysfunction, common peroneal nerve dysfunction, radial nerve dysfunction, ulnar nerve dysfunction, cranial mononeuropathy VI, cranial mononeuropathy VII, cranial mononeuropathy III (compression type), cranial mononeuropathy III (diabetic type), axillary nerve dysfunction, carpal tunnel syndrome, femoral nerve dysfunction, tibial nerve dysfunction, Bell's palsy, thoracic outlet syndrome, carpal tunnel syndrome, and sixth (abducens) nerve palsy. Finnerup NB et al., Pain 157(8):1599-1606 (2016); National Institute of Neurological Disorders and Stroke, Peripheral Neuropathy Fact Sheet, available at ninds.nih.gov / disorders / peripheralneuropathy / detail_peripheralneuropathy.htm. In some embodiments, the mononeuropathic pain is sciatica.
[0064] As used herein, "polyneuropathy" is a peripheral neuropathy involving loss of movement or sensation to an area caused by damage or destruction to multiple peripheral nerves. Polyneuropathic pain includes, but is not limited to, post-polio syndrome, post-mastectomy syndrome, diabetic neuropathy, alcoholic neuropathy, amyloid, toxins, AIDS, hypothyroidism, uremia, vitamin deficiency, chemotherapy-induced pain, 2',3'-dideoxycytidine (ddC) treatment, Guillain-Barré syndrome, or Fabry disease. Finnerup NB et al., Pain 157(8): 1599-1606 (2016); National Institute of Neurological Disorders and Stroke, Peripheral Neuropathy Information Page, available at ninds.nih.gov / disorders / peripheralneuropathy / detail_peripheralneuropathy.htm. In some embodiments, the polyneuropathy is diabetic peripheral neuropathy. In certain embodiments, diabetic peripheral neuropathy is caused by high blood glucose levels (glucose) and / or high fat (eg, triglyceride) levels in the blood of a diabetic subject, which causes damage to the subject's peripheral nerves.
[0065] In some embodiments, the peripheral neuropathies disclosed herein can be classified based on the damaged or affected portion of the nerve cell (e.g., axon, myelin sheath, or cell body). In some embodiments, peripheral neuropathy is a distal axonopathy caused by a metabolic or toxic disorder of the axon. In some embodiments, the metabolic disorder includes diabetes, renal failure, deficiency syndromes such as malnutrition, and alcoholism. In some embodiments, the metabolic disorder is diabetes, and the distal axonopathy is diabetic neuropathy.
[0066] In some embodiments, the peripheral neuropathy is a myelinopathy caused by a primary attack on myelin or myelinated Schwann cells, resulting in an acute failure of impulse conduction. The most common cause is acute inflammatory demyelinating polyneuropathy (AIDP; also known as Guillain-Barré syndrome), although other causes include chronic inflammatory demyelinating syndrome (CIDP), inherited metabolic disorders (e.g., leukodystrophy), or toxins.
[0067] In certain embodiments, peripheral neuropathy is the neuron disease due to the destruction of peripheral nervous system (PNS) neuron. In certain embodiments, neuron disease is caused by motor neuron disease, sensory neuron disease (for example, herpes zoster), toxin or autonomic dysfunction. In certain embodiments, neuron disease is caused by neurotoxins such as chemotherapeutic agent vincristine.
[0068] Neuropathic pain can be caused by or associated with a variety of etiologies, e.g., physical injury (e.g., trauma or repetitive stress), disease or condition, exposure to toxic agents, or a combination thereof. In some embodiments, neuropathic pain is caused by or associated with a traumatic injury or damage, such as a nerve compression injury (e.g., nerve crush, nerve stretch, nerve tether, or incomplete nerve transection); a spinal cord injury (e.g., a hemisection); an injury or damage to a peripheral nerve (e.g., a motor nerve, a sensory nerve, or an autonomic nerve, or a combination thereof), an amputation; a contusion; inflammation (e.g., inflammation of the spinal cord); or a surgical procedure. In some embodiments, neuropathic pain is caused by or associated with repetitive stress, including, for example, repetitive, awkward, and / or forceful activities that require moving any group of joints for an extended period of time. Without being bound by any theory, the resulting irritation may cause inflammation and swelling of the ligaments, tendons, and muscles, thereby restricting the narrow passageway through which the nerve passes (e.g., ulnar neuropathy and carpal tunnel syndrome, which are neuropathy caused by entrapment or compression of nerves at the elbow or wrist). In some embodiments, neuropathic pain is caused by or is associated with a disease or condition including, for example, an ischemic event (e.g., a stroke or heart attack), multiple sclerosis, metabolic and / or endocrine diseases or conditions (e.g., diabetes, metabolic diseases, and acromegaly, which is a condition caused by overproduction of growth hormone and characterized by abnormal enlargement of parts of the skeleton (including joints), leading to nerve entrapment and pain), small vessel disease that causes decreased oxygen supply to peripheral nerves, resulting in damage to nerve tissue (e.g., vasculitis, i.e., inflammation of the blood vessels), autoimmune diseases (e.g., Sjögren's syndrome, lupus, rheumatoid arthritis, and acute inflammatory demyelinating neuropathy). (also known as Guillain-Barré syndrome)), kidney disorders, cancer or tumors (e.g., neoplastic tumors, neuromas, paraneoplastic syndromes, and toxicity from chemotherapeutic agents and radiation for cancer treatment), infections (e.g., infections with viruses such as varicella zoster (shingles), Epstein-Barr virus, West Nile virus, cytomegalovirus, and herpes simplex virus, acquired immunodeficiency syndrome (AIDS), or bacteria such as Lyme disease, diphtheria, and leprosy), inflammatory disorders, peripheral nerve disorders (e.g., neuromas), genetic disorders (whether inherited or emerging (e.g., Charcot-Marie-Tooth disorder involves extreme weakness and wasting of the muscles of the lower legs and feet, abnormal gait, loss of tendon reflexes, and numbness of the lower extremities)), mononeuropathy or polyneuropathy. In some embodiments, the neuropathic pain is caused by or associated with an infectious agent (e.g., tick-borne infections, varicella zoster, Epstein-Barr virus, West Nile virus, cytomegalovirus, herpes simplex virus, AIDS).In some embodiments, neuropathic pain is caused by or is associated with exposure to toxic agents including, for example, drugs, alcohol, heavy metals (e.g., lead, arsenic, mercury), industrial agents (e.g., solvents, fumes from glue), or nitrous oxide.
[0069] The term "neuropathic pain associated with a disease or condition" refers to neuropathic pain that accompanies, is caused by, or results from a disease or condition, such as those disclosed herein.
[0070] As used herein, the terms "treat," "treating," and "treatment" refer to any type of intervention or procedure performed on a subject or the administration of an active agent to a subject with the goal of reversing, alleviating, ameliorating, inhibiting, slowing, or preventing the progression, development, severity, or recurrence of symptoms, complications, conditions, or biochemical markers associated with a disease. Treatment can be with respect to a subject having a disease or a subject not having a disease (e.g., for prevention).
[0071] As used herein, " administering " refers to using any method and delivery system in the whole bag of tricks well known to persons skilled in the art and therapeutic agent or the composition comprising therapeutic agent to be physically introduced into the subject. Preferred administration routes of antibody described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal, intravitreal or other parenteral administration routes, such as by injection or infusion. As used herein, phrase " parenteral administration " means generally by injection rather than enteral and topical administration mode and includes but is not limited to intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcutaneous, intravitreal, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion and electroporation in vivo. Alternatively, antibody described herein can be administered by non-parenteral route, such as local, epidermal or mucosal administration routes, such as nasal, oral, vaginal, rectal, sublingual or topical. Administration can also be performed, for example, once, multiple times, and / or over one or more extended periods of time.
[0072] As used herein, the term "therapeutically effective amount" refers to an amount of a drug, alone or in combination with another therapeutic agent, that is effective to "treat" a disease or condition in a subject or to reduce the risk, potential, likelihood, or occurrence of a disease or condition (e.g., neuropathic pain). A "therapeutically effective amount" encompasses an amount of a drug or therapeutic agent that provides some improvement or benefit to a subject having or at risk of having a disease or condition (e.g., neuropathic pain disclosed herein). Thus, a "therapeutically effective" amount is an amount that reduces the risk, potential, likelihood, or occurrence of a disease or condition or provides some relief, alleviation, and / or reduction in at least one indicator (e.g., neuropathic pain) of the condition and / or a decrease in at least one clinical symptom of the disease or condition.
[0073] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.
[0074] The term "family with sequence similarity 19 member A5" or "FAM19A5" refers to a protein that belongs to the TAFA family of five highly homologous proteins (also known as the FAM19 family) and is primarily expressed in the brain and spinal cord. FAM19A5 is also known as TAFA5 or chemokine-like protein TAFA-5.
[0075] In humans, the gene encoding FAM19A5 is located on chromosome 22. There are multiple human FAM19A5 (UniProt: Q7Z5A7) isoforms believed to be produced by alternative splicing: isoform 1 (UniProt: Q7Z5A7-1), which consists of 132 amino acids; isoform 2 (UniProt: Q7Z5A7-2), which consists of 125 amino acids; and isoform 3 (UniProt: Q7Z5A7-3), which consists of 53 amino acids. It is believed that the human FAM19A5 protein exists in two forms: membrane-bound and soluble (secreted). Isoform 1 is believed to be membrane-bound with one transmembrane region. Isoform 2, reported as a secreted protein (soluble) in Tang TY et al., Genomics 83(4): 727-34 (2004), contains a signal peptide at amino acid position 1-25. Isoform 1 is believed to be a membrane protein. Below are the amino acid sequences of the three known human FAM19A5 isoforms.
[0076] (I) Isoform 1 (UniProt: Q7Z5A7-1, transmembrane protein): This isoform has been selected as the canonical sequence.
[0077]
[0078] (II) Isoform 2 (UniProt: Q7Z5A7-2, soluble protein):
[0079]
[0080] (III) Isoform 3 (UniProt: Q7Z5A7-3):
[0081]
[0082] The term "FAM19A5" encompasses any variant or isoform of FAM19A5 naturally expressed by cells. Thus, the antibodies described herein may cross-react with different isoforms in the same species (e.g., different isoforms of human FAM19A5) or with FAM19A5 from species other than humans (e.g., mouse FAM19A5). Alternatively, the antibody may be specific for human FAM19A5 and may not exhibit any cross-reactivity with other species. FAM19A5 or any of its variants and isoforms may be isolated or recombinantly produced from cells or tissues that naturally express them. The polynucleotide encoding human FAM19A5 has GenBank accession number BC039396 and the following sequence:
[0083] Table 1A. Polynucleotide sequence of human FAM19A5
[0084]
[0085] The term "antagonist against FAM19A5 protein" refers to all antagonists that inhibit the expression of FAM19A5 protein. Such antagonists can be peptides, nucleic acids, or compounds. More specifically, the antagonist can be an antisense oligonucleotide, siRNA, shRNA, miRNA, dsRNA, aptamer, PNA (peptide nucleic acid), or a vector comprising the same that targets FAM19A5. In some embodiments, the antagonist can be an antibody or antigen-binding portion thereof that specifically binds to the FAM19A5 protein.
[0086] The terms "antibody" and "antibodies" are terms of the art and can be used interchangeably herein and refer to molecules with an antigen binding site that specifically binds to an antigen. The terms are used herein to include complete antibodies and any antigen-binding fragments thereof (i.e., "antigen-binding portion") or single chains. In some embodiments, an "antibody" refers to a glycoprotein or antigen-binding portion thereof comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. In other embodiments, an "antibody" refers to a single-chain antibody comprising a single variable domain, such as a VHH domain. Each heavy chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. In some naturally occurring antibodies, the heavy chain constant region comprises three domains, CH1, CH2, and CH3. In some naturally occurring antibodies, each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one domain, CL.
[0087] The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0088] The term "Kabat numbering" and similar terms are generally recognized in the art and refer to a system in which the amino acid residues in the heavy chain and light chain variable regions of an antibody or its antigen-binding portion thereof are numbered. In some aspects, the CDR of an antibody can be determined according to the Kabat numbering system (see, for example, Kabat EA and Wu TT (1971) Annals of the New York Academy of Sciences (Ann NY Acad Sci) 190: 382-391 and Kabat EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, the CDR in an antibody heavy chain molecule is typically present at amino acid positions 31 to 35, which may optionally include one or two additional amino acids (referred to as 35A and 35B in the Kabat numbering scheme) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, the CDRs within an antibody light chain molecule are typically located at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In specific embodiments, the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme.
[0089] The phrases "numbered as in Kabat" or "Kabat positioning" and grammatical variants thereof refer to the numbering system used for heavy chain variable domains or light chain variable domains in the compilation of antibodies in Kabat et al., Sequences of Immunologically Significant Proteins, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Maryland (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to shortening of or insertion into the FW or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and inserted residues after heavy chain FW residue 82 (e.g., residues 82a, 82b, and 82c, etc. according to Kabat). See Table 1B.
[0090] Table 1B
[0091]
[0092] The Kabat numbering of residues of a given antibody can be determined by aligning the homologous regions of the sequence of the antibody with the "standard" Kabat numbering sequence. Chothia refers instead to the position of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). When numbering using the Kabat numbering convention, the end of the Chothia CDR-H1 loop varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertion at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; and if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software.
[0093] IMGT (ImMunoGeneTics) also provides a numbering system for immunoglobulin variable regions (including CDRs). See, for example, Lefranc, MP et al., Dev. Comp. Immunol. 27:55-77 (2003), which is incorporated herein by reference. The IMGT numbering system is based on alignments of more than 5,000 sequences, structural data, and characterization of hypervariable loops and allows for easy comparison of variable and CDR regions across all species. According to the IMGT numbering scheme, VH-CDR1 is located at locations 26 to 35, VH-CDR2 is located at locations 51 to 57, VH-CDR3 is located at locations 93 to 102, VL-CDR1 is located at locations 27 to 32, VL-CDR2 is located at locations 50 to 52, and VL-CDR3 is located at locations 89 to 97.
[0094] For all heavy chain constant region amino acid positions discussed in this disclosure, numbering is according to the EU index first described in Edelman et al., 1969, Proc. Natl. Acad. Sci. USA, 63(1):78-85, which described the amino acid sequence of the myeloma protein EU that was first sequenced for human IgG1. The EU index of Edelman et al. was also elaborated in Kabat et al., 1991, Protein Sequences of Immunological Significance, 5th ed., U.S. Public Health Service, National Institutes of Health, Bethesda, MD. Thus, the phrases "EU index as shown in Kabat" or "EU index of Kabat" and "positioning according to the EU index as shown in Kabat..." and grammatical variants thereof refer to the residue numbering system for the human IgG1 EU antibody based on Edelman et al., as shown in Kabat 1991.
[0095] The numbering system used for variable domain (both heavy and light chains) and light chain constant region amino acid sequences is that set forth in Kabat 1991.
[0096] The antibody can belong to any type of immunoglobulin molecule (e.g., IgG, IgE, IgM, IgD, IgA or IgY), any class (e.g., IgD, IgG2, IgG3, IgG4, IgA1 or IgA2) or any subclass (e.g., IgG1, IgG2, IgG3 and IgG4 of humans and IgG1, IgG2a, IgG2b and IgG3 of mice). Immunoglobulins such as IgG1 exist in several allotypes that differ from each other in a maximum of a few amino acids. The antibodies disclosed herein can be from any isotype, class, subclass or allotype of the commonly known isotypes, classes, subclasses or allotypes. In certain embodiments, the antibodies described herein belong to IgG1, IgG2, IgG3 or IgG4 subclasses or any hybrid thereof. In certain embodiments, the antibodies belong to IgG2, IgG4 or IgG2 / IgG4 subclasses.
[0097] By way of example, "antibody" includes naturally occurring antibodies and non-naturally occurring antibodies; monoclonal antibodies and polyclonal antibodies; chimeric antibodies and humanized antibodies; human antibodies and non-human antibodies; fully synthetic antibodies; single-chain antibodies; monospecific antibodies; multispecific antibodies (including bispecific antibodies); tetrameric antibodies comprising two heavy chain molecules and two light chain molecules; antibody light chain monomers; antibody heavy chain monomers; antibody light chain dimers, antibody heavy chain dimers; antibody light chain-antibody heavy chain pairs; intrabodies; heteroconjugate antibodies; monovalent antibodies; single-chain antibodies; camelized antibodies; affibodies; anti-idiotypic (anti-Id) antibodies (including, for example, anti-anti-Id antibodies); and single-domain antibodies (sdAbs), which comprise binding molecules consisting of a single monomeric variable antibody domain (e.g., VH domain or VL domain) that is fully capable of antigen binding. Harmen MM and Haard HJ Appl Microbiol Biotechnol 77(1): 13-22 (2007).
[0098] As used herein, the terms "antigen-binding portion" and "antigen-binding fragment" of an antibody are interchangeable and refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., human FAM19A5). Such "fragments" are, for example, between about 8 and about 1500 amino acids in length, suitably between about 8 and about 745 amino acids in length, suitably about 8 to about 300, for example, about 8 to about 200 amino acids in length, or about 10 to about 50 or 100 amino acids in length. It has been shown that the antigen-binding function of an antibody can be performed by a fragment of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody, e.g., the anti-FAM19A5 antibody described herein, include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, and a disulfide-linked Fv (sdFv); (v) a dAb fragment consisting of a VH domain (Ward et al., (1989) Nature 341:544-546); and (vi) isolated complementarity determining regions (CDRs) or (vii) a combination of two or more isolated CDRs, optionally linked by a synthetic linker. In addition, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, the two domains can be connected using recombinant methods by a synthetic linker that enables the two domains to become a single protein chain, in which the VL region and the VH region pair to form a monovalent molecule (referred to as single-chain Fv (scFv)); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proceedings of the National Academy of Sciences of the United States of America 85: 5879-5883). Such single-chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. These antibody fragments are obtained using conventional techniques known to those skilled in the art and are screened for utility in the same manner as intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact immunoglobulins.
[0099] As used herein, the terms "variable region" and "variable domain" are used interchangeably and are common in the art. A variable region generally refers to a portion of an antibody, generally a portion of a light chain or a heavy chain, typically about 110 to 120 amino acids at the amino terminal end in a mature heavy chain and about 90 to 115 amino acids in a mature light chain, which differ greatly in sequence between antibodies and are used for the binding and specificity of a particular antibody to its specific antigen. The variability of the sequence is concentrated in those regions known as complementary determining regions (CDRs), while the more conserved regions in the variable domains are known as framework regions (FRs).
[0100] In the case of not wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light chain and heavy chain are primarily responsible for the interaction and specificity of the antibody with the antigen. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region includes rodent or murine CDRs and human framework regions (FRs). In a specific embodiment, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable region includes rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs).
[0101] As used herein, the term "heavy chain" (HC) when used with reference to an antibody can refer to any of the different types, such as alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), which give rise to antibodies of the IgA, IgD, IgE, IgG, and IgM classes, respectively, including the subclasses of IgG, such as IgG1, IgG2, IgG3, and IgG4, based on the amino acid sequence of the constant domain.
[0102] As used herein, the term "light chain" (LC) when used with reference to an antibody can refer to any of the different types, such as kappa (κ) or lambda (λ), based on the amino acid sequence of the constant domain. Light chain amino acid sequences are well known in the art. In a specific embodiment, the light chain is a human light chain.
[0103] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody.
[0104] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.
[0105] As used herein, the terms "constant region" and "constant domain" are interchangeable and have their common meanings in the art. The constant region is the portion of an antibody, e.g., the carboxyl-terminal portion of a light chain and / or a heavy chain, that is not directly involved in binding the antibody to an antigen but may exhibit various effector functions, such as interactions with Fc receptors. The constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence than the immunoglobulin variable domain.
[0106] "Fc region" (fragment crystallizable region) or "Fc domain" or "Fc" refers to the C-terminal region of the heavy chain of an antibody that mediates the binding of the immunoglobulin to host tissues or factors, including binding to Fc receptors localized on various cells of the immune system (e.g., effector cells) or binding to the first component (C1q) of the classical complement system. Thus, the Fc region includes the constant region of the antibody excluding the first constant region immunoglobulin domain (e.g., CH1 or CL). In IgG, IgA, and IgD antibody isotypes, the Fc region includes two identical protein fragments derived from the second (CH2) and third (CH3) constant domains of the two heavy chains of the antibody; IgM and IgE Fc regions include three heavy chain constant domains (CH domains 2-4) in each polypeptide chain. For IgG, the Fc region includes immunoglobulin domains Cγ2 and Cγ3 and the hinge between Cγ1 and Cγ2. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from the amino acid residue at location C226 or P230 (or the amino acid between these two amino acids) to the carboxyl terminus of the heavy chain, wherein numbering is performed according to the EU index as in Kabat. The CH2 domain of the human IgG Fc region extends from approximately amino acid 231 to approximately amino acid 340, while the CH3 domain is positioned on the C-terminal side of the Cm domain in the Fc region, i.e., it extends from approximately amino acid 341 of IgG to approximately amino acid 447. As used herein, the Fc region can be a native sequence Fc (including any allotypic variants) or a variant Fc (e.g., a non-naturally occurring Fc). Fc can also refer to this region alone or in the context of a protein polypeptide comprising Fc (e.g., a "binding protein comprising an Fc region," also referred to as an "Fc fusion protein" (e.g., an antibody or immunoadhesin)).
[0107] A "native sequence Fc region" or "native sequence Fc" includes an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include a native sequence human IgG1 Fc region; a native sequence human IgG2 Fc region; a native sequence human IgG3 Fc region; and a native sequence human IgG4 Fc region, as well as naturally occurring variants thereof. Native sequence Fc encompasses various allotypes of Fc (see, e.g., Jefferis et al. (2009) mAbs 1:1; Vidarsson G. et al. Front Immunol. 5:520 (published online October 20, 2014).
[0108] "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. The FcRs that bind to IgG antibodies include receptors of the FcγR family, including allelic variants and alternatively spliced forms of these receptors. The FcγR family consists of three activating receptors (FcγRI, FcγRIII, and FcγRIV in mice; FcγRIA, FcγRIIA, and FcγRIIIA in humans) and one inhibitory receptor (FcγRIIB). Human IgG1 binds to most human Fc receptors and elicits the strongest Fc effector functions. Human IgG1 is considered equivalent to murine IgG2a in terms of the type of activating Fc receptor it binds. In contrast, human IgG4 elicits the least Fc effector functions. Vidarsson G. et al., Frontiers in Immunology 5:520 (published online October 20, 2014).
[0109] The constant region can be manipulated, for example, by recombinant technology, to eliminate one or more effector functions. "Effector function" refers to the interaction of an antibody Fc region with an Fc receptor or ligand or the biochemical events resulting therefrom. Exemplary "effector functions" include C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, FcγR-mediated effector functions, such as ADCC and antibody-dependent cell-mediated phagocytosis (ADCP) and down-regulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require a combination of an Fc region and a binding domain (e.g., an antibody variable domain). Therefore, the term "constant region without Fc function" includes a constant region that is reduced or does not have one or more effector functions mediated by the Fc region.
[0110] The effector functions of antibodies can be reduced or avoided by different methods. By using antibody fragments lacking the Fc region (e.g., Fab, F(ab')2, single-chain Fv (scFv) or sdAb consisting of monomeric VH or VL domains), the effector functions of antibodies can be reduced or avoided. Alternatively, the sugars connected to specific residues in the Fc region can be removed to reduce the effector functions of the antibody while retaining other valuable properties of the Fc region (e.g., extended half-life and heterodimerization) to produce so-called aglycosylated antibodies. Antibodies can be produced in cells cultured in the presence of glycosylation inhibitors, for example, by deleting or changing the residues to which sugars are attached, enzymatically removing sugars, or by expressing antibodies in cells that cannot glycosylate proteins (e.g., bacterial host cells). See, for example, U.S. Publication No. 20120100140. Another approach is to use an Fc region from the IgG subclass with reduced effector function, for example, IgG2 and IgG4 antibodies are characterized by having lower levels of Fc effector function than IgG1 and IgG3. The residues closest to the hinge region in the CH2 domain of the Fc portion are responsible for the effector function of the antibody because the Fc portion contains largely overlapping binding sites for C1q (complement) and IgG-Fc receptors (FcγRs) on effector cells of the innate immune system. Vidarsson G. et al., Frontiers in Immunology 5: 520 (published online October 20, 2014). Thus, antibodies with reduced or no Fc effector function can be prepared by generating, for example, a chimeric Fc region comprising a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, or a chimeric Fc region comprising a hinge region from an IgG2 and a CH2 region from an IgG4 (see, e.g., Lau C. et al., J. Immunol. 191: 4769-4777 (2013)), or an Fc region with mutations that result in altered Fc effector function, e.g., reduced or no Fc function. Such Fc regions with mutations are known in the art. See, e.g., U.S. Publication No. 20120100140 and the U.S. and PCT applications cited therein, and An et al., mAbs 1: 6, 572-579 (2009); the disclosures of which are incorporated herein by reference in their entireties.
[0111] "Hinge", "hinge domain" or "hinge region" or "antibody hinge region" refers to the domain of the heavy chain constant region that connects the CH1 domain to the CH2 domain and comprises the upper, middle and lower portions of the hinge (Roux et al., J. Immunol. 1998 161:4083). The hinge provides different levels of flexibility between the binding and effector regions of the antibody and also provides a site for intermolecular disulfide bonding between the two heavy chain constant regions. As used herein, for all IgG isotypes, the hinge begins at Glu216 and ends at Gly237 (Roux et al., 1998 J. Immunol. 161:4083). The sequences of wild-type IgG1, IgG2, IgG3 and IgG4 hinges are known in the art. See, e.g., Kabat EA et al. (1991) Protein Sequences of Immunological Significance, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Vidarsson G. et al., Frontiers in Immunology 5:520 (published online Oct. 20, 2014).
[0112] The term "CH1 domain" refers to the heavy chain constant region that connects the variable domain to the hinge in the heavy chain constant domain. As used herein, the CH1 domain starts at A118 and ends at V215. The term "CH1 domain" includes wild-type CH1 domains and naturally occurring variants thereof (e.g., allotypes). The CH1 domain sequences of IgG1, IgG2, IgG3, and IgG4 (including wild-type and allotypes) are known in the art. See, for example, Kabat EA et al., (1991) supra and Vidarsson G. et al., Frontiers in Immunology 5: 520 (published online on October 20, 2014). Exemplary CH1 domains include CH1 domains with mutations that modify, for example, the biological activity of the antibody described in U.S. Publication No. 20120100140 and the U.S. Patents and publications cited therein, and PCT publications, such as half-life.
[0113] The term "CH2 domain" refers to the heavy chain constant region that connects the hinge to the CH3 domain in the heavy chain constant domain. As used herein, the CH2 domain begins at P238 and ends at K340. The term "CH2 domain" includes wild-type CH2 domains and naturally occurring variants thereof (e.g., allotypes). The CH2 domain sequences of IgG1, IgG2, IgG3, and IgG4 (including wild-type and allotypes) are known in the art. See, for example, Kabat EA et al. (1991) supra and Vidarsson G. et al., Frontiers in Immunology 5: 520 (published online on October 20, 2014). Exemplary CH2 domains include CH2 domains with mutations that modify the biological activity of the antibody described in, for example, U.S. Patents and publications cited therein, and PCT publications, such as half-life and / or reduced Fc effector function.
[0114] The term "CH3 domain" refers to the heavy chain constant region at the C-terminus of the CH2 domain in the heavy chain constant domain. As used herein, the CH3 domain begins at G341 and ends at K447. The term "CH3 domain" includes wild-type CH3 domains and naturally occurring variants thereof (e.g., allotypes). The CH3 domain sequences of IgG1, IgG2, IgG3, and IgG4 (including wild-type and allotypes) are known in the art. See, for example, Kabat EA et al. (1991) supra and Vidarsson G. et al., Frontiers in Immunology 5: 520 (published online on October 20, 2014). Exemplary CH3 domains include CH3 domains with mutations that modify the biological activity, such as half-life, of the antibodies described in, for example, U.S. Patent Publication No. 20120100140 and the U.S. Patents and publications cited therein, and PCT publications.
[0115] As used herein, "isotype" refers to the antibody class encoded by the heavy chain constant region genes (e.g., IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE antibodies).
[0116] "Isotype" refers to naturally occurring variants within a particular isotype group that differ in a few amino acids (see, e.g., Jefferis et al. (2009) mAbs 1:1). The antibodies described herein can be of any allotype. IgG1, IgG2, IgG3, and IgG4 allotypes are known in the art. See, e.g., Kabat EA et al. (1991) supra; Vidarsson G et al., Frontiers in Immunology 5:520 (published online October 20, 2014); and Lefranc MP, mAbs 1:4, 1-7 (2009).
[0117] The phrases "an antibody that recognizes an antigen" and "an antibody specific for an antigen" are used interchangeably herein with the term "an antibody that specifically binds to an antigen."
[0118] As used herein, an "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to FAM19A5 is substantially free of antibodies that specifically bind to antigens other than FAM19A5). However, an isolated antibody that specifically binds to an epitope of FAM19A5 may have cross-reactivity to FAM19A5 proteins from different species.
[0119] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (K D Affinity can be measured and / or expressed in a variety of ways known in the art, including but not limited to the equilibrium dissociation constant (K D ) and the equilibrium association constant (K A ). K D From k off / k on The quotient is calculated and expressed as molar concentration (M), while K A From k on / k off Calculate the quotient of k on refers to the association rate constant of, for example, an antibody to an antigen, and k off Refers to, for example, the dissociation of antibodies and antigens. on and k off The assay can be performed by techniques known to those skilled in the art, such as immunoassays (e.g., enzyme-linked immunosorbent assay (ELISA)), or kinetic exclusion assay (KinExA).
[0120] As used herein, the terms "specifically binds," "specifically recognizes," "specifically binds," "selectively binds," and "selectively binds" are analogous terms in the context of antibodies and refer to molecules (e.g., antibodies) that bind to an antigen (e.g., an epitope or immune complex), as such binding is understood by those skilled in the art. For example, a molecule that specifically binds to an antigen can generally be detected, for example, by immunoassays, The molecule specifically binds to the antigen with a K of at least 2 log, 2.5 log, 3 log, 4 log, or greater than the K of the molecule for binding to another antigen. A .
[0121] Antibodies typically have a dissociation constant (K) of 10-5 to 10-11 M or less. D ) reflects the high affinity of the antigen and its specific binding to the cognate antigen. It is generally believed that any K greater than about 10-4 M D Indicates non-specific binding. As used herein, an antibody that "specifically binds" to an antigen refers to an antibody that binds to the antigen and substantially identical antigens with high affinity, but does not bind to unrelated antigens with high affinity, when determined using a predetermined antigen in a BIACORE 2000 instrument by, for example, an immunoassay (e.g., ELISA) or surface plasmon resonance (SPR) technology, wherein high affinity means a K. D 10-7 M or less, preferably 10-8 M or less, even more preferably 10-9 M or less, and most preferably between 10-8 M and 10-10 M or less.
[0122] As used herein, the term "antigen" refers to any natural or synthetic immunogenic substance, such as a protein, peptide, or hapten. The antigen may be FAM19A5 or a fragment thereof.
[0123] As used herein, " epi-position " is the term of this area and refers to the local region of the antigen that antibody can specifically combine.Epi-position can be the continuous amino acid (linear or continuous epi-position) of such as polypeptide, or epi-position can be that two or more discontinuous regions such as from one or more polypeptide gather together (conformation, non-linear, interrupted or discontinuous epi-position).The epi-position formed by continuous amino acid is usually but not always retained when being exposed to denaturing solvent, and the epi-position formed by tertiary folding is usually lost when being treated with denaturing solvent.In unique spatial conformation, epi-position usually comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20 amino acid.Be well known in the art and comprise such as immunoblotting and immunoprecipitation assay for determining the epi-position that given antibody is combined with (that is, epi-position mapping), wherein tested the reactivity of overlapping or continuous peptide from (for example, from FMAM19A5) and specifying antibody (for example, anti-FAM19A5 antibody). Methods for determining the spatial conformation of epitopes include techniques in the art as well as those described herein, such as x-ray crystallography, 2-dimensional nuclear magnetic resonance, and HDX-MS (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GE Morris, ed. (1996)).
[0124] In certain embodiments, the epitope to which the antibody binds can be determined by, for example, NMR spectroscopy, X-ray crystallography, ELISA assays, hydrogen / deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligopeptide scanning assays, and / or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization can be accomplished using any method known in the art (e.g., Giege R et al. (1994) Acta Crystallogr D Biol Crystallogr 50(Part 4):339-350; McPherson A (1990) Eur J Biochem 189:1-23; Chayen NE (1997) Structure 5:1269-1274; McPherson A (1976) J Biol Chem 251:6300-6303). Antibody: Antigen crystals can be studied using well-known X-ray diffraction techniques and can be modified using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see, for example, Meth Enzymol (1985) Vols. 114 and 115, Wyckoff HW et al., eds.; U.S. 2004 / 0014194); and BUSTER (Bricogne G (1993) Acta Crystallographica Section D - Biological Crystallography 49(Pt 1): 37-60; Bricogne G (1997) Methods Enzymologicala 276A: 361-423, Carter CW ed.; Roversi P et al., (2000) Acta Crystallographica Section D - Biological Crystallography 56(Pt 10): 1316-1323). Mutagenesis mapping studies can be performed using any method known to those skilled in the art. For a description of mutagenesis techniques, including alanine scanning mutagenesis, see, for example, Champe M et al. (1995) J. Biol. Chem. 270: 1388-1394 and Cunningham BC and Wells JA (1989) Science 244: 1081-1085.
[0125] The term "epitope mapping" refers to the process of identifying molecular determinants for antibody-antigen recognition.
[0126] With respect to two or more antibodies, the term "binding to the same epitope" means that the antibody binds to the same segment of amino acid residues, as determined by a given method. The technology used to determine whether an antibody binds to the "same epitope on FAM19A5" with the antibodies described herein includes, for example, epitope mapping methods, such as x-ray analysis of crystals of antigen: antibody complexes at atomic resolution providing epitopes, and hydrogen / deuterium exchange mass spectrometry (HDX-MS). Other methods monitor the binding of antibodies to antigenic fragments or mutations of antigens, in which it is generally believed that the loss of binding due to modification of amino acid residues in the antigen sequence is an indication of epitope components. In addition, a computational combination method for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to affinity separate specific short peptides from a combinatorial phage display peptide library. It is desirable that antibodies with identical VH and VL or identical CDR1, CDR2, and CDR3 sequences bind to the same epitope.
[0127] "An antibody that competes with another antibody to bind to a target" refers to an antibody that inhibits (partially or completely) the binding of another antibody to a target. Known competition experiments can be used to determine whether two antibodies compete with each other to bind to a target, that is, whether and to what extent an antibody inhibits the binding of another antibody to a target. In certain embodiments, an antibody competes with another antibody for binding to a target and inhibits the binding of another antibody to a target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition can be different, depending on which antibody is a "blocking antibody" (i.e., a cold antibody that is first incubated with the target). Competition assays can be performed, for example, as described in: Ed Harlow and David Lane, Cold Spring Harb Protoc; 2006; doi: 10.1101 / Pdb.prot4277 or Chapter 11, "Using Antibodies," eds. Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 1999. Competing antibodies bind to the same epitope, an overlapping epitope, or a neighboring epitope (e.g., as demonstrated by steric hindrance).
[0128] Other competitive binding assays include: solid phase direct or indirect radioimmunoassays (RIA), solid phase direct or indirect enzyme immunoassays (EIA), sandwich competition assays (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid phase direct labeled assays, solid phase direct labeled sandwich assays (see Harlow and Lane, Antibodies: A Laboratory Manual) Manual, Cold Spring Harbor Press (1988); solid phase direct labeled RIA using I-125 labeling (see Morel et al., Mol. Immunol. 25(1):7 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546 (1990)); and direct labeled RIA (Moldenhauer et al., Scand. J. Immunol. 32:77 (1990)).
[0129] The term "single-chain Fv" or "scFv" refers to a single-chain Fv ("fragment variable") antibody in which the variable domains of the heavy and light chains of a traditional two-chain antibody have been joined to form one chain.
[0130] "Bispecific" or "bifunctional antibodies" are artificial hybrid antibodies with two different heavy chain / light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including fusing hybridomas or linking Fab' fragments. See, for example, Songsivilai and Lachmann, Clin. Exp. Immunol. 79:315-321 (1990); Kostelny et al., J. Immunol. 148, 1547-1553 (1992).
[0131] As used herein, the term "monoclonal antibody" refers to an antibody that displays a single binding specificity and affinity for a particular epitope, or an antibody composition in which all antibodies display a single binding specificity and affinity for a particular epitope. Thus, the term "human monoclonal antibody" refers to an antibody or antibody composition that displays a single binding specificity and has variable and optionally constant regions derived from human germline immunoglobulin sequences. In some embodiments, human monoclonal antibodies are produced by hybridomas comprising B cells obtained from a transgenic non-human animal, such as a transgenic mouse, thereby having a genome comprising human heavy and light chain transgenes fused to immortalized cells.
[0132] As used herein, the term "recombinant human antibody" includes all human antibodies prepared, expressed, produced or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that are transgenic or transchromosomal for human immunoglobulin genes or hybridomas prepared therefrom; (b) antibodies isolated from host cells transformed to express the antibody, such as transfectomas; (c) antibodies isolated from recombinant combinatorial human antibody libraries; and (d) antibodies prepared, expressed, produced or isolated by any other means involving splicing of human immunoglobulin gene sequences into other DNA sequences. Such recombinant human antibodies include variable and constant regions that utilize specific human germline immunoglobulin sequences encoded by germline genes, but include subsequent rearrangements and mutations that occur, for example, during antibody maturation. As is known in the art (see, e.g., Lonberg (2005) Nature Biotech. 23(9): 1117-1125), the variable region contains an antigen binding domain that is encoded by various genes that are rearranged to form an antibody specific for a foreign antigen. In addition to rearrangement, the variable region can be further modified by multiple single amino acid changes (referred to as somatic mutations or hypermutations) to increase the affinity of the antibody for the foreign antigen. The constant region will further change in response to the antigen (i.e., isotype switching). Thus, the rearranged and somatically mutated nucleic acid molecules that encode light and heavy chain immunoglobulin polypeptides in response to an antigen will not have sequence identity to the original nucleic acid molecule, but will be substantially identical or similar (i.e., have at least 80% identity).
[0133] "HuMAb" refers to an antibody with a variable region in which both the framework region and the CDR region are derived from human germline immunoglobulin sequences. In addition, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The antibodies described herein may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutations in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which the CDR sequences derived from the germline of another mammalian species such as a mouse have been transplanted onto human framework sequences. The terms "human" antibody and "fully human" antibody are used synonymously.
[0134] "Humanized" antibody refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulin. In some embodiments of the humanized form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulin, while some, most or all of the amino acids in one or more CDR regions are unchanged. Amino acid whose small addition, deletion, insertion, substitution or modification is permissible as long as they do not eliminate the ability of the antibody to bind to a specific antigen. "Humanized" antibody retains an antigenic specificity similar to that of the original antibody.
[0135] A "chimeric antibody" refers to an antibody in which the variable region is derived from one species and the constant region is derived from another species, such as an antibody in which the variable region is derived from a mouse antibody and the constant region is derived from a human antibody.
[0136] As used herein, the term "cross-reactivity" refers to the ability of the antibodies described herein to bind to FAM19A5 from different species. For example, an antibody described herein that binds to human FAM19A5 may also bind to FAM19A5 of another species (e.g., mouse FAM19A5). As used herein, cross-reactivity can be measured by detecting specific reactivity with purified antigen in a binding assay (e.g., SPR, ELISA) or binding to cells that physiologically express FAM19A5 or functionally interacting in other ways. Methods for determining cross-reactivity include standard binding assays as described herein, for example, by using BIACORE TM BIACORE 2000 SPR instrument (Biacore AB, Uppsala, Sweden) TM Surface plasmon resonance (SPR) analysis or flow cytometry techniques.
[0137] The term "naturally occurring" as applied to the objects disclosed herein refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including viruses) that can be isolated from a source in nature and has not been intentionally modified by man in the laboratory is naturally occurring.
[0138] "Polypeptide" refers to a chain of at least two consecutively linked amino acid residues, wherein there is no upper limit to the length of the chain. One or more amino acid residues in a protein may contain modifications such as, but not limited to, glycosylation, phosphorylation, or disulfide bond formation. A "protein" may include one or more polypeptides.
[0139] As used herein, the term "nucleic acid molecule" is intended to encompass DNA molecules and RNA molecules. The nucleic acid molecule can be single-stranded or double-stranded and can be a cDNA.
[0140] As used herein, the term "recombinant host cell" (or simply "host cell") is intended to refer to a cell that includes a nucleic acid that is not naturally present in the cell and may be a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Because certain modifications may occur in subsequent generations due to mutations or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.
[0141] As used herein, the term "linked" refers to the association of two or more molecules. The link can be covalent or non-covalent. The link can also be genetic (i.e., recombinant fusion). Such a link can be achieved using a variety of art-recognized techniques such as chemical conjugation and recombinant protein production.
[0142] II. Adeno-associated virus (AAV) and its derivative vectors
[0143] AAV vector disclosed herein comprises the nucleic acid that protein of interest, for example FAM19A5 antagonist, for example anti-FAM19A5 antibody is encoded.In certain embodiments, nucleic acid can also comprise one or more regulating sequences, and described one or more regulating sequences allow expression and secrete the protein of interest in some embodiments, for example promoter, enhancer, polyadenylation signal, internal ribosome entry site (IRES), sequence etc. that protein transduction domain (PTD) is encoded.Therefore, in certain embodiments, nucleic acid can comprise the promoter region operably connected with coding sequence, to cause or improve the expression of protein of interest in infected cell.Such promoter can be ubiquitous, cell or tissue-specific, strong, weak, regulatory, mosaic etc., for example, to allow in infected tissue to efficiently and stably produce protein.Although the promoter used in the disclosed method is functional usually in human cell, promoter can be with protein homology or heterology through encoding. Examples of regulatable promoters include, but are not limited to, promoters containing Tet on / off elements, rapamycin-inducible promoters, tamoxifen-inducible promoters, and metallothionein promoters. Other promoters that can be used include promoters that are tissue-specific for tissues such as the kidney, spleen, pancreas, brain, or spinal cord. Examples of ubiquitous promoters include viral promoters, particularly CMV promoter, RSV promoter, SV40 promoter, and the like, as well as cellular promoters such as PGK (phosphoglycerate kinase) promoter and β-actin promoter.
[0144] In some embodiments of the AAV vectors disclosed herein, one or more feedback elements can be used to reduce overexpression of a protein of interest. For example, some embodiments of the AAV vectors comprise one or more siRNA sequences that will target exogenous transcripts. In other embodiments, the AAV vectors comprise one or more additional promoters that can be recognized by inhibitory transcription factors. In various embodiments, the AAV vectors disclosed herein include constructs that can generate a homeostatic feedback loop that can maintain the expression level of a protein of interest at physiological levels.
[0145] In some embodiments, the AAV vectors disclosed herein include nucleic acids comprising a leader sequence (or signal peptide) that permits secretion of the encoded protein. In some embodiments, fusion of a transgene of interest with a sequence encoding a secretion signal peptide (typically located at the N-terminus of the secreted polypeptide) allows for the production of a therapeutic protein in a form that can be secreted from the transduced cells. Non-limiting examples of such signal peptides include human β-globulin, albumin, β-glucuronidase, alkaline protease, or fibronectin secretory signal peptides.
[0146] In some embodiments, the mRNA expressed from the AAV vectors of the present disclosure includes a miRNA binding site for a miRNA that is preferentially expressed in non-CNS tissues. In certain embodiments, the miRNA binding site is a binding site for miR-122. In certain embodiments, the miRNA binding site is a binding site for miR-1. In some embodiments, the mRNA expressed from a CNS-related gene does not include a miRNA binding site for a miRNA that is preferentially expressed in CNS tissues.
[0147] AAV, a member of the Parvoviridae family, is a small, nonenveloped, icosahedral virus with a single-stranded, linear DNA genome of 4.7 kilobases (kb) to 6 kb. M., Virol J 2:43 (2005). This family can be divided into two subfamilies: the Parvovirinae, which infect vertebrates, and the Parvovirinae, which infect insects. Members of the Parvovirinae are referred to herein as Parvoviruses and include the genus Dependovirus. As can be inferred from their genus name, members of the Dependovirus are unique in that they typically require co-infection with a helper virus, such as adenovirus or herpesvirus, for productive infection in cell culture. The Dependovirus genus includes AAVs that typically infect humans (e.g., serotypes 1, 2, 3A, 3B, 4, 5, and 6) or primates (e.g., serotypes 1 and 4), as well as related viruses that infect other warm-blooded animals (e.g., bovine, canine, equine, and ovine adeno-associated viruses). Further information on parvoviruses and other members of the Parvoviridae family is described in Kenneth I. Berns, "Parvoviridae: The Viruses and Their Replication," Fields Virology, Chapter 69 (3rd ed. 1996).
[0148] Replication, encapsidation, and assembly of AAV genes
[0149] The single-stranded genome of AAV consists of three genes: rep (replication), cap (capsid), and aap (assembly). These three genes generate at least nine gene products through the use of three promoters, alternative translation start sites, and differential splicing.
[0150] The rep gene encodes four proteins (Rep78, Rep68, Rep52, and Rep40) required for viral genome replication and packaging. Expression of the cap gene produces viral capsid proteins (VP1, VP2, VP3), which form the capsid shell that protects the viral genome and actively participates in cell binding and internalization. It is estimated that the viral coat contains 60 proteins arranged in an icosahedral structure. The aap gene encodes the assembly activation protein (AAP) in an alternative reading frame overlapping with the cap gene. This nucleoprotein is believed to provide a scaffolding function for capsid assembly and plays a role in the nucleolar localization of the VP protein of some AAV serotypes.
[0151] In some embodiments, the AAV vector disclosed herein is a recombinant AAV and lacks one or more of the rep gene, cap gene, and aap gene. In some embodiments, rAAV is modified so that one or more of the rep gene, cap gene, and aap gene mutate, thereby modifying the expression of one or more of the AAV genes. In some embodiments, one or more of the rep gene, cap gene, or aap gene are naturally occurring, such as the rep gene, cap gene, or app gene, including all or part of the parvovirus rep gene, cap gene, or aap gene. In some embodiments, one or more of the rep gene, cap gene, or aap gene include synthetic sequences.
[0152] It should be understood that the specific AAV genomes described herein can have genes from different AAV genomes, e.g., genomes from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11. Thus, disclosed herein are AAV vectors comprising any possible arrangement of rep, cap, or aap.
[0153] Inverted terminal repeats
[0154] Certain aspects of the present disclosure relate to nucleic acid molecules comprising a first ITR, eg, a 5' ITR, and a second ITR, eg, a 3' ITR. In some embodiments, the ITR comprises a naturally occurring, eg, ITR comprises all or a portion of a parvoviral ITR. In some embodiments, the ITR comprises a synthetic sequence.
[0155] In some embodiments, the ITR includes an ITR from the AAV genome. In some embodiments, the ITR is an ITR selected from the following AAV genomes: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and any combination thereof. In certain embodiments, the ITR is an ITR of the AAV8 or AAV9 genome. In other embodiments, the ITR is a synthetic sequence that has been genetically engineered to include one or more ITRs derived from the AAV genome at its 5' end and 3' end. In some embodiments, the ITR is derived from the same genome (e.g., a genome derived from the same virus) or from different genomes (e.g., a genome derived from two or more different AAV genomes). In certain embodiments, the ITR is derived from the same AAV genome. In other embodiments, the two ITRs present in the nucleic acid molecules of the present disclosure are identical and can specifically be AAV2 ITRs. In some embodiments, the first ITR and the second ITR are identical.
[0156] In some embodiments, the ITR is a synthetic sequence that has been genetically engineered to include an ITR at its 5' and 3' ends that is not derived from the AAV genome. In some embodiments, the ITR sequence includes one or more palindromic sequences. The palindromic sequences of the ITRs disclosed herein include, but are not limited to, natural palindromic sequences (i.e., sequences found in nature), synthetic sequences such as pseudo palindromic sequences (i.e., sequences not found in nature), and combinations or modified forms thereof. A "pseudo palindromic sequence" is a palindromic DNA sequence comprising an imperfect palindromic sequence that shares less than 80% (including less than 70%, 60%, 50%, 40%, 30%, 20%, 10% or 5%) nucleic acid sequence identity or no nucleic acid sequence identity with a sequence in a natural AAV palindromic sequence that forms a secondary structure. A natural palindromic sequence can be obtained from or derived from any genome disclosed herein. A synthetic palindromic sequence can be based on any genome disclosed herein. A palindromic sequence can be continuous or interrupted. In some embodiments, the palindromic sequence is interrupted, wherein the palindromic sequence includes an insertion of a second sequence. In some embodiments, the second sequence comprises a promoter, an enhancer, an integration site for an integrase (eg, a site for Cre or Flp recombinase), an open reading frame for a gene product, or a combination thereof.
[0157] In some embodiments, the ITRs form a hairpin loop structure. In one embodiment, the first ITR forms a hairpin structure. In another embodiment, the second ITR forms a hairpin structure. In yet another embodiment, both the first ITR and the second ITR form a hairpin structure.
[0158] In some embodiments, the ITR in the nucleic acid molecules described herein can be a transcriptionally activated ITR. A transcriptionally activated ITR can include all or a portion of a wild-type ITR that has been transcriptionally activated by comprising at least one transcriptionally activated element. Various types of transcriptionally activated elements are suitable for use in this context. In some embodiments, the transcriptionally activated element is a constitutive transcriptionally activated element. Constitutive transcriptionally activated elements provide a continuous level of gene transcription and are preferred when it is desired to express a transgene on a continuous basis. In other embodiments, the transcriptionally activated element is an inducible transcriptionally activated element. Inducible transcriptionally activated elements typically exhibit low activity in the absence of an inducer (or inducing conditions) and are upregulated in the presence of an inducer (or when converted to inducing conditions). Inducible transcriptionally activated elements may be preferred when expression is desired only at certain times or locations, or when it is desired to titrate expression levels using an inducer. Transcriptionally activated elements can also be tissue-specific; that is, they exhibit activity only in certain tissues or cell types.
[0159] Transcriptionally active elements can be incorporated into ITRs in a variety of ways. In certain embodiments, a transcriptionally active element is incorporated into any part of an ITR at 5' or into any part of an ITR at 3'. In other embodiments, the transcriptionally active element of a transcriptionally active ITR is located between two ITR sequences. If a transcriptionally active element comprises two or more elements that must be spaced apart, those elements can alternate with each part of an ITR. In certain embodiments, the hairpin structure of an ITR is missing and replaced with an inverted repeat of a transcriptionally active element. The latter arrangement will produce a hairpin that mimics the missing part in the structure. Multiple serially connected transcriptionally active elements can also be present in the transcriptionally active ITR, and these elements can be adjacent or spaced apart. In addition, a protein binding site (e.g., a Rep binding site) can be introduced into the transcriptionally active element of a transcriptionally active ITR. A transcriptionally active element can comprise any sequence of RNA formed by RNA polymerase to achieve controlled transcription of DNA and can comprise, for example, a transcriptionally active element as defined below.
[0160] The ITR of transcriptional activation provides both transcriptional activation function and ITR function to the nucleic acid molecule with a relatively limited nucleotide sequence length, which effectively maximizes the length of the transgene that can be carried and expressed from the nucleic acid molecule. The incorporation of transcriptional activation elements into the ITR can be accomplished in a variety of ways. Comparison of the sequence requirements of the ITR sequence and the transcriptional activation element can provide an understanding of the mode for encoding the element within the ITR. For example, transcriptional activity can be added to the ITR by introducing specific changes in the ITR sequence of the functional element that replicates the transcriptional activation element. There are various techniques in the art to efficiently add, delete and / or change the specific nucleotide sequence at the specific site (see, for example, Deng and Nickoloff (1992) "Analytical Biochemistry (Anal.Biochem.)" 200: 81-88). Another method for producing the ITR of transcriptional activation involves introducing restriction sites at the desired position in the ITR. In addition, multiple transcriptional activation elements can be incorporated into the ITR of transcriptional activation using methods known in the art.
[0161] By way of illustration, a transcriptionally active ITR can be generated by including one or more transcriptionally active elements such as a TATA box, a GC box, a CCAAT box, an Sp1 site, an Inr region, a CRE (cAMP regulatory element) site, an ATF-1 / CRE site, an APBβ box, an APBα box, a CArG box, a CCAC box, or any other element involved in transcription as known in the art.
[0162] FAM19A5 antagonists
[0163] The AAV vectors of the present disclosure include nucleic acids encoding one or more antagonists of the FAM19A5 protein. In some embodiments, the FAM19A5 antagonist is an antibody or antigen-binding fragment thereof that specifically binds to the FAM19A5 protein. In some embodiments, the anti-FAM19A5 antibody comprises Fab, Fab', F(ab')2, Fv, or single-chain Fv (scFv). In certain embodiments, the anti-FAM19A5 antibody is an scFv.
[0164] In some embodiments, the anti-FAM19A5 antibodies (e.g., anti-FAM19A5 scFv) expressed by the AAV vectors of the present disclosure are characterized by specific functional features or properties. For example, the antibodies specifically bind to human FAM19A5, including soluble FAM19A5 and membrane-bound FAM19A5. In addition to specifically binding to soluble and / or membrane-bound human FAM19A5, the antibodies described herein also exhibit one or more of the following functional properties:
[0165] (a) reduce, reverse and / or prevent fibrosis;
[0166] (b) reduce the formation of excess extracellular matrix (ECM);
[0167] (c) delaying tumor growth or progression;
[0168] (d) with a K of 10 nM or less as measured by enzyme-linked immunosorbent assay (ELISA) D Binds to soluble human FAM19A5;
[0169] (e) As measured by ELISA, with a K of 10 nM or less D Binds to membrane-bound human FAM19A5;
[0170] (f) reducing, reversing, delaying and / or preventing the onset of reactive gliosis;
[0171] (g) inhibiting the excessive proliferation of reactive astrocytes;
[0172] (h) reducing the expression of chondroitin sulfate proteoglycans, including neurocan and neuron-glial antigen 2 (NG2);
[0173] (i) Increased expression of c-fos and pERK in the nuclei of neurons;
[0174] (j) promoting neuronal survival;
[0175] (k) increasing the expression of GAP43 in neurons; and
[0176] (l) Promote axonal regrowth.
[0177] In some embodiments, an anti-FAM19A5 antibody (e.g., scFv) specifically binds to soluble human FAM19A5 or membrane-bound human FAM19A5 with high affinity, e.g., wherein K D is 10 -7 M or smaller, 10 -8 M or smaller, 10 -9 M (1nM) or less, 10 -10 M (0.1nM) or less, 10 -11 M or smaller or 10 -12 M or smaller, such as 10 -12 M to 10 -7 M, 10 -11 M to 10 -7 M, 10 -10 M to 10 -7 M or 10 -9 M to 10 -7 M, for example 10 -12 M, 5×10 -12 M, 10-11 M, 5×10 -11 M, 10 -10 M, 5×10 -10 M, 10 -9 M, 5×10 -9 M, 10 -8 M, 5×10 -8 M, 10 -7 M or 5×10 -7 M. Standard assays for evaluating the ability of antibodies to bind to human FAM19A5 of various species are known in the art and include, for example, ELISA, Western blot, and RIA. The binding kinetics (e.g., binding affinity) of the antibody can also be evaluated by standard assays known in the art, such as by ELISA, BIACORE™ analysis, or
[0178] In some embodiments, anti-FAM19A5 antibodies (e.g., scFv) are expressed at the following K values as determined by ELISA: D Binding to soluble human FAM19A5: 10 -7 M or smaller, 10 -8 M (10nM) or less, 10 -9 M (1nM) or less, 10 -10 M or smaller, 10 -12 M to 10 -7 M, 10 -11 M to 10 -7 M, 10 -10 M to 10 -7 M, 10 -9 M to 10 -7 M or 10 -8 M to 10 -7 In some embodiments, the anti-FAM19A5 antibody (e.g., scFv) has a K of 10 nM or less, e.g., between 0.1 and 10 nM, between 0.1 and 5 nM, between 0.1 and 1 nM, between 0.5 and 10 nM, between 0.5 and 5 nM, between 0.5 and 1 nM, between 1 and 10 nM, between 1 and 5 nM, or between 5 and 10 nM. D In some embodiments, the anti-FAM19A5 antibody (e.g., scFv) binds to soluble FAM19A5 with a K of DSpecifically binds to soluble human FAM19A5 at about 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 200 pM, 300 pM, 400 pM, 500 pM, 600 pM, 700 pM, 800 pM, or 900 pM or about 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, or 9 nM or about 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM.
[0179] In some embodiments, an anti-FAM19A5 antibody (e.g., scFv) is expressed at a K of, for example, as determined by ELISA: D Binding to membrane-bound humans: 10 -7 M or smaller, 10 -8 M (10nM) or less, 10 -9 M (1nM) or less, 10 -10 M or smaller, 10 -12 M to 10 -7 M, 10 -11 M to 10 -7 M, 10 -10 M to 10 -7 M, 10 -9 M to 10 -7 M or 10 -8 M to 10 -7 In certain embodiments, an anti-FAM19A5 antibody (e.g., scFv) is expressed at a K of DSpecifically binds to membrane-bound human FAM19A5 at a KD of about 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 10 pM, 20 pM, In some embodiments, the present invention relates to a pharmaceutical composition comprising: a) a monolayer, ...
[0180] In some embodiments, an anti-FAM19A5 antibody (eg, scFv) suitable for the methods disclosed herein cross-competes for binding to (or inhibits binding to) a human FAM19A5 epitope with an anti-FAM19A5 antibody comprising a CDR or variable region disclosed herein.
[0181] In some embodiments, an anti-FAM19A5 antibody (e.g., scFv) inhibits binding of a reference antibody comprising a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1, CDR2, and CDR3 of the reference antibody comprise the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, respectively, and the light chain CDR1, CDR2, and CDR3 of the reference antibody comprise the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively; (ii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: NO: 28; (iii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 18, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 31; (iv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 20, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 21, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 22, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 32, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 33, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 34; (v) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 2 NO:89, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:90, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:91, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:92, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:93, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:94;(vi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 100; (vii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 102, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 106; (viii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 106 NO: 107, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 108, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 112; (ix) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 114, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 115, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 118; (x) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 120 NO: 120, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 121, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 124;(xi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 130; (xii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 131, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 136; (xiii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 1 NO: 137, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 138, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 142; (xiv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 144, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 148;or (xv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 150, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 151, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 154. In some embodiments, the heavy chain CDR1, CDR2, and CDR3 of the reference antibody comprise the CDR1, CDR2, and CDR3 sequences, respectively, as shown in Table 2, and the light chain CDR1, CDR2, and CDR3 of the reference antibody comprise the CDR1, CDR2, and CDR3 sequences, respectively, as shown in Table 3.;
[0182] In some embodiments, the reference antibody comprises (a) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 35 and 39, respectively; (b) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 36 and 40, respectively; (c) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 37 and 41, respectively; (d) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 38 and 42, respectively; (e) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 155 and 166, respectively; (f) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 156 and 167, respectively; (g) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 157 and 168, respectively; (h) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 158 and 169, respectively; (i) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 159 and 160, respectively. NOs: 159 and 170; (i) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 160 and 171, respectively; (k) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 161 and 172, respectively; (l) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 162 and 173, respectively; (m) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 163 and 174, respectively; (n) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 164 and 175, respectively; or (o) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 165 and 176, respectively. In some embodiments, the reference antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence set forth in Table 4, and the VL comprises the amino acid sequence set forth in Table 5.
[0183] In some embodiments, the anti-FAM19A5 antibody (e.g., scFv) inhibits the binding of such a reference antibody to human FAM19A5 by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. Competing antibodies bind to the same epitope, overlapping epitopes, or adjacent epitopes (e.g., as demonstrated by steric hindrance). Competition assays known in the art, such as RIAs and EIAs, can be used to determine whether two antibodies compete with each other for binding to a target.
[0184] In some embodiments, the anti-FAM19A5 antibody (e.g., scFv) binds to the same FAM19A5 epitope as a reference antibody disclosed herein comprising a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 11, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 12, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 23, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 25; or (ii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 17. NO: 26, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 28; (iii) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 18, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 31; (iv) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 20, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 21, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 22, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 32, and the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: NO:33, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:34;(v) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 90, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 91, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 92, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 93, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 94; (vi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 100; (vii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: NO: 102, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 106; (viii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 107, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 108, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 112; (ix) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 114, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 115. NO: 115, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 118;(x) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 120, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 121, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 124; (xi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 130; (xii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 131 NO: 131, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 136; (xiii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 137, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 138, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 142; (xi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 144, NO: 144, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 148;or (xv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 150, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 151, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 154. In some embodiments, the heavy chain CDR1, CDR2, and CDR3 of the reference antibody comprise the CDR1, CDR2, and CDR3 sequences, respectively, as shown in Table 2, and the light chain CDR1, CDR2, and CDR3 of the reference antibody comprise the CDR1, CDR2, and CDR3 sequences, respectively, as shown in Table 3.;
[0185] In some embodiments, the reference antibody comprises (a) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 35 and 39, respectively; (b) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 36 and 40, respectively; (c) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 37 and 41, respectively; (d) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 38 and 42, respectively; (e) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 155 and 166, respectively; (f) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 156 and 167, respectively; (g) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 157 and 168, respectively; (h) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 158 and 169, respectively; (i) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 159 and 160, respectively. NOs: 159 and 170; (j) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 160 and 171, respectively; (k) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 161 and 172, respectively; (l) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 162 and 173, respectively; (m) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 163 and 174, respectively; (n) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 164 and 175, respectively; or (o) heavy chain variable region sequences and light chain variable region sequences comprising SEQ ID NOs: 165 and 176, respectively. In some embodiments, the reference antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence set forth in Table 4, and the VL comprises the amino acid sequence set forth in Table 5.
[0186] Techniques for determining whether two antibodies bind to the same epitope include, for example, epitope mapping methods, such as x-ray analysis and hydrogen / deuterium exchange mass spectrometry (HDX-MS) of antigen:antibody complexes that provide atomic resolution of the epitope; methods that monitor the binding of antibodies to antigenic fragments or mutational variants of the antigen, where loss of binding due to modification of amino acid residues within the antigen sequence is generally considered indicative of epitope composition; and computational combinatorial methods for epitope mapping.
[0187] Anti-FAM19A5 antibodies (e.g., scFv) useful in the methods disclosed herein can bind to at least one epitope of mature human FAM19A5, as determined, for example, by binding the antibody to a fragment of human FAM19A5. In some embodiments, the anti-FAM19A5 antibody binds to a fragment located within the amino acid sequence of TLDRDSSQPRRTIARQTARC (SEQ ID NO: 6 or amino acid residues 42 to 61 of SEQ ID NO: 2) (e.g., an epitope having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of SEQ ID NO: 6). In some embodiments, the anti-FAM19A5 antibody binds to SEQ ID NO: 6 at one or more amino acids corresponding to amino acid residues 46 to 51 (i.e., DSSQPR), e.g., amino acid residues 46, 50, and 52 (i.e., D---PR), e.g., amino acid residues 46, 47, 48, and 50 (i.e., DSS-P) of SEQ ID NO: 2. In some embodiments, the anti-FAM19A5 antibody binds to a fragment (e.g., an epitope having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids) located within the amino acid sequence of CDMLPCLEGEGCDLLINRSG (SEQ ID NO: 9 or amino acids 90 to 109 of SEQ ID NO: 2). In certain embodiments, an anti-FAM19A5 antibody binds to SEQ ID NO: 9 at one or more amino acid residues 99 to 107 of SEQ ID NO: 4 (i.e., EGCDLLINR), e.g., amino acid residues 102, 103, 105, and 107 (i.e., DL-IR), e.g., amino acid residues 99, 100, 102, 103, 105, and 107 (i.e., EG-DL-IR), e.g., amino acid residues 99, 100, and 107 (i.e., EG------R).
[0188] In some embodiments, the amino acid sequence of the at least one epitope is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 6. In some embodiments, the amino acid sequence of the at least one epitope is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 9.
[0189] In some embodiments, the anti-FAM19A5 antibody (e.g., scFv) binds only to a human FAM19A5 epitope that is SEQ ID NO: 5, 6, 7, 8, 9 or 10, or a fragment located within the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 9 or 10 (e.g., an epitope having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids of SEQ ID NO: 5, 6, 7, 8, 9 or 10).
[0190] In some embodiments, the anti-FAM19A5 antibodies of the present disclosure bind to SEQ ID NO: 6 or a fragment thereof in its native conformation (i.e., undenatured). In some embodiments, the anti-FAM19A5 antibodies bind to SEQ ID NO: 9 or a fragment thereof in its native conformation (i.e., undenatured). In some embodiments, the anti-FAM19A5 antibodies bind to both glycosylated and unglycosylated human FAM19A5.
[0191] In some embodiments, the anti-FAM19A5 antibody (e.g., scFv) further binds to one or more additional FAM19A5 epitopes. Thus, certain anti-FAM19A5 antibodies bind to (i) the epitope of SEQ ID NO: 6 and an additional epitope or (ii) the epitope of SEQ ID NO: 9 and an additional epitope. Other anti-FAM19A5 antibodies can bind to the epitope of SEQ ID NO: 5, the epitope of SEQ ID NO: 9, and an additional epitope. In some embodiments, the anti-FAM19A5 antibody binds to the epitope of SEQ ID NO: 6, the epitope of SEQ ID NO: 10, and an additional epitope.
[0192] In some embodiments, the one or more additional FAM19A5 epitopes are selected from QLAAGTCEIVTLDR (SEQ ID NO: 5, epitope F1), TLDRDSSQPRRTIARQTARC (SEQ ID NO: 6, epitope F2), TARCACRKGQIAGTTRARPA (SEQ ID NO: 7, epitope F3), ARPACVDARIIKTKQWCDML (SEQ ID NO: 8, epitope F4), CDMLPCLEGEGCDLLINRSG (SEQ ID NO: 9, epitope F5) or NRSGWTCTQPGGRIKTTTVS (SEQ ID NO: 10, epitope F6), or fragments thereof located within the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10, or any combination thereof. Fragments located within the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10 include fragments having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids of any one of SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10. In some embodiments, the one or more additional FAM19A5 epitopes are selected from SEQ ID NO: 5, 6, 7, 8, 9 or 10 or fragments located within the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 9 or 10 (e.g., fragments having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids of SEQ ID NO: 5, 6, 7, 8, 9 or 10), or any combination thereof. In some embodiments, the anti-FAM19A5 antibodies of the present disclosure bind to any of the one or more additional epitopes in their native conformation (i.e., undenatured). In some embodiments, the anti-FAM19A5 antibodies bind to both glycosylated and non-glycosylated epitopes of the one or more additional FAM19A5 epitopes.
[0193] In some embodiments, the anti-FAM19A5 antibodies (e.g., scFvs) of the present disclosure bind to at least one FAM19A5 epitope identified as EP2, EP4, and / or EP8, wherein EP2 comprises, consists essentially of, or consists of the amino acids DSSQP (SEQ ID NO: 66), wherein EP4 comprises, consists essentially of, or consists of the amino acids ARCACRK (SEQ ID NO: 68), and wherein EP8 comprises, consists essentially of, or consists of the amino acids TCTQPGGR (SEQ ID NO: 72). In some embodiments, the amino acid sequence of the at least one epitope is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to EP2, EP4, or EP8. In some embodiments, the anti-FAM19A5 antibodies bind only to EP2. In some embodiments, the anti-FAM19A5 antibodies bind to both EP4 and EP8.
[0194] In some embodiments, the anti-FAM19A5 antibody binds to at least one FAM19A5 epitope identified as EP6, EP7, or EP8, wherein EP6 comprises the amino acids KTKQWCDML (SEQ ID NO: 70), wherein EP7 comprises the amino acids GCDLLINR (SEQ ID NO: 71), and wherein EP8 comprises the amino acids TCTQPGGR (SEQ ID NO: 72). In some embodiments, the amino acid sequence of the at least one epitope is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to EP6, EP7, or EP8. In some embodiments, the anti-FAM19A5 antibody binds only to EP6, EP7, or EP8. In some embodiments, the anti-FAM19A5 antibody binds to EP6, EP7, and EP8. In some embodiments, the anti-FAM19A5 antibody binds to EP7 and EP8. In some embodiments, the anti-FAM19A5 antibody binds to EP7.
[0195] In some embodiments, the anti-FAM19A5 antibody binds to one or more FAM19A5 epitopes selected from the group consisting of SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, and any combination thereof.
[0196] In some embodiments, provided herein are antibodies that bind to FAM19A5 (e.g., people FAM19A5) with an affinity higher than that of another protein in the FAM19A family as measured by, for example, immunoassay (e.g., ELISA), surface plasmon resonance, or kinetic exclusion assays. In a specific embodiment, provided herein are antibodies that bind to FAM19A5 (e.g., people FAM19A5) without cross-reactivity as measured by, for example, immunoassays, surface plasmon resonance, or kinetic exclusion assays.
[0197] In some embodiments, the anti-FAM19A5 antibody is not a natural antibody or is not a naturally occurring antibody. For example, the anti-FAM19A5 antibody has a post-translational modification that is different from the post-translational modification of a naturally occurring antibody, such as by having more, fewer, or different types of post-translational modifications.
[0198] Exemplary anti-FAM19A5 antibodies
[0199] Specific antibodies that can be expressed by the AAV vectors disclosed herein are antibodies (e.g., scFv) having CDR and / or variable region sequences of anti-FAM19A5 antibodies 1-65, 3-2, and 2-13, and antibodies having at least 80% identity (e.g., at least 85%, at least 90%, at least 95%, or at least 99% identity) to their variable region sequences or CDR sequences. See U.S. Patent No. 9,579,398; International Application No. PCT / IB2017 / 001490. Tables 2 and 3 provide exemplary heavy chain and light chain CDR sequences, respectively. The CDRs of the following antibodies were identified using the Kabat numbering scheme (see above): 1-65, 3-2, 2-13, 1-28, P2-C12, 13B4, 13F7, 15A9, P1-A03, P1-A08, P1-F02, P2-A01, P2-A03, P2-F07, P2-F11, SS01-13, SS01-13-s5, and S5-2.GKNG. The CDRs of the following antibodies were identified using the IMGT numbering system (see above): 1-7A-IT, Low-PI, 1-30, 1-17, 1-32, 4-11, 6-10, 2-13D, 2-13D-37, 2-13D-37-1.5W-41, and 2-13D-37-3W-16. The VH and VL amino acid sequences of various anti-FAM19A5 antibodies of the present disclosure are provided in Tables 4 and 5, respectively.
[0200] Table 2. Variable heavy chain CDR amino acid sequences
[0201]
[0202]
[0203]
[0204] Table 3 Variable light chain CDR amino acid sequences
[0205]
[0206]
[0207] Table 4: Variable heavy chain amino acid sequences
[0208]
[0209]
[0210]
[0211] Table 5: Variable light chain amino acid sequences
[0212]
[0213]
[0214]
[0215] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 35-38, 155-165 or 232-240 (see Table 4). In other embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region CDR selected from the group consisting of SEQ ID NO: 35-38, 155-165 or 232-240 (see Table 4).
[0216] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39-42, 166-176 or 241-250 (see Table 5). In other embodiments, the anti-FAM19A5 antibody comprises a light chain variable region CDR selected from the group consisting of SEQ ID NO: 39-42, 166-176 or 241-250 (see Table 5).
[0217] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region CDR selected from the group consisting of SEQ ID NOs: 35-38, 155-165, or 232-240 (see Table 4) and a light chain variable region CDR selected from the group consisting of SEQ ID NOs: 39-42, 166-176, or 241-250 (see Table 5).
[0218] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, (i) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 37 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 41; (ii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 40; (iii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 35 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39; (iv) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 38 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 42; (v) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 155 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 166; (vi) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 156 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 167; (vii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: (viii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 158 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 169; (ix) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 159 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 170; (x) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 160 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 171; (xi) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 161 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 172; (xii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 162 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 173; (xiii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 163 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 174. NO:174; (xiv) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:164 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:175;and (xv) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 165 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 176; in some embodiments, the isolated anti-FAM19A5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the VH sequence shown in Table 4, and the VL comprises the VL sequence shown in Table 5.;
[0219] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence shown in SEQ ID NO: 35-38, 155-165, or 232-240 (see Table 4).
[0220] In some embodiments, the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence shown in SEQ ID NO: 39-42, 166-176, or 241-250 (see Table 5).
[0221] In some embodiments, an anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence shown in SEQ ID NO: 35-38, 155-165, or 232-240 (see Table 4), and wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence shown in SEQ ID NO: 39-42, 166-176, or 241-250 (see Table 5).
[0222] In some embodiments, the anti-FAM19A5 antibody comprises:
[0223] (a) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 35 and 39, respectively;
[0224] (b) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 36 and 40, respectively;
[0225] (c) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 37 and 41, respectively;
[0226] (d) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 38 and 42, respectively;
[0227] (e) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 155 and 166, respectively;
[0228] (f) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 156 and 167, respectively;
[0229] (g) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 157 and 168, respectively;
[0230] (h) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 158 and 169, respectively;
[0231] (i) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 159 and 170, respectively;
[0232] (j) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 160 and 171, respectively;
[0233] (k) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 161 and 172, respectively;
[0234] (1) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 162 and 173, respectively;
[0235] (m) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 163 and 174, respectively;
[0236] (n) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 164 and 175, respectively;
[0237] (o) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 165 and 176, respectively;
[0238] (p) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 232 and 241, respectively;
[0239] (q) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 233 and 242, respectively;
[0240] (r) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 234 and 242, respectively;
[0241] (s) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 235 and 243, respectively;
[0242] (t) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 236 and 244, respectively;
[0243] (u) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 236 and 245, respectively;
[0244] (v) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 236 and 246, respectively;
[0245] (w) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 236 and 247, respectively;
[0246] (x) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 236 and 248, respectively;
[0247] (v) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 236 and 249, respectively;
[0248] (z) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 237 and 250, respectively;
[0249] (aa) comprising the heavy chain variable region sequence and light chain variable region sequence of SEQ ID NOs: 238 and 250, respectively;
[0250] (bb) a heavy chain variable region sequence and a light chain variable region sequence comprising SEQ ID NOs: 239 and 250, respectively; or
[0251] (cc) includes the heavy chain variable region sequence and light chain variable region sequence of SEQ ID NOs: 240 and 250, respectively.
[0252] In certain embodiments, the anti-FAM19A5 antibody comprises (i) a heavy chain CDR1, CDR2, and CDR3 of 1-65 or a combination thereof and / or a light chain CDR1, CDR2, and CDR3 of 1-65 or a combination thereof; (ii) a heavy chain CDR1, CDR2, and CDR3 of 3-2 or a combination thereof and / or a light chain CDR1, CDR2, and CDR3 of 3-2 or any combination thereof; (iii) a heavy chain CDR1, CDR2, and CDR3 of 2-13 or a combination thereof and / or a light chain CDR1, CDR2, and CDR3 of 2-13 or any combination thereof; (iv) a heavy chain CDR1, CDR2, and CDR3 of 1-28 or a combination thereof and / or a light chain CDR1, CDR2, and CDR3 of 1-28. 1, CDR2 and CDR3 or any combination thereof; (v) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of P2-C12 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of P2-C12; (vi) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 13B4 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of 13B4; (vii) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 13F7 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of 13F7; (viii) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 15A9 and / or 15 (ix) the heavy chain CDR1, CDR2, and CDR3 of P1-A03 or their combination and / or the light chain CDR1, CDR2, and CDR3 of P1-A03 or their combination; (x) the heavy chain CDR1, CDR2, and CDR3 of P1-A08 or their combination and / or the light chain CDR1, CDR2, and CDR3 of P1-A08 or their combination; (xi) the heavy chain CDR1, CDR2, and CDR3 of P1-F02 or their combination and / or the light chain CDR1, CDR2, and CDR3 of P1-F02 or their combination; (xii) the heavy chain CDR1, CDR2, and CDR3 of P2-A01 or their combination; (xiii) the heavy chain CDR1, CDR2, and CDR3 of P2-A03 or a combination thereof and / or the light chain CDR1, CDR2, and CDR3 of P2-A03 or any combination thereof; (xiv) the heavy chain CDR1, CDR2, and CDR3 of P2-F07 or a combination thereof and / or the light chain CDR1, CDR2, and CDR3 of P2-F07 or any combination thereof; (xv) the heavy chain CDR1, CDR2, and CDR3 of P2-F11 or a combination thereof and / or the light chain CDR1, CDR2, and CDR3 of P2-F11 or any combination thereof;(xvi) the heavy chain CDR1, CDR2 and CDR3 or a combination thereof of SS01-13 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of SS01-13; (xvii) the heavy chain CDR1, CDR2 and CDR3 or a combination thereof of SS01-13-s5 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of SS01-13-s5; (xviii) the heavy chain CDR1, CDR2 and CDR3 or a combination thereof of S5-2.GKNG and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of S5-2.GKNG; (xi (x) the heavy chain CDR1, CDR2 and CDR3 or combinations thereof of 1-7A-IT and / or the light chain CDR1, CDR2 and CDR3 or any combinations thereof of 1-7A-IT; (xx) the heavy chain CDR1, CDR2 and CDR3 or combinations thereof of low PI and / or the light chain CDR1, CDR2 and CDR3 or any combinations thereof of low PI; (xxi) the heavy chain CDR1, CDR2 and CDR3 or combinations thereof of 1-30 and / or the light chain CDR1, CDR2 and CDR3 or any combinations thereof of 1-30; (xxii) the heavy chain CDR1, CDR2 and CDR3 or combinations thereof of 1-17 and / or 1 (xxiii) heavy chain CDR1s, CDR2s, and CDR3s of 1-32 or any combination thereof and / or light chain CDR1s, CDR2s, and CDR3s of 1-32 or any combination thereof; (xxiv) heavy chain CDR1s, CDR2s, and CDR3s of 4-11 or any combination thereof and / or light chain CDR1s, CDR2s, and CDR3s of 4-11 or any combination thereof; (xxv) heavy chain CDR1s, CDR2s, and CDR3s of 6-10 or any combination thereof and / or light chain CDR1s, CDR2s, and CDR3s of 6-10 or any combination thereof; (xxvi) ) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 2-13D and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of 2-13D; (xxvii) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 2-13D-37 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of 2-13D-37; (xxviii) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 2-13D-37-1.5W-41 and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of 2-13D-37-1.5W-41;or (xxiv) the heavy chain CDR1, CDR2, and CDR3 of 2-13D-37-3W-16, or any combination thereof, and / or the light chain CDR1, CDR2, and CDR3 of 2-13D-3W-16, or any combination thereof. Table 2 provides the amino acid sequences of the VH CDR1, CDR2, and CDR3 of various anti-FAM19A5 antibodies disclosed herein. Table 3 provides the amino acid sequences of the VL CDR1, CDR2, and CDR3 of various anti-FAM19A5 antibodies disclosed herein.
[0253] In some embodiments, the anti-FAM19A5 antibody comprises:
[0254] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 17; and / or
[0255] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 18; and / or
[0256] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO: 19.
[0257] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VH CDRs.
[0258] In some embodiments, the anti-FAM19A5 antibody comprises:
[0259] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and / or
[0260] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 30; and / or
[0261] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 31.
[0262] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VL CDRs.
[0263] In some embodiments, the anti-FAM19A5 antibody comprises:
[0264] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 17;
[0265] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 18;
[0266] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 19;
[0267] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 29;
[0268] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 30; and / or
[0269] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 31.
[0270] In some embodiments, the anti-FAM19A5 antibody comprises:
[0271] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 14;
[0272] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; and / or
[0273] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO:16.
[0274] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VH CDRs.
[0275] In some embodiments, the anti-FAM19A5 antibody comprises:
[0276] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 26;
[0277] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and / or
[0278] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO:28.
[0279] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VL CDRs.
[0280] In some embodiments, the anti-FAM19A5 antibody comprises:
[0281] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 14;
[0282] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
[0283] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 16;
[0284] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 26;
[0285] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and / or
[0286] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28.
[0287] In some embodiments, the anti-FAM19A5 antibody comprises:
[0288] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 11;
[0289] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 12; and / or
[0290] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO:13.
[0291] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VH CDRs.
[0292] In some embodiments, the anti-FAM19A5 antibody comprises:
[0293] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 23;
[0294] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and / or
[0295] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO:25.
[0296] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VL CDRs.
[0297] In some embodiments, the anti-FAM19A5 antibody comprises:
[0298] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 11;
[0299] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 12;
[0300] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 13;
[0301] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 23;
[0302] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and / or
[0303] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 25.
[0304] In some embodiments, the anti-FAM19A5 antibody comprises:
[0305] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 20;
[0306] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 21; and / or
[0307] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO:22.
[0308] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VH CDRs.
[0309] In some embodiments, the anti-FAM19A5 antibody comprises:
[0310] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 32;
[0311] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 33; and / or
[0312] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 34.
[0313] In some embodiments, an anti-FAM19A5 antibody comprises one, two, or all three of the above VL CDRs.
[0314] In some embodiments, the anti-FAM19A5 antibody comprises:
[0315] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 20;
[0316] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 21;
[0317] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 22;
[0318] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 32;
[0319] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 33; and / or
[0320] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 34.
[0321] In some embodiments, the anti-FAM19A5 antibodies (e.g., scFv) disclosed herein include one, two, three, four, five, or six of the above CDRs. In some embodiments, the anti-FAM19A5 antibodies (e.g., scFv) disclosed herein include one, two, three, four, five, or six of the CDRs provided in Table 2 or Table 3.
[0322] In some embodiments, the VH domain and VL domain described herein can be connected by a flexible linker to produce a single-chain Fv antibody. Thus, in some embodiments, an anti-FAM19A5 antibody or antigen-binding portion thereof comprises a VH domain selected from Table 4 and a VL domain selected from Table 5, wherein the VH domain and the VL domain are connected by a flexible linker. In some embodiments, the flexible linker comprises the sequence SGGGGSSGGGGS (SEQ ID NO: 207). In other embodiments, the flexible linker comprises the sequence GQSSRSSGGGGSSGGGGS (SEQ ID NO: 300). The amino acid sequence of an exemplary anti-FAM19A5 scFv is provided in Table 6 below (VH domains are underlined, VL domains are bolded, and linkers are italicized).
[0323] Table 6: Variable heavy chain amino acid sequences
[0324]
[0325]
[0326]
[0327] The VH domains described herein, or one or more CDRs thereof, can also be linked to constant domains to form heavy chains, such as full-length heavy chains. Similarly, the VL domains described herein, or one or more CDRs thereof, can be linked to constant domains to form light chains, such as full-length light chains. Full-length heavy chains and full-length light chains are combined to form full-length antibodies.
[0328] Therefore, in a specific embodiment, an antibody comprising an antibody light chain and a heavy chain (e.g., a separate light chain and a heavy chain) that can be used in the methods disclosed herein is provided. With respect to the light chain, in a specific embodiment, the light chain of the antibody described herein is a kappa light chain. In another specific embodiment, the light chain of the antibody described herein is a lambda light chain. In yet another specific embodiment, the light chain of the antibody described herein is a human kappa light chain or a human lambda light chain. In a specific embodiment, an antibody that specifically binds to a FAM19A5 polypeptide (e.g., human FAM19A5) that can be used in the methods disclosed herein includes a light chain comprising any VL or VL CDR amino acid sequence described herein, and wherein the constant region of the light chain includes the amino acid sequence of a human kappa light chain constant region. In a specific embodiment, an antibody that specifically binds to a FAM19A5 polypeptide (e.g., human FAM19A5) that can be used in the methods disclosed herein includes a light chain comprising a VL or VL CDR amino acid sequence described herein, and wherein the constant region of the light chain includes the amino acid sequence of a human lambda light chain constant region. Non-limiting examples of human constant region sequences have been described in the art, eg, see US Pat. No. 5,693,780 and Kabat EA et al. (1991) supra.
[0329] With respect to the heavy chain, in some embodiments, the heavy chain of the antibodies described herein may be an α (a), δ (δ), ε (ε), γ (γ) or μ (μ) heavy chain. In another specific embodiment, the heavy chain of the antibodies described may include human α (a), δ (δ), ε (ε), γ (γ) or μ (μ) heavy chain. In some embodiments, the antibodies described herein that specifically bind to a FAM19A5 polypeptide (e.g., human FAM19A5) that can be used in the methods disclosed herein include a heavy chain comprising a VH or VH CDR amino acid sequence described herein, and wherein the constant region of the heavy chain comprises the amino acid sequence of a human γ (γ) heavy chain constant region. In other embodiments, the antibodies described herein that specifically bind to a FAM19A5 polypeptide (e.g., human FAM19A5) include a heavy chain comprising a VH or VH CDR amino acid sequence disclosed herein, and wherein the constant region of the heavy chain comprises the amino acid sequence of a human heavy chain described herein or known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat EA et al. (1991) supra.
[0330] In some embodiments, the antibodies described herein that specifically bind to FAM19A5 (e.g., human FAM19A5) that can be used in the methods disclosed herein include a VL domain and a VH domain comprising a VH or VH CDR and a VL and VL CDR as described herein, and wherein the constant region comprises an amino acid sequence of a constant region of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule or a human IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule. In another specific embodiment, the antibodies described herein that specifically bind to FAM19A5 (e.g., human FAM19A5) include a VL domain and a VH domain comprising any amino acid sequence described herein, and wherein the constant region comprises an amino acid sequence of a constant region of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any subclass of immunoglobulin molecules (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2). In some embodiments, the constant region comprises the amino acid sequence of a constant region of a naturally occurring human IgG, including its subclasses (e.g., IgG1, IgG2, IgG3, or IgG4) and allotypes (e.g., G1m, G2m, G3m, and nG4m), and variants. See, for example, Vidarsson G. et al. Frontiers in Immunology 5:520 (published online October 20, 2014) and Jefferis R. and Lefranc MP, mAbs 1:4, 1-7 (2009). In some embodiments, the constant region comprises the amino acid sequence of a constant region of human IgG1, IgG2, IgG3, or IgG4, or a variant thereof.
[0331] In certain embodiments, the disclosed anti-FAM19A5 antibodies useful in the methods disclosed herein do not have Fc effector functions, such as complement-dependent cytotoxicity (CDC) and / or antibody-dependent cellular phagocytosis (ADCP). Effector functions are mediated by the Fc region, and the residues closest to the hinge region in the CH2 domain of the Fc region are responsible for the effector functions of the antibody because the Fc region contains largely overlapping binding sites for C1q (complement) and IgG-Fc receptors (FcγRs) on effector cells of the innate immune system. In addition, IgG2 and IgG4 antibodies have lower levels of Fc effector functions than IgG1 and IgG3 antibodies. Effector functions of antibodies can be reduced or avoided by various methods known in the art, including (1) using antibody fragments lacking an Fc region (e.g., Fab, F(ab')2, single-chain Fv (scFv), or sdAbs composed of monomeric VH or VL domains); (2) generating aglycosylated antibodies, which can be generated by, for example, deleting or changing the residue to which the sugar is attached, enzymatically removing the sugar, generating the antibody in cells cultured in the presence of a glycosylation inhibitor, or by expressing the antibody in cells that are unable to glycosylate proteins (e.g., bacterial host cells, see, e.g., U.S. Publication No. 20120100140); (3) employing an Fc region of the IgG subclass with reduced effector function (e.g., an Fc region from an IgG2 or IgG4 antibody or a chimeric Fc region comprising a CH2 domain from an IgG2 or IgG4 antibody, see, e.g., U.S. Publication Nos. 20120100140 and Lau et al., 20120100140). C. et al., J. Immunol. 191:4769-4777 (2013); and (4) generating Fc regions with mutations that result in reduced or no Fc function. See, e.g., U.S. Publication No. 20120100140 and the U.S. and PCT applications cited therein, and An et al., mAbs 1:6, 572-579 (2009).
[0332] Thus, in some embodiments, the anti-FAM19A5 antibodies useful in the methods disclosed herein are Fab, Fab', F(ab')2, Fv, single-chain Fv (scFv), or sdAbs consisting of monomeric VH or VL domains. Such antibody fragments are well known in the art and are described above.
[0333] In some embodiments, the anti-FAM19A5 antibodies useful in the methods disclosed herein include an Fc region with reduced or no Fc effector function. In some embodiments, the constant region includes the amino acid sequence of the Fc region of human IgG2 or IgG4. In some embodiments, the anti-FAM19A5 antibodies are of the IgG2 / IgG4 isotype. In some embodiments, the anti-FAM19A5 antibodies include a chimeric Fc region comprising the CH2 domain of an IgG antibody of the IgG4 isotype and the CH3 domain of an IgG antibody of the IgG1 isotype, or a chimeric Fc region comprising the hinge region of IgG2 and the CH2 region of IgG4, or an Fc region with a mutation that results in reduced or no Fc function. Fc regions with reduced or no Fc effector function include those known in the art. See, for example, Lau C. et al., Journal of Immunology 191: 4769-4777 (2013); An et al., mAbs 1: 6, 572-579 (2009); and U.S. Publication No. 20120100140 and the U.S. patents and publications cited therein and PCT publications. One of ordinary skill in the art can also readily prepare an Fc region with reduced or no Fc effector function.
[0334] Nucleic acid molecules
[0335] Another aspect described herein relates to one or more nucleic acid molecules encoded to any one of the antibodies disclosed herein or its antigen-binding portion thereof.Such nucleic acid molecules can be expressed in AAV vectors disclosed herein.When purified by standard techniques (comprising alkali / SDS treatment, CsCl banding, column chromatography, restriction enzymes, agarose gel electrophoresis and other technologies well known in the art) away from other cellular components or other contaminants, such as other cellular nucleic acids (for example, other chromosomal DNA, such as chromosomal DNA connected with the DNA separated in nature) or protein, nucleic acid is "isolated" or "presented as substantially pure". Referring to F.Ausubel et al., ed., (1987) " Molecular Biology Experiment Guide (Current Protocols in Molecular Biology)", Greene Publishing Company and Wiley International Science Platform (Greene Publishing and Wiley Interscience), New York.Nucleic acid described herein can be, for example, DNA or RNA and can contain or may not contain intron sequences.In certain embodiments, nucleic acid is a cDNA molecule.
[0336] Certain nucleic acid molecules described herein are those encoding the VH and VL sequences of the anti-FAM19A5 antibodies of the present disclosure. Exemplary DNA sequences encoding the VH sequences of such antibodies are shown in SEQ ID NOs: 43-46, 177, and 265-278 (Table 7). Exemplary DNA sequences encoding the VL sequences of such antibodies are shown in SEQ ID NOs: 47-50, 178, and 279-292 (Table 8). Exemplary DNA sequences encoding 1-65, 3-2, and 2-13 scFv antibodies are provided in Table 9.
[0337] Table 7: Variable heavy chain polynucleotide sequences
[0338]
[0339]
[0340]
[0341]
[0342] Table 8: Variable light chain polynucleotide sequences
[0343]
[0344]
[0345]
[0346]
[0347] Table 9: Variable scFv polynucleotide sequences
[0348]
[0349]
[0350]
[0351]
[0352] To generate the anti-FAM19A5 scFv antibodies disclosed herein, DNA fragments encoding VH and VL are operably linked to another fragment encoding a flexible linker, such as the amino acid sequence (Gly4-Ser)3, such that the VH and VL sequences can be expressed as a continuous single-chain protein in which the VL and VH regions are connected by a flexible linker (see, e.g., Bird et al., (1988), Science 242: 423-426; Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883; McCafferty et al., (1990), Nature 348: 552-554). Such nucleic acid sequences can then be inserted into the AAV vectors disclosed herein, which can then be used to generate scFv antibodies, e.g., as demonstrated in the Examples.
[0353] Alternatively, nucleotide sequences encoding the heavy and light chains of anti-FAM19A5 antibodies (with or without signal peptides), such as SEQ ID NOs: 43 and 47, SEQ ID NOs: 44 and 48, SEQ ID NOs: 45 and 49, SEQ ID NOs: 46 and 50, SEQ ID NOs: 177 and 178, respectively, can be inserted into one or more AAV vectors of the present disclosure. Such AAV vectors can then be used to produce full-length antibodies. Host cells that have been transduced with the AAV vectors of the present disclosure are encompassed herein.
[0354] Methods for producing AAV vectors as disclosed herein are well known in the art and include, for example, methods using packaging cells, helper viruses or plasmids and / or baculovirus systems (see, e.g., Samulski et al., J. Virology 63, 3822 (1989); Xiao et al., J. Virology 72, 2224 (1998); Inoue et al., J. Virology 72, 7024 (1998); WO 1998 / 022607; and WO 2005 / 072364).
[0355] Also known are methods for producing pseudotyped AAV vectors (see, e.g., WO 00 / 28004 ) and various modifications or formulations of AAV vectors to reduce their immunogenicity when administered in vivo (see, e.g., WO 01 / 23001 ; WO 00 / 73316 ; WO 04 / 112727 ; WO 05 / 005610 ; and WO 99 / 06562 ). In some embodiments, AAV vectors can be prepared or derived from various serotypes of AAV, which can be mixed together or with other types of viruses to produce chimeric (e.g., pseudotyped) AAV viruses.
[0356] III. Pharmaceutical Compositions
[0357] Provided herein are compositions comprising an AAV vector of the present disclosure (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA) of desired purity in the form of a physiologically acceptable carrier, excipient, or stabilizer. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include: buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); a low molecular weight (less than about 1% to 2% hydroxybenzoic acid) or a combination thereof. 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TM or polyethylene glycol (PEG).
[0358] In some embodiments, the pharmaceutical composition comprises an AAV vector as described herein and optionally one or more additional prophylactic or therapeutic agents (in the form of a pharmaceutically acceptable carrier). In a specific embodiment, the pharmaceutical composition comprises an effective amount of an antibody as described herein or its antigen-binding portion thereof and optionally one or more additional prophylactic or therapeutic agents (in the form of a pharmaceutically acceptable carrier). In some embodiments, the antibody is the only active ingredient contained in the pharmaceutical composition. The pharmaceutical compositions described herein can be used to reduce FAM19A5 activity and treat conditions such as central nervous system damage, diseases or disorders such as neuropathic pain.
[0359] The pharmaceutically acceptable carrier used in parenteral preparations comprises aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending agents and dispersants, emulsifiers, isolating agents or chelating agents and other pharmaceutically acceptable substances. The example of aqueous vehicles comprises sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringer's injection. Non-aqueous parenteral vehicles comprise fixed oils, cottonseed oil, corn oil, sesame oil and peanut oil of plant origin. Antimicrobial agents with antibacterial or antifungal concentrations can be added to the parenteral preparations packaged in multidose containers, and the multidose containers comprise phenol or cresol, mercury, benzyl alcohol, chlorobutanol, methylparaben and propylparaben, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents comprise sodium chloride and dextrose. Buffers comprise phosphate and citrate. The antioxidant comprises sodium bisulfate. The local anesthetic comprises procaine hydrochloride. The suspending and dispersing agents comprise sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinyl pyrrolidone. The emulsifier comprises polysorbate 80 ( 80). Metal ion sequestrants or chelators include EDTA. The drug carrier also includes ethanol, polyethylene glycol, and propylene glycol for water-soluble vehicles; and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.
[0360] The pharmaceutical compositions of the present invention can be formulated for any route of administration for a subject. Specific examples of routes of administration include intranasal, oral, parenteral, intrathecal, intracerebroventricular, pulmonary, subcutaneous, intraperitoneal, intravitreal, epidural, subretinal, or intraventricular. Parenteral administration characterized by subcutaneous, intramuscular, or intravenous injection is also contemplated herein. Injections can be prepared in conventional forms as liquid solutions or suspensions, solid forms suitable for dissolving or suspending in liquids before injection, or as emulsions. Injections, solutions, and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, dextrose, glycerol, or ethanol. In addition, if desired, the pharmaceutical composition to be administered can also contain a small amount of non-toxic auxiliary substances, such as wetting agents or emulsifiers, pH buffers, stabilizers, solubilizers, and other such agents, such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, and cyclodextrins.
[0361] Preparations for parenteral administration of antibodies include sterile solutions ready for injection, sterile dry soluble products such as lyophilized powders (including hypodermic tablets) ready for injection, sterile suspensions ready for injection, sterile dry insoluble products ready for combination with a vehicle just before use, and sterile emulsions. Solutions can be aqueous or non-aqueous.
[0362] If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS) and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol and polypropylene glycol, and mixtures thereof.
[0363] Topical mixtures comprising the antibodies are prepared as described for local and systemic administration. The resulting mixtures can be solutions, suspensions, emulsions, etc. and can be formulated into creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, rinses, sprays, suppositories, bandages, skin patches, or any other formulation suitable for topical administration.
[0364] The AAV vectors described herein can be formulated as aerosols for topical application, such as by inhalation (see, for example, U.S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivering steroids useful for treating inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for use in a nebulizer, or as a finely divided powder for insufflation, alone or in combination with an inert carrier such as lactose. In such cases, the diameter of the particles of the formulation will, in some embodiments, be less than 50 microns, and in some embodiments, less than 10 microns.
[0365] The AAV vectors described herein can be formulated for topical or local application, such as in the form of gels, creams, and lotions for topical application to the skin and mucous membranes, such as the eye, as well as for application to the eye or for intracranial or intraspinal application. Topical administration for transdermal delivery and for administration to the eye or mucous membranes or for inhalation therapy is contemplated. Nasal solutions of the antibodies, alone or in combination with other pharmaceutically acceptable excipients, can also be administered.
[0366] In some embodiments, pharmaceutical compositions comprising the AAV vectors described herein are lyophilized powders that can be reconstituted for administration as solutions, emulsions, and other mixtures. The lyophilized powders can also be reconstituted and formulated into solids or gels. The lyophilized powders are prepared by dissolving the antibodies described herein, or their antigen-binding portions, or pharmaceutically acceptable derivatives thereof, in a suitable solvent. In some embodiments, the lyophilized powders are sterile. The solvent may contain excipients that improve the stability of the powder or a reconstituted solution prepared from the powder, or other pharmacological components. Excipients that can be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerol, glucose, sucrose, or other suitable agents. The solvent may also contain a buffer such as citrate, sodium phosphate, or potassium phosphate, or other such buffers known to those skilled in the art, which, in some embodiments, are at approximately neutral pH. The solution is then sterile-filtered and then lyophilized under standard conditions known to those skilled in the art to provide the desired formulation. In some embodiments, the resulting solution is dispensed into vials for lyophilization. Each vial will contain a single or multiple doses of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4°C to room temperature.
[0367] Reconstitution of this lyophilized powder with water for injection provides a formulation for use in parenteral administration. For reconstitution, the lyophilized powder is added to sterile water or other suitable carrier. The exact amount depends on the selected compound. This amount can be determined empirically.
[0368] The AAV vectors described herein and other compositions provided herein can also be formulated to target specific tissues, receptors, or other areas of the body of the subject to be treated. Many such targeting methods are well known to those skilled in the art. All such targeting methods are contemplated herein for use in the compositions of the present invention. For non-limiting examples of targeted approaches, see, e.g., U.S. Pat. Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542, and 5,709,874. In certain embodiments, the AAV vectors described herein are targeted to treat a disease or disorder, such as central nervous system damage, brain degenerative disease, or neuropathic pain.
[0369] Compositions for in vivo administration may be sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes.
[0370] IV. Kit
[0371] Also provided herein are kits comprising one or more AAV vectors described herein. In some embodiments, provided herein are pharmaceutical packages or kits comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein (e.g., one or more AAV vectors provided herein), optionally with instructions for use. In some embodiments, the kits contain pharmaceutical compositions described herein and any prophylactic or therapeutic agents such as those described herein.
[0372] V. Therapeutic Uses and Methods
[0373] In certain aspects, presented herein are methods for reducing injury or damage to the CNS of a subject, the methods comprising administering to the subject an AAV vector of the present disclosure.
[0374] In other aspects, presented herein are methods for inhibiting, slowing down, suppressing, curbing, reducing, reversing or preventing the onset or initiation of gliosis in the CNS of a subject and its associated deleterious effects, the methods comprising administering an AAV vector disclosed herein to the subject. In some embodiments, presented herein are methods for inhibiting, slowing down, suppressing, curbing, reducing, reversing or preventing the excessive or abnormal proliferation of reactive astrocytes in the CNS of a subject and its associated deleterious effects, the methods comprising administering an AAV vector of the present disclosure to the subject. In some embodiments, presented herein are methods for reducing, inhibiting or reducing the expression of chondroitin sulfate proteoglycans (including neuroglycans, NG2 or the level of both) or reducing the activity of neuroglycans, NG2 or both of the subject or inactivating them, the methods comprising administering an AAV vector described herein to the subject. In some embodiments, presented herein are methods for stimulating, promoting, increasing or activating the growth of neurons in a subject, preferably after injury or damage, the methods comprising administering an AAV vector as described herein to the subject. In other embodiments, methods for increasing the level of c-fos mRNA, c-fos protein or c-fos protein activity in the nuclei of preferably neurons of a subject in need thereof, and increasing the level of ERK mRNA, ERK protein or pERK activity are presented herein, the methods comprising administering to the subject an AAV vector of the present disclosure. In certain embodiments, methods for enhancing or increasing the level of GAP43 mRNA, GAP43 protein or increasing the activity of GAP43 protein in preferably neurons of a subject in need thereof are presented herein, the methods comprising administering to the subject an AAV vector as disclosed herein. In certain embodiments, methods for enhancing or promoting the survival of neurons in a subject in need thereof and / or promoting the regeneration of axons are presented herein, the methods comprising administering to the subject an AAV vector disclosed herein. In some embodiments, the subject is a human, preferably a human with damage or injury to neurons due to, for example, CNS damage, trauma, injury, cerebral spinal cord damage, brain tumor, infection, ischemia, stroke, autoimmune reaction and / or neurodegenerative disease.
[0375] In some embodiments, the present invention also presents a method for treating a disease or condition in a subject in need thereof, wherein the disease or condition comprises central nervous system damage, cerebrospinal system damage, brain degenerative disease, degenerative cerebrospinal cord or neurological disease or neuropathic pain, the method comprising administering an AAV vector disclosed herein to the subject. In some embodiments, central nervous system damage is traumatic brain injury, cerebrospinal cord damage, stroke, brain tumor, or a combination thereof. In some embodiments, the brain degenerative disease is Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), or a combination thereof. Therefore, in certain embodiments, disclosed herein is a method for treating traumatic brain injury, cerebrospinal cord damage, stroke, brain tumor, or a combination thereof in a subject in need thereof, the method comprising administering an AAV vector disclosed herein, or a composition thereof, to the subject. In some embodiments, disclosed herein are methods for treating Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, ALS in a subject in need thereof, the methods comprising administering to the subject an AAV vector disclosed herein or a composition thereof. In some embodiments, the subject is a human.
[0376] In certain embodiments, presented herein are methods for treating, reducing, reversing, preventing, improving, controlling or suppressing fibrosis in a subject in need thereof, comprising administering an AAV vector disclosed herein or its composition to the subject. In certain embodiments, fibrosis is benign (i.e., does not cause any symptoms). In other embodiments, fibrosis is associated with a pathological state that may be reversible or irreversible. In certain embodiments, fibrosis is selected from the group consisting of: liver fibrosis, lung fibrosis, kidney fibrosis, bone marrow fibrosis, pancreatic fibrosis, skin fibrosis, cardiac fibrosis, arterial fibrosis, breast fibrosis, muscle fibrosis, retroperitoneal fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis and pleural fibrosis. In one embodiment, fibrosis is liver fibrosis or lung fibrosis. In another embodiment, fibrosis is associated with tumors derived from cancers such as liver cancer, lung cancer, kidney cancer, breast cancer and / or pancreatic cancer. In one embodiment, the method alleviates, reverses, alleviates, improves, inhibits or slows down or prevents fibrosis, the symptoms associated with fibrosis, the root cause of fibrosis or its combination.
[0377] In other embodiments, the AAV vectors disclosed herein can treat, reduce, reverse, prevent, ameliorate, control, or inhibit a fibrosis-related disease or condition in a subject in need thereof. The term "fibrosis associated with a disease or condition" refers to fibrosis that accompanies a disease or condition or is caused or contributed to by a disease or condition. The term encompasses fibrosis that is caused or contributed to by a disease or condition disclosed above or that accompanies a disease or condition.
[0378] In yet other embodiments, the AAV vectors of the present disclosure can treat, reduce, reverse, prevent, delay, ameliorate, control, or inhibit liver cancer, lung cancer, kidney cancer, breast cancer, and / or pancreatic cancer in a subject in need thereof, wherein the method comprises administering the AAV vector to the subject. In some embodiments, the liver cancer, lung cancer, kidney cancer, breast cancer, and / or pancreatic cancer is associated with or caused by fibrosis.
[0379] In some embodiments, a therapeutically effective amount of an AAV vector of the present disclosure or a composition thereof is administered. When treating a subject (e.g., a human), the therapeutically effective amount of an AAV vector disclosed herein depends on factors such as age, sex, severity of the disease, and the like.
[0380] In some embodiments, the disclosed AAV vectors or compositions thereof are administered intravenously, orally, parenterally, transthecally, intrathecally, intracerebroventricularly, intramuscularly, pulmonary, intraperitoneally, intravitreally, subcutaneously, epidurally, subretinally, or intraventricularly.
[0381] In some embodiments, the AAV vectors disclosed herein, or compositions thereof, may be administered with one or more additional agents for treating fibrosis (e.g., pirfenidone for idiopathic pulmonary fibrosis). or nintedanib The dosage and administration of one or more additional therapeutic agents are known in the art, for example, as indicated on the product labels of the corresponding drugs.
[0382] In some embodiments, the AAV vectors described herein, or compositions thereof, can be administered in combination with one or more additional agents for treating central nervous system damage (e.g., traumatic brain injury, cerebrospinal cord damage, stroke, or brain tumor), cerebrospinal system damage, brain degenerative disorders (e.g., Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, ALS), degenerative cerebrospinal or neurological disorders, or neuropathic pain. For example, non-limiting exemplary agents for treating Huntington's disease include tetrabenazine. Antipsychotics such as haloperidol Chlorpromazine, risperidone and quetiapine
[0383] Non-limiting exemplary agents for treating Parkinson's disease include levodopa (with or without carbidopa), dopamine agonists such as pramipexole, Ropinirole and rotigotine and apomorphine Selegiline ( and ), rasagiline Entacapone benztropine trihexyphenidyl and amantadine.
[0384] Non-limiting exemplary agents for treating Alzheimer's disease include Donepezil Galantamine and rivastigmine
[0385] Non-limiting exemplary agents for treating multiple sclerosis include Glatiramer acetate Dimethyl fumarate Fingolimod Teriflunomide Natalizumab Alemtuzumab and mitoxantrone.
[0386] Non-limiting exemplary agents for treating ALS include riluzole
[0387] The dosage and administration of the one or more additional therapeutic agents are known in the art, for example, as indicated on the product label of the corresponding drug.
[0388] The following examples are offered by way of illustration and not by way of limitation.
[0389] Example 1: Adeno-associated virus (AAV) vector construction
[0390] AAV vectors encoding single chain variable fragments (scFv) of anti-FAM19A5 antibody clones 1-65, 2-13, or 3-2 were constructed as follows. Briefly, to construct AAV vectors encoding 3-2 scFv, a pscAAV-MCS expression vector (Cell Biolabs, catalog number VPK-430) was digested with EcoRI and NotI. Then, a transgene encoding human β-globin intron and 3-2 scFv under the CMV promoter was inserted into the AAV vector. Figure 1 The pscAAV-MCS vector shown. The human β-globin intron was inserted to maximize gene expression. To produce AAV vectors encoding 1-65 or 2-13cFv, the above AAV vectors were digested with EcoRV and NotI to remove the 3-2scFv transgene. The transgene encoding 1-65 or 2-13ScFv was then inserted into the AAV vector. The transgene encoding 3-2, 1-65 or 2-13ScFv was codon-optimized for optimal expression in mice. All AAV vectors contain a mouse IgGκ signal peptide in front of the scFv transgene to promote cellular secretion. The AAV vector also contains a FLAG tag on the back of the scFv transgene to assist in detecting gene expression. Once constructed, the AAV vector was transformed into E. coli for culture, and large amounts of AAV vectors were obtained using maxiprep. AAV vectors encoding 1-30 scFv or mouse IL-10 or GFP were generated and provided by Signagen Laboratories (Rockville, Maryland).
[0391] The following recombinant AAVs were used in the examples described below: (i) scAAV8-CMV-3-2-ScFv (Sirion, Germany); (ii) scAAV9-CMV-3-2-ScFv (Signagen Laboratories, USA); (iii) scAAV9-CMV-1-65-ScFv (Signagen Laboratories, USA) scAAV9-CMV-2-13-ScFv (Signagen Laboratories, USA); iv) scAAV1-CMV-3-2-ScFv (Signagen Laboratories, USA); (v) scAAV9-CMV-1-30-ScFv (Signagen Laboratories, USA); (vi) scAAV9-CMV-mIL-10 (Signagen Laboratories, USA); (vii) scAAV9-CMV-GFP (Signagen Laboratories, USA); (viii) scAAV1-CMV-GFP (Signagen Laboratories, USA).
[0392] Example 2: Analysis of Anti-FAM19A5 ScFv Gene Expression
[0393] The expression of anti-FAM19A5 ScFv was tested using the AAV vectors constructed above (scAAV8-CMV-3-2-ScFv, scAAV9-CMV-3-2-ScFv, scAAV9-CMV-1-65-ScFv, and scAAV9-CMV-2-13-ScFv). Briefly, HEK293 cells (1.2×10 6 Cells were seeded in 60 mm 2 The cells were cultured in a culture dish and incubated for 24 hours. Afterwards, the culture medium was replaced with Opti-MEM medium (low serum) and HEK293 cells were transduced with different AAV vectors (using multiple multiplicity of infection (MOI)). Supernatants were collected on day 1, day 4, and day 8 after transduction. To confirm gene expression, ABSbio TM DYKDDDK tag ELISA kit (Advanced Bioreagent, catalog number SE002-flag) was used to detect the FLAG tag contained on the back of the scFv gene (see Figure 1and Example 1). The collected supernatant was diluted 1 to 10 times, and then 100 μL of the diluted supernatant was added to the wells of the ELISA plate and allowed to react at room temperature at 350 rpm for 2 hours. Afterwards, the plate was washed, and 100 μL of detection antibody was added to each well in the well and allowed to react at room temperature at 350 rpm for 1 hour. Next, the plate was washed again, 100 μL of TMB solution was added to each well and allowed to reach 10-30 minutes. Then, 100 μL of stop solution was added to the wells, and the absorbance was measured at 450 nm. The amount of FLAG was measured by a calibration curve, and the amount of scFv was calculated by multiplying the ratio of FLAG expression to the molecular weight of the standard.
[0394] like Figure 2A As shown, for the scAAV8-CMV-3-2-scFv vector, anti-FAM19A5 scFv (MOI of 1 × 10 5 By day 8 after transduction, approximately 100 ng / mL of 3-2scFv was detected in the supernatant (MOI of 1×10 5 Using the scAAV9-CMV-3-2-scFv vector, approximately 70 ng / mL of 3-2 scFv was detected in the supernatant on day 8 after transduction (MOI of 2×10 5 Similar results were observed using scAAV9-CMV-1-65-ScFv and scAAV9-CMV-2-13-ScFv. Figure 2C As shown, approximately 120 ng / mL and 115 ng / mL of 1-65 scFv and 2-13 scFv, respectively, were detected in the supernatant 4 days after transduction.
[0395] The above data demonstrate that all AAV vectors constructed in Example 1 were correctly constructed and could induce anti-FAM19A5 scFv expression when transduced into cells.
[0396] Example 3: Inhibition of FAM19A5 binding in U87MG cells
[0397] To evaluate the binding ability of the anti-FAM19A5 scFv produced by the above AAV constructs, a binding inhibition assay using U87MG cells (a primary human glioblastoma cell line that can bind to human FAM19A5-Fc protein) was performed. Briefly, scAAV8-CMV-2-3-ScFv (MOI of 1×10 5 ), scAAV9-CMV-1-65-ScFv (MOI was 2×10 5) or scAAV9-CMV-2-13-ScFv (MOI of 2×10 5 ) were transduced into U87MG cells. Then, on day 4 after transduction, 0.1 μg of human FAM19A5-Fc protein was mixed with 200 μL of supernatant, and the mixture was incubated at 4°C for 30 minutes. Negative controls consisted of PBS or supernatant from HEK293 cells transduced with scAAV9-CMV-GFP vector. After incubation for 30 minutes, 100 μL of the mixture (human FAM19A5-Fc + supernatant from cells transfected with anti-FAM19A5 scFv AAV construct) was added to U87MG cells (2×10 5 ) and reacted at 4°C for 1 hour. The cells were then washed with PBS, treated with 100 μL of goat anti-human IgG 488 antibody (Invitrogen, catalog number A11013) (1:50 dilution), and incubated at 4°C for another 30 minutes. The cells were then washed again, and the binding of human FAM19A5-Fc to U87MG cells was analyzed using flow cytometry.
[0398] like Figure 3A 、 3B As shown in Figures 3 and 3C, when U87MG cells were treated with a mixture (human FAM19A5-Fc + supernatant from cells transfected with an anti-FAM19A5 scFv AAV construct), binding of human FAM19A5-Fc to the cells was reduced compared to cells treated with a control mixture (human FAM19A5-Fc + supernatant from cells transfected with an scAAV9-CMV-GFP construct). This was true for all anti-FAM19A5 scFv AAV constructs tested. Compared with the corresponding controls (supernatants from cells transfected with AAV-GFP vector or treated with PBS), supernatants from cells transduced with scAAV9-CMV-1-65-ScFv, scAAV9-CMV-2-13-ScFv, and scAAV8-CMV-3-2-ScFv respectively reduced the mean fluorescence intensity (MFI) of human FAM19A5-Fc binding to U87MG cells by 19% ( Figure 3A )、68%( Figure 3B ) and 42% ( Figure 3C ).
[0399] These results demonstrate that the anti-FAM19A5 scFv produced by the AAV construct described in Example 1 can bind to human FAM19A5 efficiently and with high affinity.
[0400] Example 4: Inhibition of FAM19A5 binding in C8-D1A cells
[0401] To confirm the binding inhibition observed in Example 3, C8-D1A cells were used in a binding inhibition assay. C8-D1A cells are an astrocyte cell line and can secrete FAM19A5 into the surrounding culture medium when cultured. If the anti-FAM19A5 scFv produced by the AAV construct can effectively bind to human FAM19A5, then treating C8-D1A cell culture medium with supernatant from cells transduced with the anti-FAM19A5 scFv AAV should result in a decrease in FAM19A5 protein levels in the culture medium.
[0402] Briefly, C8-D1A cells were plated into 6-well plates (2 × 10 5 The supernatant containing anti-FAM19A5 scFv was generated by transfecting HEK293 cells with one of the following: (i) scAAV8-CMV-3-2-ScFv (MOI of 1×10 5 ); (ii) scAAV9-CMV-1-65-ScFv (MOI=2×10 5 ); or (iii) scAAV9-CMV-2-13-ScFv (MOI = 2 × 10 5 ), and then the supernatant was collected on day 8 after transduction. To activate C8-D1A cells, TGF-β (20 ng / mL) was added to the cells with supernatant containing anti-FAM19A5 scFv. PBS or supernatant from cells transduced with scAAV-9-CMV-GFP was used as a negative control. The cells were incubated for 24 hours, and then the anti-FAM19A5 protein level in the culture was measured using an ELISA assay (see Example 1 for the method used in the ELISA assay).
[0403] like Figure 4A As shown, when C8-D1A cells were activated in the presence of supernatant from cells transduced with scAAV8-CMV-3-2-ScFv, the level of FAM19A5 protein detected in the culture medium was reduced by approximately 38% compared to the corresponding control (PBS). Supernatants from cells transduced with scAAV9-CMV-2-13-ScFv and scAAV9-CMV-1-65-ScFv reduced the level of FAM19A5 protein in the culture medium by approximately 63% and 14%, respectively, compared to the corresponding control (supernatant from cells transfected with GFP AAV vector). Figure 4B .
[0404] The above data further confirmed that the anti-FAM19A5 scFv produced by the AAV vector can effectively bind to human FAM19A5.
[0405] Example 5: In vivo expression analysis
[0406] To confirm in vivo anti-FAM19A5 scFv expression, the scAAV8-CMV-3-2-ScFv construct was intrathecally administered to C57BL / 6 mice (1×10 11 Viral genomes (vg) / mouse). Mice were then sacrificed at 1 and 2 weeks after administration, and spinal cord tissue (lumbar spinal cord) was analyzed. To detect gene expression, anti-FLAG antibodies and fluorescence microscopy were used.
[0407] like Figure 5 As shown, there was no positive antibody expression in naive animals (i.e., no AAV vector administration) at week 1 (upper left panel) and week 2 (lower left panel) after administration. In contrast, in animals treated with scAAV8-CMV-3-2-ScFv, anti-FLAG (i.e., anti-FAM19A5 scFv) expression was observed in ventral horn neurons at week 1 after administration (upper right panel). By week 2, expression was higher, including in the dorsal horn region.
[0408] This data confirms earlier in vitro expression data (see Example 2) and suggests that anti-FAM19A5 AAV vectors can transduce surrounding cells when administered intrathecally, resulting in anti-FAM19A5 scFv production.
[0409] Example 6: Evaluation of pain relief in a chronic neuropathic pain model (CCI) using scAAV8-CMV-3-2-ScFv
[0410] To evaluate the in vivo effects of administering anti-FAM19A5 scFv AAV constructs, a mouse model of chronic constriction injury (CCI) was used. Briefly, PBS (control) or scAAV8-CMV-3-2-ScFv was administered intrathecally to C57BL / 6 mice (into the vertebrae). Then, approximately 1 week after administration, peripheral nerve injury was induced in the animals by scrotal nerve ligation. At various time points after injury, both mechanical allodynia (response to physical external stimuli) and thermal hyperalgesia (response to elevated temperature) were assessed in the animals. Mechanical allodynia was assessed by applying von Frey microfilaments (0.16 g) to the injured foot multiple times and observing the frequency of the animals' pain responses. Thermal hyperalgesia was assessed using the Hargreaves test, in which a radial heat stimulus (intensity: 30) was applied to the injured foot and the paw withdrawal latency was determined.
[0411] like Figure 6A As shown, animals receiving scAAV8-CMV-3-2 responded less frequently to von Frey filaments than control animals (PBS only). Similar results were observed for thermal hyperalgesia. Figure 6B These results demonstrate that in vivo administration of anti-FAM19A5 AAV constructs can alleviate neuropathic pain after peripheral nerve injury.
[0412] Example 7: Evaluation of pain relief in a chronic neuropathic pain model (CCI) using scAAV9-CMV-3-2-ScFv
[0413] The in vivo effects of scAAV9-CMV-3-2-ScFv were also tested using a mouse model of chronic constriction injury (CCI) as described in Example 6. Briefly, the scAAV9-CMV-3-2-ScFv construct was administered intrathecally to C57BL6 mice. Control animals received the scAAV9-CMV-GFP construct. Then, approximately 1 week after administration, peripheral nerve injury was induced. The animals were then assessed for mechanical allodynia and thermal hyperalgesia at various time points as described in Example 6.
[0414] like Figure 7A and 7B As shown in the study, animals that received scAAV9-CMV-3-2-ScFv appeared to have a higher tolerance to pain after peripheral nerve injury. For example, mice that received scAAV9-CMV-3-2-ScFv showed a lower frequency of responses to von Frey filaments ( Figure 7A ) and have a longer incubation period to elevated temperatures ( Figure 7B ).
[0415] Overall, these results demonstrate that anti-FAM19A5 scFv can be efficiently delivered in vivo using AAV vectors and that the anti-FAM19A5 scFv produced by AAV vectors is fully functional (eg, binds to human FAM19A5 and alleviates neuropathic pain).
[0416] Example 8: Evaluation of pain relief in a chronic neuropathic pain model (CCI) using scAAV1-CMV-3-2-ScFv
[0417] To further evaluate whether the above effects depend on the type of AAV used, the in vivo effects of scAAV1-CMV-3-2-ScFv were tested. Briefly, C57BL / 6 mice received two doses (each dose = 1×10 11 vg / mouse) scAAV1-CMV-3-2-ScFv. One week after the last administration, peripheral nerve injury was induced, and mechanical allodynia and thermal hyperalgesia were assessed as described in Example 6.
[0418] As observed in Examples 6 and 7, animals treated with scAAV1-CMV-3-2-ScFv showed improved mechanical allodynia (i.e., less frequent responses to von Frey filament stimulation) compared to the control group starting around day 4 after injury induction (i.e., a few days after surgery). Figure 8A This improvement was maintained until the end of the experiment on day 24 after injury induction. Regarding thermal hyperalgesia, improvements (i.e., longer latency to heat stimulation) were also observed in animals treated with scAAV1-CMV-3-2-ScFv, starting approximately day 5 after injury induction and lasting at least until day 12 after injury induction. Figure 8B .
[0419] These results further confirm the efficacy of 3-2 anti-FAM19A5 scFv in treating neuropathic pain and demonstrate that the therapeutic benefit is not dependent on the type of AAV vector used.
[0420] Example 9: Evaluation of pain relief in a chronic neuropathic pain model (CCI) using scAAV9-CMV-2-13-ScFv or scAAV9-CMV-1-30-ScFv
[0421] To evaluate whether other clones of anti-FAM19A5 antibodies could also treat neuropathic pain, the chronic constriction injury (CCI) mouse model described in Example 6 was used again. Briefly, scAAV9-CMV-2-13-ScFv (two doses at two weeks intervals; each dose = 1×10 11 vg / mouse) or scAAV9-CMV-1-30-ScFv (single dose; 1 × 10 11 vg / mouse) were administered to C57BL / 6 mice. Control animals received scAAV9-CMV-GFP. Approximately one week after the last administration, peripheral nerve injury was induced, and both mechanical allodynia and thermal hyperalgesia were assessed at various time points after injury induction (see Example 6).
[0422] like Figure 9A 、 9B As shown in Figures 10A and 10B, animals treated with scAAV9-CMV-2-13-ScFv or scAAV9-CMV-1-30-ScFv showed improvement in both mechanical allodynia and thermal hyperalgesia. These results demonstrate that different clones of anti-FAM19A5 antibodies can be used to treat neuropathic pain.
[0423] Example 10: Evaluation of pain relief in a chronic neuropathic pain model (CCI) using anti-FAM19A5 ScFv in combination with IL-10
[0424] To determine the efficacy of anti-FAM19A5 ScFv in combination with other therapeutic agents (i.e., IL-10), C57BL / 6 mice were administered one of the following regimens via intrathecal administration: (i) scAAV1-CMV-GFP; (ii) scAAV1-CMV-3-2-ScFv; (iii) scAAV1-CMV-3-2-ScFv + scAAV9-CMV-mIL-10; and (iv) scAAV9-CMV-mIL-10. The different treatment regimens were administered at a dose of 1×10 11 A dose of 1 μg / mouse was administered to mice twice (two weeks apart). One week after the last administration, peripheral nerve injury was induced and mechanical allodynia was assessed at various time points (see Example 6).
[0425] As observed in the earlier examples, animals treated with scAAV1-CMV-3-2-ScFv alone were more tolerant to physical stimulation (i.e., responded less frequently to von Frey filament application) than the control group (i.e., scAAV1-CMV-GFP). Similar responses were observed in animals treated with scAAV9-CMV-miL-10 alone ( Figure 11A Animals showed greater improvement when treated with the combination of scAAV1-CMV-3-2-ScFv and scAAV9-CMV-mIL-10 compared to animals treated with either monotherapy regimen. Figure 11B ) and scAAV9-CMV-1-30-ScFv ( Figure 11C ), similar results were observed.
[0426] These results further demonstrate the efficacy of anti-FAM19A5 scFv delivered via AAV vector in treating neuropathic pain. The results also demonstrate that this efficacy can be further enhanced when used in combination with other therapeutic agents such as IL-10.
[0427] This PCT application claims the benefit of priority to U.S. Provisional Application No. 62 / 668,634, filed May 8, 2018, which is incorporated herein by reference in its entirety. Sequence Listing <110> NEURACLE SCIENCE CO., LTD. <120> Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies <130> 3763.010PC01 / CK / DKC <150> US 62 / 668,634 <151> 2018-05-08 <160> 301 <170> PatentIn version 3.5 <210> 1 <211> 132 <212> PRT <213> Homo sapiens <40130 <210> 2 <211> 125 <212> PRT <213> Homo sapiens <400> 2 Met Gln Leu Leu Lys Ala Leu Trp Ala Leu Ala Gly Ala Ala Leu Cys 1 5 10 15 Cys Phe Leu Val Leu Val Ile His Ala Gln Phe Leu Lys Glu Gly Gln 20 25 30 Leu Ala Ala Gly Thr Cys Glu Ile Val Thr Leu Asp Arg Asp Ser Ser 35 40 45 Gln Pro Arg Arg Thr Ile Ala Arg Gln Thr Ala Arg Cys Ala Cys Arg 50 55 60 Lys Gly Gln Ile Ala Gly Thr Thr Arg Ala Arg Pro Ala Cys Val Asp 65 70 75 80 Ala Arg Ile Ile Lys Thr Lys Gln Trp Cys Asp Met Leu Pro Cys Leu 85 90 95 Glu Gly Glu Gly Cys Asp Leu Leu Ile Asn Arg Ser Gly Trp Thr Cys 100 105 110 Thr Gln Pro Gly Gly Arg Ile Lys Thr Thr Thr Val Ser 115 120 125 <210> 3 <211> 53 <212> PRT <213> Homo sapiens <400> 3 Met Tyr His His Arg Glu Trp Pro Ala Arg Ile Ile Lys Thr Lys Gln 1 5 10 15 Trp Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu 20 25 30 Ile Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys 35 40 45 Thr Thr Thr Val Ser 50 <210> 4 <211> 1501 <212> DNA <213> Homo sapiens <400> 4 ggcggcggag gatggcgcgc gcggggcccg cacgtggagg ccggcgcggg ggcgcgggca 60 gggccggctg ctgagacgcg ctgctgcccc ccgcgcgggc gccgcggctt caatggcgcc 120 atcgcccagg accggcagcc ggcaagatgc gaccgccctg cccagcatgt cctcaacttt 180 ctgggcgttc atgatcctgg ccagcctgct catcgcctac tgcagtcagc tggccgccgg 240 cacctgtgag attgtgacct tggaccggga cagcagccag cctcggagga cgatcgcccg 300 gcagaccgcc cgctgtgcgt gtagaaaggg gcagatcgcc ggcaccacga gagcccggcc 360 cgcctgtgtg gacgcaagaa tcatcaagac caagcagtgg tgtgacatgc ttccgtgtct 420 ggagggggaa ggctgcgact tgttaatcaa ccggtcaggc tggacgtgca cgcagcccgg 480 cgggaggata aagaccacca cggtctcctg acaaacacag cccctgaggg ggccccggga 540 gtggccttgg ctccctggag agcccacgtc tcagccacag ttctccactc gcctcggact 600 tcacccgttc tctgccgccc gcccactccg tttccctgtg gtccgtgaag gacggcctca 660 ggccttggca tcctgagctt cggtctgtcc agccgacccg aggaggccgg actcagacac 720 ataggcgggg ggcggcacct ggcatcagca atacgcagtc tgtgggagcc cggccgcgcc 780 cagcccccgc cgaccgtggc gttggccctg ctgtcctcag aggaggagga ggaggaggca 840 gctccggcag ccacagaagg ctgcagccca gcccgcctga gacacgacgc ctgccccagg 900 ggactgtcag gcacagaagc ggcctcctcc cgtgccccag actgtccgaa ttgcttttat 960 tttcttatac tttcagtata ctccatagac caaagagcaa aatctatctg aacctggacg 1020 caccctcact gtcagggtcc ctggggtcgc ttgtgcgggc gggagggcaa tggtggcaga 1080 gacatgctgg tggccccggc ggagcggaga gggcggccgt ggtggaggcc tccaccccag 1140 gagcaccccg cacaccctcg gaggacgggc ttcggctgcg cggaggccgt ggcacacctg 1200 cgggaggcag cgacggcccc cacgcagacg ccgggaacgc aggccgcttt attcctctgt 1260 acttagatca acttgaccgt actaaaatcc ctttctgttt taaccagtta aacatgcctc 1320 ttctacagct ccatttttga tagttggata atccagtatc tgccaagagc atgttgggtc 1380 tcccgtgact gctgcctcat cgatacccca tttagctcca gaaagcaaag aaaactcgag 1440 taacacttgt ttgaaagaga tcattaaatg tattttgcaa agcccaaaaa aaaaaaaaaa 1500 a 1501 <210> 5 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Epitope F1 <400> 5 Gln Leu Ala Ala Gly Thr Cys Glu Ile Val Thr Leu Asp Arg 1 5 10 <210> 6 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Epitope F2 <400> 6 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 7 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Epitope F3 <400> 7 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 1 5 10 15 Ala Arg Pro Ala 20 <210> 8 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Epitope F4 <400> 8 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 1 5 10 15 Cys Asp Met Leu 20 <210> 9 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Epitope F5 <400> 9 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 1 5 10 15 Asn Arg Ser Gly 20 <210> 10 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Epitope F6 <400> 10 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 1 5 10 15 Thr Thr Val Ser 20 <210> 11 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 2-13 Antibody VH-CDR1 <400> 11 Ser His Gly Met Phe 1 5 <210> 12 <211> 17 <212> PRT <213> Artificial sequence <220> <223> 2-13; 2-13D; 2-13D-37; 2-13D-37-1.5W-41; 2-13D-37-3W-16 VH-CDR2 <400> 12 Glu Ile Thr Asn Asp Gly Ser Gly Thr Asn Tyr Gly Ser Ala Val Lys 1 5 10 15 Gly <210> 13 <211> 20 <212> PRT <213> Artificial sequence <220> <223> 2-13; 2-13D; 2-13D-37 VH-CDR3 <400> 13 Ser Thr Tyr Glu Cys Pro Gly Gly Phe Ser Cys Trp Gly Asp Thr Gly 1 5 10 15 Gln Ile Asp Ala 20 <210> 14 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 3-2 Antibody VH-CDR1 <400> 14 Ser Phe Asn Met Phe 1 5 <210> 15 <211> 17 <212> PRT <213> Artificial sequence <220> <223> 3-2 Antibody VH-CDR2 <400> 15 Gln Ile Ser Ser Ser Gly Ser Ser Thr Asn Tyr Ala Pro Ala Val Arg 1 5 10 15 Gly <210> 16 <211> twenty two <212> PRT <213> Artificial sequence <220> <223> 3-2; 1-7A-IT; low PI; 1-30; 1-17; 1-32; 4-11; 6-10 VH-CDR3 <400> 16 Ser Ser Tyr Asp Cys Pro Tyr Gly His Cys Ser Ser Gly Val Asp Ser 1 5 10 15 Ala Gly Glu Ile Asp Ala 20 <210> 17 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 1-65; SS01-13; SS01-13-s5; S5-2.GKNG VH-CDR1 <400> 17 Ser Tyr Gln Met Gly 1 5 <210> 18 <211> 10 <212> PRT <213> Artificial sequence <220> <223> 1-65; SS01-13 VH-CDR2 <400> 18 Val Ile Asn Lys Ser Gly Ser Asp Thr Ser 1 5 10 <210> 19 <211> 13 <212> PRT <213> Artificial sequence <220> <223> 1-65; SS01-13; SS01-13-s5; S5-2.GKNG VH-CDR3 <400> 19 Gly Ser Ala Ser Tyr Ile Thr Ala Ala Thr Ile Asp Ala 1 5 10 <210> 20 <211> 8 <212> PRT <213> Artificial sequence <220> <223> 1-28 Antibody VH-CDR1 <400> 20 Gly Phe Asp Phe Ser Asp Tyr Gly 1 5 <210> twenty one <211> 8 <212> PRT <213> Artificial sequence <220> <223> 1-28 Antibody VH-CDR2 <400> twenty one Ile Arg Ser Asp Gly Ser Asn Pro 1 5 <210> twenty two <211> 29 <212> PRT <213> Artificial sequence <220> <223> 1-28 Antibody VH-CDR3 <400> twenty two Ala Lys Asp Gly Asn Gly Tyr Cys Ala Leu Asp Ala Tyr Arg Ser Gly 1 5 10 15 Gly Tyr Ser Cys Gly Val Tyr Pro Gly Ser Ile Asp Ala 20 25 <210> twenty three <211> 8 <212> PRT <213> Artificial sequence <220> <223> 2-13 antibody VL-CDR1 <400> twenty three Ser Gly Gly Ser Tyr Ser Tyr Gly 1 5 <210> twenty four <211> 7 <212> PRT <213> Artificial sequence <220> <223> 2-13; 2-13D; 2-13D-37; 2-13D-37-1.5W-41; 2-13D-37-3W-16 VL-CDR2 <400> twenty four Trp Asp Asp Glu Arg Pro Ser 1 5 <210> 25 <211> 11 <212> PRT <213> Artificial sequence <220> <223> 2-13; 2-13D; 2-13D-37; 2-13D-37-1.5W-41; 2-13D-37-3W-16 VL-CDR3 <400> 25 Gly Thr Glu Asp Ile Ser Gly Thr Ala Gly Val 1 5 10 <210> 26 <211> 13 <212> PRT <213> Artificial sequence <220> <223> 3-2; 1-7A-IT; 1-17; 1-32; 4-11; 6-10 VL-CDR1 <400> 26 Ser Gly Gly Gly Ser Tyr Ala Gly Ser Tyr Tyr Tyr Gly 1 5 10 <210> 27 <211> 7 <212> PRT <213> Artificial sequence <220> <223> 3-2 Antibody VL-CDR2 <400> 27 Glu Ser Asn Lys Arg Pro Ser 1 5 <210> 28 <211> 10 <212> PRT <213> Artificial sequence <220> <223> 3-2;1-7A-IT VL-CDR3 <400> 28 Gly Ser Trp Asp Ser Ser Asn Gly Gly Ile 1 5 10 <210> 29 <211> 11 <212> PRT <213> Artificial sequence <220> <223> 1-65 antibody VL-CDR1 <400> 29 Ser Gly Gly Gly Ser Ser Gly Tyr Gly Tyr Gly 1 5 10 <210> 30 <211> 7 <212> PRT <213> Artificial sequence <220> <223> 1-65 antibody VL-CDR2 <400> 30 Trp Asn Asp Lys Arg Pro Ser 1 5 <210> 31 <211> 14 <212> PRT <213> Artificial sequence <220> <223> 1-65; ss01-13; SS01-13-S5; S5-2.GKNG VL-CDR3 <400> 31 Gly Asn Asp Asp Tyr Ser Ser Asp Ser Gly Tyr Val Gly Val 1 5 10 <210> 32 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 1-28 Antibody VL-CDR1 <400> 32 Gly Tyr Gly Tyr Gly 1 5 <210> 33 <211> 3 <212> PRT <213> Artificial sequence <220> <223> 1-28 antibody VL-CDR2 <400> 33 Gln Asn Asp 1 <210> 34 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 1-28 antibody VL-CDR3 <400> 34 Gly Ser Glu Asp Ser Ser Thr Leu Ala Gly Ile 1 5 10 <210> 35 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> 2-13 antibody VH <400> 35 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser His 20 25 30 Gly Met Phe Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Tyr Val �5 40 45 Ala Glu Ile Thr Asn Asp Gly Ser Gly Thr Asn Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Thr Tyr Glu Cys Pro Gly Gly Phe Ser Cys Trp Gly Asp 100 105 110 Thr Gly Gln Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser 115 120 125 Ser <210> 36 <211> 131 <212> PRT <213> Artificial sequence <220> <223> 3-2 antibody VH <400> 36 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 305] Asn Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Gln Ile Ser Ser Ser Gly Ser Ser Thr Asn Tyr Ala Pro Ala Val 50 55 60 [[ID=*4]]Arg Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 It seems there might be a small typo in your original text where [ID=*4] should probably be . I've translated it as is but you may want to double-check that.Leu Gln Leu Asn Asn Pro Gly Ala Glu Asp Thr Gly Thr Tyr Tyr Cys 85 90 95 Ala Lys Ser Ser Tyr Asp Cys Pro Tyr Gly His Cys Ser Ser Gly Val 100 105 110 Asp Ser Ala Gly Glu Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile 115 120 125 Val Ser Ser 130 <210> 37 <211> 122 <212> PRT <21^23> Artificial sequence <220> <223> VH of antibody 1-65 <400> 37 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gln Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Asn Lys Ser Gly Ser Asp Thr Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 It should be noted that there may be some inaccuracies in the translation of some terms in the context of patent texts, and it is recommended to consult relevant professional materials for more accurate expressions according to specific patent content.Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Lys Gly Ser Ala Ser Tyr Ile Thr Ala Ala Thr Ile Asp Ala Trp 100 105 110 Gly His Gly Thr Glu Val Ile Val Ser Ser 115 120 <210> 38 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VH <400> 38 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Asp Phe Ser Asp Tyr 20 25 30 Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ala Ile Arg Ser Asp Gly Ser Asn Pro Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Lys Asp Asn Gly Arg Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Asn Gly Tyr Cys Ala Leu Asp Ala Tyr Arg Ser Gly 100 105 110 Gly Tyr Ser Cys Gly Val Tyr Pro Gly Ser Ile Asp Ala Trp Gly His 115 120 125 Gly Thr Glu Val Ile Val Ser Ser 130 135 <210> 39 <211> 104 <212> PRT <213> Artificial sequence <220> <223> 2-13 antibody VL <400> 39 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Ser Tyr Ser Tyr Gly Trp Phe Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Leu Val Thr Val Ile Tyr Trp Asp Asp Glu 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ala Leu Ser Gly Ser 50 55 60 Thr Asn Thr Leu Thr Ile Thr Gly Val Gln Ala Asp Asp Glu Ala Val 65 70 75 80 Tyr Phe Cys Gly Thr Glu Asp Ile Ser Gly Thr Ala Gly Val Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu 100 <210> 40 <211> 108 <212> PRT <213> Synthetic Sequence <220> <223> 3-2 Antibody VL <400> 40 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Tyr Ala Gly Ser Tyr Tyr Tyr 20 25 30 Gly Trp Tyr Gln Gln Lys Ala Pro Gly Ser Ala Pro Val Thr Leu Ile 35 40 45 Tyr Glu Ser Asn Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Thr Ser Gly Ser Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala 65 70 75 80 Asp Asp Glu Ala Ile Tyr Tyr Cys Gly Ser Trp Asp Ser Ser Asn Gly 85 90 95 Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val Leu 100 105 <210> 41 <211> 110 <212> PRT <213> Synthetic Sequence <220> <223> 1-65 antibody VL <400> 41 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Ser Gly Tyr Gly Tyr Gly Trp 20 25 30 Tyr Gln Gln Lys Ser Pro Ser Ser Ala Pro Leu Thr Val Ile Tyr Trp 35 40 45 Asn Asp Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys 50 55 60 Ser Gly Ser Thr His Thr Leu Thr Ile Thr Gly Val Gln Ala Glu Asp 65 70 75 80 Glu Ala Val Tyr Phe Cys Gly Asn Asp Asp Tyr Ser Ser Asp Ser Gly 85 90 95 Tyr Val Gly Val Phe Gly Ala Gly Thr Thr Leu Thr Val Leu 100 105 110 <210> 42 <211> 104 <212> PRT <213> Artificial sequence <220> <223> 1-28 antibody VL <400> 42 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Leu Glu Gly Thr Val 1 5 10 15 Glu Ile Thr Cys Ser Gly Ser Gly Tyr Gly Tyr Gly Trp Tyr Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Gln Asn Asp Lys 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser 50 55 60 Thr Gly Thr Leu Thr Ile Thr Gly Val Gln Val Glu Asp Glu Ala Val 65 70 75 80 Tyr Tyr Cys Gly Ser Glu Asp Ser Ser Thr Leu Ala Gly Ile Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu 100 <210> 43 <211> 388 <212> DNA <213> Artificial sequence <220> <223> 2 - 13 antibody VH <400> 43 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt caccttcagc agccatggca tgttctgggt gcgacagacg 120 cccggcaagg ggttggaata tgtcgctgaa attaccaatg atggtagtgg cacaaactac 180 gggtcggcgg tgaagggccg tgccaccatc tcgagggaca acgggcagag cacagtgagg 240 ctgcagctga acaacctcag ggctgaggac accggcacct acttctgcgc cagatctact 300 tatgaatgtc ctggtggttt tagttgttgg ggtgatactg gtcaaataga cgcatggggc 360 cacgggaccg aagtcatcgt ctcctcca 388 <210> 44 <211> 394 <212> DNA <213> Artificial sequence <220> <223> 3-2 antibody VH <400> 44 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt caccttcagc agcttcaaca tgttctgggt gcgacaggcg 120 cccggcaagg ggctggaata cgtcgctcaa attagcagca gtggtagtag cacaaactac 180 gcacccgcgg tgaggggccg tgccaccatc tcgagggaca acgggcagag cacagtgagg 240 ctgcagctga acaaccccgg ggctgaagac accggcacct actactgcgc caaaagtagt 300 tatgactgtc cttacggtca ttgtagtagt ggtgttgata gtgctggtga gatcgacgca 360 tggggccacg ggaccgaagt catcgtctcc tcca 394 <210> 45 <211> 366 <212> DNA <213> Artificial sequence <220> <223> 1-65 antibody VH <400> 45 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt caccttcagc agctatcaga tgggctgggt gcgacaggcg 120 cccggcaagg ggctggaatg ggtcggtgtt attaacaaga gtggtagtga cacatcatac 180 gggtcggcgg tgaagggccg tgccaccatc tcgagggaca acgggcagag cacagtgagg 240 ctgcagctga acaacctcag ggctgaggac accggcacct acttctgcgc caaaggttct 300 gctagttata taactgctgc taccatcgac gcatggggcc acgggaccga agtcatcgtc 360 tcctcc 366 <210> 46 <211> 408 <212> DNA <213> Artificial sequence <220> <223> 1-28 antibody VH <400> 46 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt cgacttcagc gattatggca tgggttgggt gcgacaggct 120 ccaggcaagg ggctggagtg ggttgctgct attagaagtg atggtagtaa cccatcatac 180 gggtcggcgg tgaagggccg tgccaccatc tcgaaggaca acgggcgaag cacagtgagg 240 ctgcagctga acaacctcag ggctgaggac accgccacct actactgcgc caaggatggt 300 aatggttact gtgctctcga tgcttatcgt agtggtggtt atagttgtgg tgtttatcct 360 ggtagcatcg acgcatgggg ccacgggacc gaagtcatcg tctcctcc 408 <210> 47 <211> 315 <212> DNA <213> Artificial Sequence <220> <223> 2 - 13 Antibody VL <400> 47 ggccctgact cagccgtcct cggtgtcagc aaacccagga gaaaccgtca agataacctg 60 ctccgggggt agctatagct atggctggtt ccagcagaag tctcctggca gtgcccttgt 120 cactgtgatc tactgggatg atgagagacc ctcggacatc ccttcacgat tctccggtgc 180 cctatccggc tccacaaaca cattaaccat cactggggtc caagccgacg acgaggctgt 240 ctatttctgt gggactgaag acatcagcgg cactgctggt gtatttgggg ccgggacaac 300 cctgaccgtc ctggg 315 <210> 48 <211> 327 <212> DNA <213> Artificial sequence <220> <223> 3-2 antibody VL <400> 48 ggccctgact cagccgtcct cggtgtcagc aaacccagga gaaaccgtca agatcacctg 60 ctccgggggt ggcagctatg ctggaagtta ctattatggc tggtaccagc agaaggcacc 120 tggcagtgcc cctgtcactc tgatctatga aagcaacaag agaccctcgg acatcccttc 180 acgattctcc ggttccacat ctggctccac agccacacta accatcactg gggtccaagc 240 cgatgacgag gctatctatt actgtgggag ctgggacagt agcaatggtg gtatatttgg 300 ggccgggaca accctgaccg tcctagg 327 <210> 49 <211> 331 <212> DNA <213> Artificial sequence <220> <223> 1-65 antibody VL <400> 49 ggccctgact cagccgtcct cggtgtcagc aaaccctggg gaaactgtca agatcacctg 60 ctccgggggt ggtagcagtg gctatggtta tggctggtat cagcagaagt cacctagcag 120 tgcccctctc actgtgatct actggaacga caagagaccc tcggacatcc cttcacgatt 180 ctccggttcc aaatccggct ccacacacac attackc actggggtcc aagccgagga cgaggctgta tatttctgtg ggaatgatga ctacagcagt gatagtggat atgtcggtgt atttggggcc gggacaaccc tgaccgtcct a331 <210> 50 <211> 312 <212> DNA <213> The snowstorm <220> <223> 1-28th March VL <400> 50 gccctgactc agccgtcctc ggtgtcagca aacctggaag gaaccgtcga gatcacctgc tccggggagtg gctatggtta tggctggtat cagcagaagt ctcctggcag tgcccctgtc 120 actgtgatct atcagaacga caagagaccc tcggacatcc cttcacgatt ctccggttcc 240. aaatccggct ccacgggcac attackc actggggtcc aagtcgagga cgaggctgtc tattactgtg ggagtgaaga cagcagcact cttgctggta tatttggggc cgggacaacc 312 of ctgaccgtcc <210> 51 <211> 100 <212> PRT <213> The snowstorm <220> <223> M3 properties <400> 51 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Ile Glu Glu Arg Ser Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 52 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M4 Mutant <400> 52 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Val Lys Cys Ser Cys Phe Pro Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 53 <211> 100 [[ID=२4]]<212> PRT <213> Artificial Sequence <220> <223> M5 Mutant <400> 53 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Asn Lys Pro Ser Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 54 <211> 100 <212> PRT <213> Artificial sequence <220> <223> M6 mutant <400> 54 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Leu Gln Arg Trp Trp 50 55 60 Cys Gln Met Glu Leu Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 55 <211> 100 <212> PRT <213> Artificial sequence <220> <223> M7 mutant <400> 55 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Glu Cys Lys Thr Leu Pro 65 70 75 80 Asp Asn Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 56 <211> 101 <212> PRT <213> Artificial sequence <220> <223> M8 mutant <400> 56 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Ser Cys Ser Ser Gly Asn Lys Ile Lys 85 90 95 Thr Thr Thr Val Ser 100 <210> 57 <211> 459 <212> PRT <213> Synthetic Sequence <220> <223> 2-13 Antibody HC <400> 57 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser His 20 25 30 Gly Met Phe Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Glu Ile Thr Asn Asp Gly Ser Gly Thr Asn Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Thr Tyr Glu Cys Pro Gly Gly Phe Ser Cys Trp Gly Asp 100 105 110 Thr Gly Gln Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser 115 120 125 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 130 135 140 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 145 150 155 160 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 165 170 175 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 180 185 190 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 195 200 205 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 210 215 220 Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 225 230 235 240 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 245 250 255 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 260 265 270 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 275 280 285 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 290 295 300 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 305 310 315 320 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 325 330 335 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 340 345 350 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 355 360 365 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 370 375 380 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 385 390 395 400 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 405 410 415 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 420 425 430 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 435 440 445 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 58 <211> 461 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody HC <400> 58 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Asn Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Gln Ile Ser Ser Ser Gly Ser Ser Thr Asn Tyr Ala Pro Ala Val 50 55 60 Arg Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Pro Gly Ala Glu Asp Thr Gly Thr Tyr Tyr Cys 85 90 95 Ala Lys Ser Ser Tyr Asp Cys Pro Tyr Gly His Cys Ser Ser Gly Val 100 105 110 Asp Ser Ala Gly Glu Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile 115 120 125 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 130 135 140 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 145 150 155 160 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 165 170 175 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 180 185 190 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 195 200 205 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 210 215 220 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 225 230 235 240 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 245 250 255 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 260 265 270 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 275 280 285 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 290 295 300 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 305 310 315 320 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 325 330 335 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 340 345 350 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 355 360 365 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 370 375 380 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 385 390 395 400 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 405 410 415 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 420 425 430 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 435 440 445 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460 <210> 59 <211> 452 <212> PRT <213> artificial sequence <220> <223> 1-65 antibodyHC <400> 59 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gln Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Asn Lys Ser Gly Ser Asp Thr Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Lys Gly Ser Ala Ser Tyr Ile Thr Ala Ala Thr Ile Asp Ala Trp 100 105 110 Gly His Gly Thr Glu Val Ile Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Light 450 <210> 60 <211> 466 <212> PRT <213> artificial sequence <220> <223> 1-28 antibodyHC <400> 60 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Asp Phe Ser Asp Tyr 20 25 30 Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ala Ile Arg Ser Asp Gly Ser Asn Pro Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Lys Asp Asn Gly Arg Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Asn Gly Tyr Cys Ala Leu Asp Ala Tyr Arg Ser Gly 100 105 110 Gly Tyr Ser Cys Gly Val Tyr Pro Gly Ser Ile Asp Ala Trp Gly His 115 120 125 Gly Thr Glu Val Ile Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 130 135 140 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 145 150 155 160 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 210 215 220 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 225 230 235 240 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 245 250 255 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 275 280 285 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 305 310 315 320 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 340 345 350 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 385 390 395 400 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 420 425 430 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 450 455 460 Gly Lys 465 <210> 61 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody LC <400> 61 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Ser Tyr Ser Tyr Gly Trp Phe Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Leu Val Thr Val Ile Tyr Trp Asp Asp Glu 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ala Leu Ser Gly Ser 50 55 60 Thr Asn Thr Leu Thr Ile Thr Gly Val Gln Ala Asp Asp Glu Ala Val 65 70 75 80 Tyr Phe Cys Gly Thr Glu Asp Ile Ser Gly Thr Ala Gly Val Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu Arg Ser Val Ala Ala Pro Ser Val 100 105 110 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser 115 120 125 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 130 135 140 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 145 150 155 160 Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 165 170 175 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 180 185 190 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg 195 200 205 Gly Glu Cys 210 <210> 62 <211> 215 <212> PRT <213> artificial sequence <220> <223> 3-2 antibody LC <400> 62 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Tyr Ala Gly Ser Tyr Tyr Tyr 20 25 30 Gly Trp Tyr Gln Gln Lys Ala Pro Gly Ser Ala Pro Val Thr Leu Ile 35 40 45 Tyr Glu Ser Asn Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Thr Ser Gly Ser Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala 65 70 75 80 Asp Asp Glu Ala Ile Tyr Tyr Cys Gly Ser Trp Asp Ser Ser Asn Gly 85 90 95 Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val Leu Arg Ser Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 63 <211> 217 <212> PRT <213> Artificial sequence <220> <223> 1-65 antibody LC <400> 63 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Ser Gly Tyr Gly Tyr Gly Trp 20 25 30 Tyr Gln Gln Lys Ser Pro Ser Ser Ala Pro Leu Thr Val Ile Tyr Trp 35 40 45 Asn Asp Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys 50 55 60 Ser Gly Ser Thr His Thr Leu Thr Ile Thr Gly Val Gln Ala Glu Asp 65 70 75 80 Glu Ala Val Tyr Phe Cys Gly Asn Asp Asp Tyr Ser Ser Asp Ser Gly 85 90 95 Tyr Val Gly Val Phe Gly Ala Gly Thr Thr Leu Thr Val Leu Arg Ser 100 105 110 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 115 120 125 Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 130 135 140 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 145 150 155 160 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 165 170 175 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 180 185 190 Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 195 200 205 Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 64 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody LC <400> 64 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Leu Glu Gly Thr Val 1 5 10 15 Glu Ile Thr Cys Ser Gly Ser Gly Tyr Gly Tyr Gly Trp Tyr Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Gln Asn Asp Lys 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser 50 55 60 Thr Gly Thr Leu Thr Ile Thr Gly Val Gln Val Glu Asp Glu Ala Val 65 70 75 80 Tyr Tyr Cys Gly Ser Glu Asp Ser Ser Thr Leu Ala Gly Ile Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu Arg Ser Val Ala Ala Pro Ser Val 100 105 110 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser 115 120 125 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 130 135 140 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 145 150 155 160 Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 165 170 175 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 180 185 190 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg 195 200 205 Gly Glu Cys 210 <210> 65 <211> 5 <212> PRT <213> Artificial sequence <220> <223> EP1 epitope <400> 65 Ile Val Thr Leu Asp 1 5 <210> 66 <211> 5 <212> PRT <213> Artificial sequence <220> <223> EP2 epitope <400> 66 Asp Ser Ser Gln Pro 1 5 <210> 67 <211> 5 <212> PRT <213> Artificial sequence <220> <223> EP3 epitope <400> 67 Arg Thr Ile Ala Arg 1 5 <210> 68 <211> 7 <212> PRT <213> Artificial sequence <220> <223> EP4 epitope <400> 68 Ala Arg Cys Ala Cys Arg Lys 1 5 <210> 69 <211> 4 <212> PRT <213> Artificial sequence <220> <223> EP5 epitope <400> 69 Ala Arg Pro Ala 1 <210> 70 <211> 9 <212> PRT <213> Artificial sequence <220> <223> EP6 epitope <400> 70 Lys Thr Lys Gln Trp Cys Asp Met Leu 1 5 <210> 71 <211> 8 <212> PRT <213> Artificial sequence <220> <223> EP7 epitope <400> 71 Gly Cys Asp Leu Leu Ile Asn Arg 1 5 <210> 72 <211> 8 <212> PRT <213> Artificial sequence <220> <223> EP8 epitope <400> 72 Thr Cys Thr Gln Pro Gly Gly Arg 1 5 <210> 73 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-01-BSA (#1) <400> 73 Thr Ala Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 74 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-02-BSA (#2) <400> 74 Thr Leu Ala Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 75 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-03-BSA (#3) <400> 75 Thr Leu Asp Arg Ala Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 76 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-04-BSA (#4) <400> 76 Thr Leu Asp Arg Asp Ala Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 77 <211> 20 <212> PRT Thr Leu Asp Arg Asp Ser Ala Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 78 <211> 20 <212> PRT <213> Synthetic Sequence <220> <223> F2-06-BSA (#6) <400> 78 Thr Leu Asp Arg Asp Ser Ser Ala Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 79 <211> 20 <212> PRT <213> Synthetic Sequence <220> <223> F2-07-BSA (#7) <400> 79 Thr Leu Asp Arg Asp Ser Ser Gln Ala Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 80 <211> 20 <212> PRT <213> Synthetic Sequence <220> <223> F2-08-BSA (#8) <400> 80 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Ala Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 81 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-09-BSA (#9) <400> 81 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Ala Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 82 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-10-BSA (#10) <400> 82 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ala Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 83 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-11-BSA (#11) <400> 83 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Arg Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 84 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-12-BSA (#12) <400> 84 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Ala Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 85 <211> 20 <212> PRT <213> Artificial sequence <220> <223> F2-12-BSA (#13) <400> 85 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Val Arg Cys 20 <210> 86 <211> 100 <212> PRT <213> Artificial sequence <220> <223> Wild-type FAM19A5 isoform (without signal peptide) <400> 86 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 87 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M1 Mutant <400> 87 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Val Ile 1 5 10 15 Ala Ala His Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 88 <211> 100 <212> PRT <213> Synthetic sequence <220> <223> M2 mutant <400> 88 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Cys Cys Asn Lys Asn Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 89 <211> 5 <212> PRT <213> Synthetic sequence <220> <223> P2-C12 antibody VH CDR1 <400> 89 Thr Tyr Ala Val Thr 1 5 <210> 90 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P2-C12 antibody VH CDR2 <400> 90 Tyr Ile Asn Trp Arg Gly Gly Thr Ser Tyr Ala Asn Trp Ala Lys Gly 1 5 10 15 <210> 91 <211> 15 <212> PRT <213> Artificial sequence <220> <223> P2-C12 antibody VH CDR3 <400> 91 Asp Ala Ser Ser Gly Ala Ala Phe Gly Ser Tyr Gly Met Asp Pro 1 5 10 15 <210> 92 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P2-C12 Antibody VL CDR1 <400> 92 Gln Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser 1 5 10 <210> 93 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P2-C12 antibody VL CDR2 <400> 93 Glu Ala Ser Lys Leu Ala Ser 1 5 <210> 94 <211> 12 <212> PRT <213> Artificial sequence <220> <223> P2-C12 Antibody VL CDR3 <400> 94 Gln Gln Gly Tyr Ser Ser Thr Asn Val Trp Asn Ala 1 5 10 <210> 95 <211> 6 <212> PRT <213> Artificial sequence <220> <223> 13B4 antibody VH CDR1 <400> 95 Ser Ser Asn Trp Trp Ser 1 5 <210> 96 <211> 16 <212> PRT <213> Artificial sequence <220> <223> 13B4 antibody VH CDR2 <400> 96 Glu Ile Tyr His Gly Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Gly 1 5 10 15 <210> 97 <211> 9 <212> PRT <213> Artificial sequence <220> <223> 13B4 antibody VH CDR3 <400> 97 Trp Gln Leu Val Gly Gly Leu Asp Val 1 5 <210> 98 <211> 11 <212> PRT <213> Artificial sequence <220> <223> 13B4 antibody VL CDR1 <400> 98 Ser Gly Asp Lys Leu Gly Asn Val Tyr Ala Ser 1 5 10 <210> 99 <211> 7 <212> PRT <213> Artificial sequence <220> <223> 13B4 antibody VL CDR2 <400> 99 Gln Asp Asn Lys Arg Pro Ser 1 5 <210> 100 <211> 9 <212> PRT <213> Artificial sequence <220> <223> 13B4 antibody VL CDR3 <400> 100 Gln Ala Trp Asp Ser Ser Thr Ala Val 1 5 <210> 101 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 13F7 antibody VH CDR1 <400> 101 Gly Tyr Ser Trp Thr 1 5 <210> 102 <211> 16 <212> PRT <213> Artificial sequence <220> <223> 13F7 antibody VH CDR2 <400> 102 Glu Ile Ser His Phe Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 103 <211> 15 <212> PRT <213> Artificial sequence <220> <223> 13F7 antibody VH CDR3 <400> 103 Ala Leu Arg Gly Thr Tyr Ser Arg Phe Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 104 <211> 16 <212> PRT <213> Artificial sequence <220> <223> 13F7 antibody VL CDR1 <400> 104 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 105 <211> 7 <212> PRT <213> Artificial sequence <220> <223> 13F7 antibody VL CDR2 <400> 105 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 106 <211> 9 <212> PRT <213> Artificial sequence <220> <223> 13F7 antibody VL CDR3 <400> 106 Met Gln Ala Arg Gln Thr Pro Leu Thr 1 5 <210> 107 <211> 5 <212> PRT <213> Artificial sequence <220> <223> 15A9 antibody VH CDR1 <400> 107 Ser Tyr Tyr Trp Ser 1 5 <210> 108 <211> 16 <212> PRT <213> Artificial sequence <220> <223> 15A9 antibody VH CDR2 <400> 108 Tyr Ile Tyr Pro Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 109 <211> 12 <212> PRT <213> Artificial sequence <220> <223> 15A9 antibody VH CDR3 <400> 109 Val Asn Pro Phe Gly Tyr Tyr Tyr Ala Met Asp Val 1 5 10 <210> 110 <211> 11 <212> PRT <213> Artificial sequence <220> <223> 15A9 antibody VL CDR1 <400> 110 Arg Ala Ser Gln Ser Ile Ser Thr Ser Leu Asn 1 5 10 <210> 111 <211> 7 <212> PRT <213> Artificial sequence <220> <223> 15A9 antibody VL CDR2 <400> 111 Gly Ala Ser Thr Leu Gln Ser 1 5 <210> 112 <211> 9 <212> PRT <213> Artificial sequence <220> <223> 15A9 antibody VL CDR3 <400> 112 Gln Glu Ser Ala Ser Ile Pro Arg Thr 1 5 <210> 113 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P1-A03 antibody VH CDR1 <400> 113 Ser Asp Tyr Met Ser 1 5 <210> 114 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P1-A03 antibody VH CDR2 <400> 114 Ile Ile Tyr Pro Ser Thr Thr Thr Tyr Tyr Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 115 <211> 10 <212> PRT <213> Artificial sequence <220> <223> P1-A03 antibody VH CDR3 <400> 115 Gly Ser Asn Trp Ser Ser Gly Met Asn Leu 1 5 10 <210> 116 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P1-A03 antibody VL CDR1 <400> 116 Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser 1 5 10 <210> 117 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P1-A03 antibody VL CDR2 <400> 117 Gly Ala Ser Asn Leu Glu Ser 1 5 <210> 118 <211> 12 <212> PRT <213> Artificial sequence <220> <223> P1-A03 antibody VL CDR3 <400> 118 Leu Gly Gly Tyr Ser Tyr Ser Ser Thr Gly Leu Thr 1 5 10 <210> 119 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P1-A08 antibody VH CDR1 <400> 119 Thr Tyr Tyr Met Ser 1 5 <210> 120 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P1-A08 antibody VH CDR2 <400> 120 Ile Val Tyr Pro Ser Gly Thr Thr Tyr Tyr Ala Asn Trp Ala Lys Gly 1 5 10 15 <210> 121 <211> 8 <212> PRT <213> Artificial sequence <220> <223> P1-A08 antibody VH CDR3 <400> 121 Gly Asp Ser Phe Gly Tyr Gly Leu 1 5 <210> 122 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P1-A08 antibody VL CDR1 <400> 122 Thr Ala Asp Thr Leu Ser Arg Ser Tyr Ala Ser 1 5 10 <210> 123 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P1-A08 antibody VL CDR2 <400> 123 Arg Asp Thr Ser Arg Pro Ser 1 5 <210> 124 <211> 13 <212> PRT <213> Artificial sequence <220> <223> P1-A08 antibody VL CDR3 <400> 124 Ala Thr Ser Asp Gly Ser Gly Ser Asn Tyr Gln Tyr Val 1 5 10 <210> 125 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VH CDR1 <400> 125 Asn Tyr Tyr Met Gly 1 5 <210> 126 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VH CDR2 <400> 126 Ile Ile Tyr Ala Ser Gly Ser Thr Tyr Tyr Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 127 <211> 17 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VH CDR3 <400> 127 Ile Asp Ile Gly Val Gly Asp Tyr Gly Trp Ala Tyr Asp Arg Leu Asp 1 5 10 15 Leu <210> 128 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VL CDR1 <400> 128 Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser 1 5 10 <210> 129 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VL CDR2 <400> 129 Gly Ala Ser Asn Leu Glu Ser 1 5 <210> 130 <211> 10 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VL CDR3 <400> 130 Leu Gly Gly Tyr Ser Tyr Ser Ser Ile Thr 1 5 10 <210> 131 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P2-A01 antibody VH CDR1 <400> 131 Gly Tyr Tyr Met Ser 1 5 <210> 132 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P2-A01 antibody VH CDR2 <400> 132 Ile Ile Tyr Pro Ser Gly Ser Thr Asp Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 133 <211> 15 <212> PRT <213> Artificial sequence <220> <223> P2-A01 antibody VH CDR3 <400> 133 Val Ala Gly Tyr Val Gly Tyr Gly Tyr Glu Thr Phe Phe Asp Ile 1 5 10 15 <210> 134 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P2-A01 Antibody VL CDR1 <400> 134 Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser 1 5 10 <210> 135 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P2-A01 Antibody VL CDR2 <400> 135 Gly Ala Ser Asn Leu Glu Ser 1 5 <210> 136 <211> 14 <212> PRT <213> Artificial sequence <220> <223> P2-A01 Antibody VL CDR3 <400> 136 Leu Gly Gly Val Thr Tyr Ser Ser Thr Gly Thr His Leu Thr 1 5 10 <210> 137 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P2-A03 antibody VH CDR1 <400> 137 Asn Tyr Asp Met Ser 1 5 <210> 138 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P2-A03 antibody VH CDR2 <400> 138 Phe Met Asp Thr Asp Gly Ser Ala Tyr Tyr Ala Thr Trp Ala Lys Gly 1 5 10 15 <210> 139 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P2-A03 antibody VH CDR3 <400> 139 Arg Gly Ser Ser Tyr Tyr Gly Gly Ile Asp Ile 1 5 10 <210> 140 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P2-A03 antibody VL CDR1 <400> 140 Gln Ala Ser Gln Ser Ile Gly Gly Asn Leu Ala 1 5 10 <210> 141 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P2-A03 antibody VL CDR2 <400> 141 Arg Ala Ser Thr Leu Ala Ser 1 5 <210> 142 <211> 14 <212> PRT <213> Artificial sequence <220> <223> P2-A03 antibody VL CDR3 <400> 142 Gln Ser Pro Ala Tyr Asp Pro Ala Ala Tyr Val Gly Asn Ala 1 5 10 <210> 143 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P2-F07 antibody VH CDR1 <400> 143 Ser Tyr Tyr Met Asn 1 5 <210> 144 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P2-F07 antibody VH CDR2 <400> 144 Ile Ile Tyr Pro Ser Gly Thr Thr Tyr Tyr Tyr Ala Gly Trp Ala Lys Gly 1 5 10 15 <210> 145 <211> 8 <212> PRT <213> Artificial sequence <220> <223> P2-F07 antibody VH CDR3 <400> 145 Thr Val Ser Gly Tyr Phe Asp Ile 1 5 <210> 146 <211> 11 <212> PRT <213> Artificial sequence <220> <223> P2-F07 antibody VL CDR1 <400> 146 Leu Ala Ser Glu Asp Ile Tyr Ser Ala Leu Ala 1 5 10 <210> 147 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P2-F07 antibody VL CDR1 <400> 147 Gly Thr Ser Asn Leu Glu Ser 1 5 <210> 148 <211> 9 <212> PRT <213> Artificial sequence <220> <223> P2-F07 antibody VL CDR3 <400> 148 Gln Gly Tyr Ser Ser Tyr Pro Leu Thr 1 5 <210> 149 <211> 5 <212> PRT <213> Artificial sequence <220> <223> P2-F11 antibody VH CDR1 <400> 149 Ser Tyr Gly Val Ser 1 5 <210> 150 <211> 16 <212> PRT <213> Artificial sequence <220> <223> P2-F11 antibody VH CDR2 <400> 150 Tyr Ile Ala Asn Asn Tyr Asn Pro His Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 151 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P2-F11 antibody VH CDR3 <400> 151 Asp Asn Tyr Gly Met Asp Pro 1 5 <210> 152 <211> 13 <212> PRT <213> Artificial sequence <220> <223> P2-F11 antibody VL CDR1 <400> 152 Gln Ala Ser Gln Ser Val Tyr Asn Asn Lys Asn Leu Ala 1 5 10 <210> 153 <211> 7 <212> PRT <213> Artificial sequence <220> <223> P2-F11 antibody VL CDR2 <400> 153 Ala Ala Ser Thr Leu Ala Ser 1 5 <210> 154 <211> 13 <212> PRT <213> Artificial sequence <220> <223> P2-F11 antibody VL CDR3 <400> 154 Gln Gly Glu Phe Ser Cys Ser Ser Ala Asp Cys Asn Ala 1 5 10 <210> 155 <211> 121 <212> PRT <213> Artificial sequence <220> <223> P2-C12 antibody VH <400> 155 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Tyr Ala 20 25 30 Val Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 35 40 45 Tyr Ile Asn Trp Arg Gly Gly Thr Ser Tyr Ala Asn Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Met 65 70 75 80 Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp 85 90 95 Ala Ser Ser Gly Ala Ala Phe Gly Ser Tyr Gly Met Asp Pro Trp Gly 100 105 110 Pro Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 156 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> 13B4 Antibody VH <400> 156 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly 1 5 10 15 Thr Leu Ser Leu Asn Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser 20 25 30 Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Glu Ile Tyr His Gly Gly Thr Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Gly Arg Val Thr Met Ser Val Asp Lys Thr Lys Asn Gln Phe Ser 65 70 75 80 Leu Arg Leu Ser Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gln Leu Val Gly Gly Leu Asp Val Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 157 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> VH of 13F7 Antibody <400> 157 Gln Val Gln Leu Gln Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Asn Ala Glu Ser Phe Asn Gly Tyr 20 25 30 Ser Trp Thr Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Ser His Phe Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Ala Thr Ile Ser Ala Asp Lys Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ala Leu Arg Gly Thr Tyr Ser Arg Phe Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 158 <211> 120 <212> PRT <213> artificial sequence <220> <223> 15A9 antibodyVH <400> 158 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Pro Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Asn Leu Lys Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Asn Pro Phe Gly Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 159 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> VH of P1-A03 Antibody <400> 159 Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Asp Tyr 20 25 30 Met Ser Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly 35 40 45 Ile Ile Tyr Pro Ser Thr Thr Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Glu Leu Lys Met 65 70 75 80 Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly 85 90 95 Ser Asn Trp Ser Ser Gly Met Asn Leu Trp Gly Pro Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 160 <211> 113 <212> PRT <213> Artificial sequence <220> <223> VH of P1 - A08 antibody <400> 160 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Thr Tyr Tyr 20 25 30 Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 35 40 45 Ile Val Tyr Pro Ser Gly Thr Thr Tyr Tyr Ala Asn Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Thr Ala Ser Thr Thr Val Asp Leu Met Ile Thr 65 70 75 80 Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Asp 85 90 95 Ser Phe Gly Tyr Gly Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 161 <211> 122 <212> PRT <213> Artificial sequence <220> <223> VH of P1 - F02 antibody <400> 161 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asn Tyr Tyr 20 25 30 Met Gly Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly 35 40 45 Ile Ile Tyr Ala Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Met Thr 65 70 75 80 Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ile Asp 85 90 95 Ile Gly Val Gly Asp Tyr Gly Trp Ala Tyr Asp Arg Leu Asp Leu Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 162 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> VH of P2-A01 Antibody <400> 162 Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr 1 5 10 15 Pro Leu Thr Leu Ser Cys Thr Ala Ser Gly Phe Phe Leu Ser Gly Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Ile Ile Tyr Pro Ser Gly Ser Thr Asp Tyr Ala Ser Trp Ala Lys 50 55 60 Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile 65 70 75 80 Thr Thr Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Val 85 90 95 Ala Gly Tyr Val Gly Tyr Gly Tyr Glu Thr Phe Phe Asp Ile Trp Gly 100 105 110 Pro Gly Thr Leu Val Thr Val Ser Leu 115 120 <210> 163 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> P2-A03 antibody VH <400> 163 Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Asn Asn Tyr Asp 20 25 30 Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly 35 40 45 Phe Met Asp Thr Asp Gly Ser Ala Tyr Tyr Ala Thr Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met Thr 65 70 75 80 Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Arg Gly 85 90 95 Ser Ser Tyr Tyr Gly Gly Ile Asp Ile Trp Gly Pro Gly Thr Pro Val 100 105 110 Thr Val Ser Leu 115 <210> 164 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> VH of P2 - F07 Antibody <400> 164 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Tyr 20 25 30 Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 35 40 45 Ile Ile Tyr Pro Ser Gly Thr Thr Tyr Tyr Ala Gly Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr 65 70 75 80 Ser Pro Thr Ser Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Val 85 90 95 Ser Gly Tyr Phe Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser 100 105 110 Leu <210> 165 <211> 114 <212> PRT <213> Synthetic sequence <220> <223> VH of P2-F11 antibody <400> 165 Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr 20 25 30 Gly Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Ala Asn Asn Tyr Asn Pro His Tyr Ala Ser Trp Ala Lys 50 55 60 Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys 65 70 75 80 Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg 85 90 95 Asp Asn Tyr Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val 100 105 110 Looking Looking <210> 166 <211> 110 <212> PRT <213> artificial sequence <220> <223> P2-C12 antibody VL <400> 166 Glu Leu Asp Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys 65 70 75 80 Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Thr Asn 85 90 95 Val Trp Asn Ala Phe Gly Gly Gly Thr Asn Val Glu Ile Lys 100 105 110 <210> 167 <211> 106 <212> PRT <213> Artificial Sequence <220> <223> 13B4 Antibody VL <400> 167 Ser Tyr Glu Leu Thr Gln Pro Leu Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asn Val Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Thr Leu Val Ile Tyr 35 40 45 Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Lys Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Leu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 168 <211> 112 <212> PRT <213> artificial sequence <220> <223> 13F7 antibody VL <400> 168 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ala Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Val Gln Lys Pro Gly Gln Pro 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Arg Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 169 <211> 107 <212> PRT <213> artificial sequence <220> <223> 15A9 antibody VL <400> 169 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Ile Thr Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Thr Ser 20 25 30 Leu Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Gly Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Thr Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Ser Ala Ser Ile Pro Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Asp Ile Lys 100 105 <210> 170 <211> 110 <212> PRT <213> artificial sequence <220> <223> P1-A03 antibody VL <400> 170 Glu Leu Val Met Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Glu Thr Val Arg Ile Arg Cys Leu Ala Ser Glu Asp Ile Tyr Ser Gly 20 25 30 Ile Ser Trp Tyr Gln Gln Lys Pro Glu Lys Pro Pro Thr Leu Leu Ile 35 40 45 Ser Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Gly Gly Val Gln Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Tyr Ser Tyr Ser Ser 85 90 95 Thr Gly Leu Thr Phe Gly Ala Gly Thr Asn Val Glu Ile Lys 100 105 110 <210> 171 <211> 110 <212> PRT <213> artificial sequence <220> <223> P1-A08 antibody VL <400> 171 Glu Leu Val Leu Thr Gln Ser Pro Ser Val Gln Val Asn Leu Gly Gln 1 5 10 15 Thr Val Ser Leu Thr Cys Thr Ala Asp Thr Leu Ser Arg Ser Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Leu Ile Tyr 35 40 45 Arg Asp Thr Ser Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Ser Asp Gly Ser Gly Ser Asn 85 90 95 Tyr Gln Tyr Val Phe Gly Gly Gly Thr Gln Leu Thr Val Thr 100 105 110 <210> 172 <211> 108 <212> PRT <213> Artificial sequence <220> <223> P1-F02 antibody VL <400> 172 Glu Leu Asp Met Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Glu Thr Val Arg Ile Arg Cys Leu Ala Ser Glu Asp Ile Tyr Ser Gly 20 25 30 Ile Ser Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Thr Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Gly Gly Val Gln Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Tyr Ser Tyr Ser Ser 85 90 95 Ile Thr Phe Gly Ala Gly Thr Asn Val Glu Ile Lys 100 105 <210> 173 <211> 112 <212> PRT <213> artificial sequence <220> <223> P1- A01 antibody VL <400> 173 Glu Leu Val Met Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Glu Thr Val Arg Ile Arg Cys Leu Ala Ser Glu Asp Ile Tyr Ser Gly 20 25 30 Ile Ser Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Thr Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Ser Asp Tyr Thr Leu Thr Ile Gly Gly Val Gln Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Val Thr Tyr Ser Ser 85 90 95 Thr Gly Thr His Leu Thr Phe Gly Ala Gly Thr Asn Val Glu Ile Lys 100 105 110 <210> 174 <211> 112 <212> PRT <213> Synthetic Sequence <220> <223> P2 - A03 antibody VL <400> 174 Glu Leu Asp Leu Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly 1 5 10 15 Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Gly Gly Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys 65 70 75 80 Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Pro Ala Tyr Asp Pro Ala 85 90 95 Ala Tyr Val Gly Asn Ala Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu 100 105 110 <210> 175 <211> 107 <212> PRT <213> artificial sequence <220> <223> P2-F07 antibody VL <400> 175 Glu Leu Asp Leu Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Leu Ala Ser Glu Asp Ile Tyr Ser Ala 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Thr Leu Leu Ile 35 40 45 Ser Gly Thr Ser Asn Leu Glu Ser Gly Val Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Gly Gly Val Gln Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Phe Cys Gln Gly Tyr Ser Ser Tyr Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Asn Val Glu Ile Lys 100 105 <210> 176 <211> 113 <212> PRT <213> artificial sequence <220> <223> P2-F11 antibody VL <400> 176 Glu Leu Asp Leu Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Tyr Asn Asn 20 25 30 Lys Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Ala Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val 65 70 75 80 Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Glu Phe Ser Cys 85 90 95 Ser Ser Ala Asp Cys Asn Ala Phe Gly Gly Gly Thr Glu Leu Glu Ile 100 105 110 Leu <210> 177 <211> 363 <212> DNA <213> Synthetic Sequence <220> <223> P2-C12 Antibody VH <400> 177 cagtcgctgg aggagtccgg gggtcgcctg gtcacgcctg ggacacccct gacactcacc 60 tgcaccgtct ctggattctc cctcagtacc tatgcagtga cctgggtccg ccaggctcca 120 gggaaggggc tggaatggat cggatacatt aattggcgtg gtgggacatc ctacgcgaac 180 240. tgggcgaaag gccgattcac catctccaaa acctcgtcga ccacggtgga tctgaaaatg accagtccga caaccgagga cacggccacc tatttctgtg ccagagatgc tagtagtggt gctgcttttg ggtcttacgg catggacccc tggggcccag ggaccctcgt caccgtctct 360 tca 363 <210> 178 <211> 330 <212> DNA <213> The snowstorm <220> <223> P2-C12VL <400> 178 60. gagctcgata tgacccagac tccatcctcc gtgtctgcag ctgtgggagg cacagtcacc atcaagtgcc aggccagtca gagcattagt agctacttat cctggtatca gcagaaacca gggcagcctc ccaagctcct gatctatgaa gcatccaaac tggcctctgg ggtcccatcg cggttcagcg gcagtggata tgggacagag ttcactctca ccatcagcga cctggagtgt 240 gccgatgctg ccacttacta ctgtcaacag ggttatagta gtactaatgt ttggaatgct ttcggcggag gcaccaatgt ggaaatcaaa <210> 179 <211> 451 <212> PRT <213> Artificial sequence <220> <223> P2-C12HC <400> 179 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Tyr Ala 20 25 30 Val Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 35 40 45 Tyr Ile Asn Trp Arg Gly Gly Thr Ser Tyr Ala Asn Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Met 65 70 75 80 Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp 85 90 95 Ala Ser Ser Gly Ala Ala Phe Gly Ser Tyr Gly Met Asp Pro Trp Gly 100 105 110 Pro Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 180 <211> 448 <212> PRT <213> Artificial sequence <220> <223> 13B4HC <400> 180 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly 1 5 10 15 Thr Leu Ser Leu Asn Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser 20 25 30 Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Glu Ile Tyr His Gly Gly Thr Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Gly Arg Val Thr Met Ser Val Asp Lys Thr Lys Asn Gln Phe Ser 65 70 75 80 Leu Arg Leu Ser Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gln Leu Val Gly Gly Leu Asp Val Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 181 <211> 453 <212> PRT <213> Artificial Sequence <220> <223> 13F7HC <400> 181 Gln Val Gln Leu Gln Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Asn Ala Glu Ser Phe Asn Gly Tyr 20 25 30 Ser Trp Thr Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Ser His Phe Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Ala Thr Ile Ser Ala Asp Lys Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ala Leu Arg Gly Thr Tyr Ser Arg Phe Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 ...
Claims
1. An adeno-associated virus (AAV) vector comprising a nucleic acid encoding an antagonist to a family 19 member A5 (FAM19A5) protein having sequence similarity (FAM19A5 antagonist), wherein the FAM19A5 antagonist is an antibody (anti-FAM19A5 antibody) or an antigen-binding portion thereof, wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2 and CDR3 and a light chain CDR1, CDR2 and CDR3, wherein: (a) the heavy chain CDR1 consists of the amino acid sequence shown in SEQ ID NO: 212, (b) the heavy chain CDR2 consists of the amino acid sequence shown in SEQ ID NO: 213, (c) the heavy chain CDR3 consists of the amino acid sequence shown in SEQ ID NO: 16, (d) the light chain CDR1 consists of the amino acid sequence shown in SEQ ID NO: 222, (e) the light chain CDR2 consists of the amino acid sequence shown in SEQ ID NO: 225, and (f) The light chain CDR3 consists of the amino acid sequence shown in SEQ ID NO:
224.
2. The AAV vector according to claim 1, further comprising an intron, a signal peptide and / or one or more adeno-associated virus inverted terminal repeats (ITRs) or a combination thereof.
3. The AAV vector according to claim 1 or 2, wherein the anti-FAM19A5 antibody comprises Fab, Fab', F(ab')2, Fv, single-chain Fv (scFv) or a combination thereof.
4. The AAV vector of claim 3, wherein the anti-FAM19A5 antibody is a scFv.
5. The AAV vector of any one of claims 1 to 4, wherein the nucleic acid is codon-optimized.
6. The AAV vector according to any one of claims 1 to 5, wherein the nucleic acid encoding scFv comprises the nucleotide sequence shown in SEQ ID NO:
301.
7. The AAV vector of claim 4, wherein the scFv comprises an amino acid sequence as shown in SEQ ID NO:
256.
8. The AAV vector according to any one of claims 1 to 7, wherein the anti-FAM19A5 antibody exhibits a property selected from the following: (a) As measured by enzyme-linked immunosorbent assay (ELISA), with a K of 10 nM or less D Binds to soluble human FAM19A5; (b) With a K of 10 nM or lower as measured by ELISA D Binds to membrane-bound human FAM19A5; or (c) Both (a) and (b).
9. The AAV vector according to any one of claims 1-8, wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 236 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
245.
10. A method for producing recombinant adeno-associated virus (AAV) particles, comprising (a) culturing host cells that have been transfected with an AAV vector according to any one of claims 1 to 9 to provide a cell culture and (b) recovering the recombinant AAV particles from the supernatant of the cell culture.
11. Use of the AAV vector according to any one of claims 1 to 9 for the preparation of a medicament for treating neuropathic pain in a subject in need thereof.
12. The use according to claim 11, wherein the neuropathic pain is peripheral neuropathic pain.
13. The use according to any one of claims 11 to 12, wherein the AAV vector administered to the subject is suitable for intravenous, oral, parenteral, intrathecal, intracerebroventricular, pulmonary, intramuscular, subcutaneous, intraperitoneal, intravitreal, epidural, subretinal or intraventricular administration.
14. The use according to any one of claims 11 to 13, wherein the subject is a human.
